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Presentación 
El virus vaccinia está siendo utilizado como vector vacunal en varias enfermedades 
animales y humanas. La capacidad de inducir una respuesta de células T específicas 
fretne a los antígenos exógenos constituye la mejor propiedad inmune de este virus que 
genera protección frente a distintos patógenos. MVA y NYVAC, con capacidad 
reducida de replicación en las células humanas, representan los vectores más utilizados 
del virus vaccinia en ensayos clínicos. 
Este trabajo se dirige hacia la comprensión de los mecanismos involucrados en la 
generación de respuestas inmunes específicas hacia antígenos y a la mejora de la 
capacidad de inducir esta respuesta por parte de los poxvirus. En este sentido, hemos 
desarrollado diferentes estrategias y distintos candidatos vacunales del virus vaccinia 
para mejorar las respuestas inmunes específicas hacia antígenos heterólogos. 
Hemos modificado el vector NYVAC-C, que expresa antígenos del virus VIH-1 de 
subtipo C, mediante deleción de genes (A52R, K7R, B15R) para enfocarnos en la vía de 
señalización de NFκB en la célula huésped. Se encontró que estos genes actúan 
conjuntamente para inhibir la vía de señalización de NFκB, descartando la sinergia entre 
estas proteínas como modo de acción. Se estudió la capacidad de este virus 
recombinante de inducir respuestas inmunes innatas que dependen de NFκB y se 
demostró que los neutrófilos aumentan las respuestas inmunitarias adaptativas de 
células T hacia antígenos de VIH. Definimos el tráfico de neutrófilos desde el sitio de 
infección hacia diversos órganos linfoides secundarios y describimos que después de la 
estimulación por quimiocinas, los neutrófilos polarizan hacia fenotipos funcionales 
distintos que regulan la magnitud y la calidad de la respuesta inmune. 
Hemos generado nuevos promotores del virus vaccinia para mejorar la expresión de 
los antígenos GFP y LACK de Leishmania y aumentar las respuestas de células T 
específicas hacia estos antígenos. Tras el análisis bioinformático, se definió una nueva 
secuencia del promotor para mejorar los niveles de expresión temprana del antígeno 
GFP. Por otra parte, hemos modificado la longitud del espaciador del promotor para 
aumentar la expresión de estos dos antígenos heterólogos. Los vectores recombinantes 
de MVA con estas modificaciones en el promotor aumentaron la expresión del gen 
heterólogo y positivamente influyeron en la magnitud y la calidad de las respuestas de 
memoria de células T específicas. Estos resultados proporcionan importantes 
conocimientos sobre el mecanismo de la respuesta inmune inducida por el virus 
vaccinia y estrategias alternativas para el diseño de vectores vacunales. 
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Summary 
Vaccinia virus (VACV) is being used as vaccine vector for several animal and 
human diseases.  Its capacity to induce specific T cell responses to foreign antigens 
define the best immune property of this virus, which generates protection against 
distinct pathogens.  The MVA and NYVAC virus strains, which have limited 
replication in human cells, are the most-used VACV vector in clinical trials.  
This study is directed to understanding the poxvirus-dependent mechanisms involved 
in the generation of antigen-specific immune responses, and to improving poxvirus 
capacity to induce this response.  Here we developed different strategies and distinct 
VACV-based vaccine candidates to improve foreign antigen-specific immune responses.  
We modified NYVAC-C that expressed HIV-1 clade C antigens by gene deletion (A52R, 
K7R, B15R) to target the NFκB central host-cell signaling pathway.  We found that 
these genes act together to inhibit NFκB signaling, ruling out synergy between these 
proteins as a mode of action. Our study of the ability of this recombinant virus to induce 
NFκB-dependent innate immune responses demonstrated that neutrophils increase the 
T cell adaptive immune response to HIV antigens.  We tracked the neutrophil 
trafficking from the infection site to various secondary lymphoid organs and showed 
that, after chemokine stimulation, neutrophils polarize to distinct functional phenotypes 
that regulate the magnitude and quality of the immune response. 
We generated new VACV promoters to improve the timing of GFP (green 
fluorescent protein) and LACK (Leishmania homologue of receptors for activated C-
kinase) expression and to increase antigen-specific T cell responses.  Using 
bioinformatics analysis, we defined a new early promoter motif to improve GFP antigen 
early expression.  Furthermore, we modified the promoter spacer length to increase this 
heterologous antigen expression. The recombinant MVA vectors with these promoter 
modifications increased heterologous gene expression and positively influenced the 
magnitude and the quality of antigen-specific T cell memory responses. 
These findings provide important insights into the mechanism of the VACV-induced 
immune response and alternative strategies for vaccine vector design. 
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A 
AIDS: acquired immune deficiency syndrome 
AP-1: activator protein-1 
APC: antigen presenting cells  
 
B 
Bcl-2: B-cell lymphoma 2  
 
C 
CCR1: chemokine (C-C motif) receptor 1 
CCR2: chemokine (C-C motif) receptor 2 
CCR5: chemokine (C-C motif) receptor 5 
CD: cluster of differentiation 
CEV:  cell-associated enveloped virus 
CVA: chorioallantois vaccinia virus Ankara 
 
D 
DC: dendritic cells 
DNA: deoxyribonucleic acid!
 
E 
EEV: extracellular enveloped virus 
Env: envelope protein 
ETF: early transcription factor  
EV: enveloped virion 
 
G 
GFP: green fluorescent protein 
GLA: glucopyranosyl lipid adjuvant 
GM: granulocyte macrophage-colony-stimulating factor 
GP120: glycoprotein 120 
GPN: Gag-Pol-Nef 
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H 
mH5: modified H5 
HIV: human immunodeficiency virus 
 
I 
ICTV: International Committee on Taxonomy of Viruses 
IEV: intracellular enveloped virus 
IFN: interferon 
IFN-α: interferon alpha  
IFN-γ: interferon gamma 
IKK: IκB kinase  
IL-1β: interleukin 1 beta 
IL-2: interleukin 2 
IL-4: interleukin 4 
IL-6: interleukin 6 
IL-8: interleukin 8!
IL-10: interleukin 10 
IL-13: interleukin 13 
IMV: intracellular mature virus 
IRF 3: IFN-regulatory factor 3 
IRF 7: IFN-regulatory factor 7 
IRAK: IL-1R-associated kinase 
 
L 
LACK: Leishmania homologue of receptors for activated C kinase  
LEO: late-early optimized  
LEO99: late-early optimized 99 
LEO160: late-early optimized 160 
dLN: draining lymph nodes 
 
M 
Mφ: macrophage 
MAL: MyD88-adaptor-like  
MCP-1/CCL2: monocyte chemoattractant protein-1 
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MEME: Multiple EM for Motif Elicitation  
MHC-II: major histocompatibility complex type II 
MIP 1α/CCL3: macrophage inflammatory protein 1 alpha 
MIP-1β/CCL4: macrophage inflammatory protein 1 beta 
MV: mature virion 
MVA: modified vaccinia virus Ankara 
MyD88: myeloid differentiation factor 88 
 
N 
Nα: neutrophil alpha  
Nβ: neutrophil beta 
NET: neutrophil extracellular trap 
NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NK: natural killer 
NLR: NOD-like receptor 
NOD: nucleotide-binding oligomerization domain 
nt: nucleotide 
NYVAC: New York vaccinia virus 
 
O 
ORF: open reading frame 
 
P!
PAMP: pathogen-associated molecular pattern 
PRR: pattern recognition receptor 
pS: synthetic promoter 
 
R 
RAP94: RNA polymerase-associated protein 94 
RIG: retinoic acid inducible gene!
RLR: RIG like receptor 
RNA: ribonucleic acid!
mRNA: messenger RNA!
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S 
SIV: simian immunodeficiency virus 
 
T 
TAB1: TAK1-binding protein 1 
TAB2: TAK1-binding protein 2 
TAN: tumor-associated neutrophil 
TAK1: TGF-β-activated kinase 1 
TGF-β: transforming growth factor beta 
Th: T helper cell 
TIR: Toll/IL-1 receptor 
TLR: Toll-like receptor 
TNF: tumor necrosis factor 
TNFα: tumor necrosis factor alpha 
TRAF 6: TNF receptor-associated factor 6 
TRAM: TRIF-related adaptor molecule 
TRIF: TIR domain-containing adapter inducing IFNβ 
 
V 
VACV: vaccinia virus 
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Introduction 
 
 
1.1. Poxvirus 
Poxviruses are enveloped DNA viruses that replicate in the cell cytoplasm and their 
complex morphogenesis includes the de novo synthesis of virus-specific membranes 
(Buller and Palumbo, 1991).  According to the International Committee on Taxonomy 
of Viruses (ICTV), the Poxviridae family is divided into two subfamilies, the 
Entomopoxvirinae and the Chordopoxvirinae, which infect invertebrates and vertebrates, 
respectively.  Orthopoxvirus includes species isolated from mammals and is one of the 
ten Chordopoxvirinae genera. Although variola virus, the causative agent of smallpox, 
is the most famous member of the genus, the prototype vaccinia virus (VACV) is the 
most studied specie. 
 
1.1.1. Vaccinia virus 
Vaccinia virus (VACV) has a brick-shaped structure with fixed dimensions of 360 x 
270 x 250 nm (Cyrklaff et al., 2005) (Figure 1A).  Infectious VACV particles present 
two forms; the mature virion (MV) is composed by a nucleoprotein core, inclusion 
bodies, structural proteins and enzymes used for the early gene transcription, 
surrounded by a lipoprotein membrane (Condit et al., 2006), whereas the enveloped 
virion (EV) has six additional proteins associated to an antigenically distinct outer 
membrane that is generated  by fusion with the host cell membrane (Smith et al., 2002).  
These six additional proteins are involved in virus entry into host cells and immune 
evasion (Payne, 1978) (Figure 1B). 
 
Figure 1.  VACV structure and morphology 
(A) Cryo-electron tomography of vaccinia virus (Cyrklaff et al., PNAS, 2005).  
(B) Structure of infectious vaccinia virus particles (Swiss Institute of Bioinformatics, 2008). 
  
Mature  Virion (MV) Enveloped  Virion (EV) 
A B 
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VACV has a double-stranded DNA genome of 62.3 µm (Esteban et al., 1977) and 
~200 kb, which encodes 250 genes (Goebel et al., 1990).  The gene open reading frames 
(ORF) are named according to size in kb, location, position, and direction of 
transcription (L, left; R, right) within the HindIII digestion sites (Roseman and 
Slabaugh, 1990).  The most-conserved genes are located centrally and are involved in 
replication or virion assembly, and most-variable genes are located terminally and 
participate in host range restriction or immune evasion (Seet et al., 2003). 
The VACV life cycle (Figure 2) begins with virion entry into the cell by fusion with 
the plasma membrane or by endocytic uptake (macropinocytosis) and with the core 
release into the host cytoplasm (McFadden, 2005).  After core uncoating, VACV itself 
carries on its early gene transcription.  The early mRNA are translated into early 
proteins involved in DNA replication, 
intermediate transcription and host 
immune evasion (McFadden, 2005).  
The intermediate proteins participate in 
the late transcription of proteins 
involved in virus assembly. During 
morphogenesis, core protein and 
condensed DNA enclosed by a 
membrane form the intracellular mature 
virus (IMV)! (McFadden, 2005).  IMV 
particles assemble and migrate via 
microtubule-mediated trafficking and 
are then wrapped with Golgi-derived 
membranes to form intracellular 
enveloped virus (IEV)! (McFadden, 
2005).  IEV can nucleate the formation 
of actin tails that aid its movement to 
the cell surface (Cudmore et al., 1995).  
IEV can fuse with the plasma 
membrane to form the cell-associated enveloped viruses (CEV) that remain attached to 
the cell and are involved in cell-to-cell spread, as well as the extracellular enveloped 
viruses (EEV) that are shed by the cell and mediate long-range virus dissemination 
(Blasco and Moss, 1991). 
 
Figure 2.  VACV life cycle 
(adapted from McFadden et al. Nat Rev 
Microbiol 2005). 
EV MV
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Figure 2: VACV life cycle 
 (adapted from McFadden, Nature Revews Microbiology, 2005)  
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1.1.2.  VACV as a vaccine vector 
VACV was used as a vaccine to eradicate smallpox (Wehrle, 1980); several later 
studies demonstrated that VACV vector can stably incorporate different exogenous 
DNAs and  induces protection against distinct pathogens (Moss, 1991; Paoletti, 1996).  
VACV has unique vaccine features (Pastoret and Vanderplasschen, 2003): 
• High stability of the freeze-dried vector 
• Low production cost 
• Easy manufacture and production 
• Ability to incorporate large amounts (up to 25 kb) of DNA 
• High heterologous antigen expression 
• Good capacity to induce cellular and humoral responses 
The safety issues, due to some adverse reactions in VACV vaccination programs 
(Lane et al., 1969; Redfield et al., 1987), led to the generation of attenuated VACV such 
as MVA and NYVAC, that have limited replication in human cells (Moss, 1996). 
 
1.1.3. Modified vaccinia virus Ankara (MVA) 
 MVA was derived from the chorioallantois vaccinia Ankara (CVA) strain after 570 
passages on chicken embryo fibroblasts (Hochstein-Mintzel et al., 1975), resulting in 
the loss of ~15% (30 kb) of the parental viral genome (Antoine et al., 1998) (Figure 
3A); the deleted genes are involved in virulence and host immune evasion (Meyer et al., 
1991).  MVA expresses early, intermediate and late proteins, but does not carry out 
virion assembly during morphogenesis in HeLa cells (Sancho et al., 2002). 
MVA, which generates an immune response more rapidly than fully replication-
competent viruses (Earl et al., 2008), is widely studied as a new generation of poxvirus 
vaccine!(McCurdy et al., 2004) for its capacity to induce protection in mice and in non-
human primate models (Stittelaar et al., 2005; Wyatt et al., 2004).  MVA has been 
recently tested as a vaccine candidate in several clinical trials for prevention and 
treatment of human diseases such as AIDS (acquired immune deficiency syndrome) 
(Keefer et al., 2011; Kibler et al., 2011), hepatitis!(Fournillier et al., 2013), malaria!(de 
Barra et al., 2014), tuberculosis (Meyer et al., 2013) and cancer (Harrop et al., 2006). 
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1.1.4. New York vaccinia virus  (NYVAC) 
NYVAC was derived from the Copenhagen vaccine strain by the precise deletion of 
18 open reading frames (ORF) from the parental viral genome (Tartaglia et al., 1992); 
the deleted genes (15 kb) are involved in pathogenicity, virulence and host-range 
regulatory functions (Tartaglia et al., 1992) (Figure 3B).  In HeLa cells, through a 
transcription blockade, NYVAC does not express certain late proteins that participate in 
morphogenesis (Tartaglia et al., 1992).  
NYVAC has been studied for its ability to induce good antigen-specific immune 
responses in the mouse and non-human primates (Flynn et al., 2011; Gomez et al., 
2007c), and has been tested as a human immunodeficiency virus (HIV) vaccine 
candidate in clinical trials (Bart et al., 2014; Harari et al., 2012). 
 
 
Figure 3.  VACV genomes 
(A) MVA genome,  (B) NYVAC genome (adapted from Gomez et al., Curr Gene Ther, 2011). 
 
Comparison of MVA and NYVAC in vivo dissemination showed that both viruses 
reach and infect target tissues, although with different kinetics; MVA induces a faster 
antiviral response and viral clearance than NYVAC, which expresses viral genes for 
72 h post-infection, 24 h more than MVA (Gomez et al., 2007a).  Several microarray 
studies demonstrated that MVA and NYVAC infection regulate distinct gene expression 
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profiles in human cells (Guerra et al., 2004; Guerra et al., 2006; Guerra et al., 2007), 
which influences virus capacity to escape the immune system (Gomez et al., 2008).  
Variation in virus capacity to activate the innate signaling pathway and to control viral 
gene expression is responsible for generation of different T cell responses (Obst et al., 
2005); specifically, MVA elicited more CD8 and less CD4 T cells responsive to HIV 
antigens than NYVAC in a primate model (Mooij et al., 2008). 
 
1.1.5. MVA and NYVAC vaccine strategies to increase antigen immunogenicity 
Attenuated VACV vectors such as MVA and NYVAC are being tested as candidate 
vaccines to express heterologous pathogen antigens, and are being further improved to 
potentiate antigen-specific immune responses (immunogenicity)! (Garcia-Arriaza and 
Esteban, 2014).  The distinct levels of immunogenicity of all antigens expressed by a 
virus define the viral immunodominance hierarchy! (Yewdell and Bennink, 1999).  
Immunodominance is the phenomenon whereby only a small fraction of all of possible 
pathogen epitopes (the part of the antigen recognized by the immune system) elicits an 
immune response in an infected individual (Pasquetto et al., 2005).  During infection in 
specific T cell immune conditions such as pre-priming of T cells or regulatory T cell 
depletion (Assarsson et al., 2007), subdominant epitopes, which are immunogenic and 
generated by natural antigen processing but not normally recognized by immune 
responses! (Franke et al., 2000), can break this hierarchy at the expense of dominant 
epitopes.  Viral antigen uptake (Siddiqui and Basta, 2011), the timing and quantity of its 
expression (Wilson and Hunter, 2008), its cellular transport (Li et al., 1997), and/or  its 
processing/proteolysis (Jing et al., 2007; Pamer and Cresswell, 1998) can positively 
influence its immunogenicity.  The VACV vectors and/or the route of infection could 
also influence the immunodominance hierarchy (Tscharke et al., 2005). 
Several strategies have been developed to improve immunogenicity to heterologous 
antigens expressed by MVA and NYVAC vectors (Garcia-Arriaza and Esteban, 2014; 
Gomez et al., 2012a, 2013): 
• heterologous prime/boost immunization protocols such as DNA-MVA, DNA- 
NYVAC, MVA-NYVAC, NYVAC-MVA, MVA-MVA and NYVAC-
NYVAC  protocols to selectively increase the antigen-specific T cell 
response (Boukhebza et al., 2012; Gomez et al., 2007b) 
31
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• use of MVA virus with costimulatory molecules and cytokines such as 
CD40L (Gomez et al., 2009) or IL-2 (Ramlau et al., 2008) to directly induce 
T cell activation and proliferation 
• insertion of host range viral genes such as  K1L (Kovarik et al., 2001), C7L 
(Najera et al., 2010), or both (Kibler et al., 2011; Mooij et al., 2015) to 
generate attenuated replication-competent vectors that guarantee higher 
antigen expression 
• insertion of  synthetic or natural early promoters (Baur et al., 2010; Isshiki et 
al., 2014; Sato et al., 2013; Wennier et al., 2013) to increase the quality of 
antigen expression 
• deletion of  immunodulatory genes that encode inhibitors of apoptosis 
pathways such as F1 (Perdiguero et al., 2012), interferon (IFN) receptor-
mediated signals such as B8 and B19 (Gomez et al., 2012b), Toll-like 
receptor (TLR) pathways  such as C6 (Garcia-Arriaza et al., 2011) or N2!
(Garcia-Arriaza et al., 2014), to increase antigen uptake by the innate immune 
system 
• use of MVA virus with adjuvants such as IC31 (Pattacini et al., 2012), TLR 9 
agonist, or the TLR 4 agonists A27 fusion protein (Vijayan et al., 2012) and 
glucopyranosyl lipid adjuvant (GLA) (McKay et al., 2014), to increase 
antigen recognition in the innate immune response. 
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1.2. Antiviral innate immunity 
 
Pathogen-associated molecular patterns (PAMP) such as viral protein and genomic 
DNA or RNA induce the innate immune response by activation of host cell pattern 
recognition receptors (PRR)! (Smith et al., 2013).  The PRR include membrane-
associated TLR, retinoic acid inducible gene I (RIG-I)-like receptors (RLR), nucleotide-
binding oligomerization domain (NOD)-like receptors (NLR) and cytoplasmic DNA 
sensors (Perdiguero and Esteban, 2009).  NLR regulate interleukin (IL)-1β maturation 
(Kanneganti et al., 2007), whereas TLR and RLR are involved in the transcription of 
type I interferon (IFN) cytokines and chemokines (Smith et al., 2013).  This gene 
transcription is mediated by IFN-regulatory factor (IRF) 3, nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), and activator protein 1 (AP-1), which form 
an enhanceosome complex that binds to the IFN-β promoter (Wathelet et al., 1998); the 
IRF-7 transcription factor also promotes IFN-α gene expression (Marie et al., 1998). 
 
1.2.1. TLR signaling pathway and NFκB activation 
NFκB pathway activation depends on virus capacity to interact with TLR.  Viral 
envelope proteins interact with TLR2 and TLR4 on the plasma membrane (Akira et al., 
2006), while RNA and DNA recognize endosomic TL3/7/8 and TLR9, respectively.  
PAMP binding induces TLR2 and TLR4 homo- or heterodimerization (Jin and Lee, 
2008), followed by recruitment of Toll/IL-1 receptor (TIR) domain-containing adaptor 
proteins such as myeloid differentiation factor 88 (MyD88) and MyD88-adaptor-like 
(MAL) or TIR domain-containing adapter inducing IFNβ (TRIF) and TRIF-related 
adaptor molecule (TRAM).  MyD88 mediates the activation of tumor necrosis factor 
(TNF) receptor-associated factor 6 (TRAF6) by phosphorylation of IL-1R-associated 
kinase (IRAK) 1,2 and 4; TRIF interacts directly with TRAF6.  TRAF6 recruits 
transforming growth factor (TGF)-β-activated kinase (TAK1) as well as TAK1-binding 
proteins 1 (TAB1) and 2 (TAB2) to phosphorylate TAK1 and to activate the IκB kinase 
(IKK) complex; this activation leads to IκBα phosphorylation and subsequent 
degradation mediated by proteasome, allowing release of the NFκB complex (comprised 
of p65/p50 or p65/p52 heterodimers) into the cell nucleus.  NFκB then binds the κB site 
and regulates transcription of pro-inflammatory cytokine and chemokine genes (Akira et 
al., 2006). 
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1.2.2 VACV and TLR/NFκB pathway 
The VACV envelope interacts with TLR2 and TLR4 (Delaloye et al., 2009; 
Hutchens et al., 2008), and produces early viral inhibitors of the NFκB pathway 
(Figure 4) such as: 
• A46, which disrupts the TLR4 receptor:TIR adaptor link (Stack et al., 2005) 
• A49, which inhibits IκBα degradation (Mansur et al., 2013) 
• A52, which blocks IRAK2 and TRAF6 activation (Harte et al., 2003) 
• B14 (B15 in NYVAC), which impedes IκBα phosphorylation (Chen et al., 2008) 
• C4, which inhibits NFκB activation downstream of IKK (Ember et al., 2012) 
• E3, which sequesters RNA to avoid binding with PRR (Myskiw et al., 2009) 
• K1, which prevents IκBα degradation (Shisler and Jin, 2004) 
• K7, which blocks IRAK2 and TRAF6 activation (Schroder et al., 2008) 
• M2, which avoids NFκB translocation to the nucleus (Gedey et al., 2006) 
• N1, which inhibits IKK activation (Maluquer de Motes et al., 2011) 
 
 
Figure 4.  NFκB pathway and VACV inhibitors 
(adapted from Smith et al., J Gen Virol, 2013) 
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1.2.3 Neutrophils 
NFκB regulates the transcription of cytokine and chemokine pro-inflammatory 
signals for the recruitment of several cell types that act as the first cell line of defense in 
the innate immune response (Medzhitov, 2007), including monocytes, macrophages, 
dendritic cells (DC), natural killers (NK), B1 cells and granulocytes (Luster, 2002).  
Among the granulocytes, neutrophils are short-lived effector cells of the innate immune 
system that represent the first barrier against microbial pathogens (Mantovani et al., 
2011). During microbial invasion, neutrophils (Figure 5) counteract infection 
immediately in a process termed microbial sterilization (Nathan, 2006), for which they 
engulf extracellular pathogens, infected and apoptotic cells (Hashimoto et al., 2007; 
Sorensen et al., 2001), they produce reactive oxygen intermediates (Borregaard, 2010), 
they release lytic enzymes and antimicrobial peptides from granules (Nathan, 2006), 
and they generate neutrophil extracellular 
traps (NET) (Brinkmann et al., 2004). 
Recent studies demonstrate that neutrophils 
can also induce antigen-specific T cell 
responses by migrating to the lymph nodes 
(Chtanova et al., 2008)! where they can 
efficiently cross-prime T cells (Beauvillain et 
al., 2007).  Neutrophils polarize to distinct 
phenotypes in response to environmental 
signals (Araki et al., 2004).  In the presence of 
granulocyte macrophage-colony-stimulating 
factor (GM-CSF) (Matsushima et al., 2013), 
TNF-α, IL-4 (Oehler et al., 1998) or IFN-γ 
(Fanger et al., 1997), neutrophils can adopt an antigen-presenting cell (APC) phenotype, 
thus triggering T cell activation.  Neutrophils can acquire a macrophage (Abdel-Salam 
and Ebaid, 2008; Araki et al., 2004) or dendritic phenotype (Matsushima et al., 2013), 
and such hybrid neutrophil populations with APC-like properties participate in adaptive 
immune responses (Matsushima et al., 2013).  The tumor cytokine/chemokine 
environment polarizes neutrophils; in the presence of TGF-β, neutrophil ability to 
activate CD8 T cells is impaired! (Fridlender et al., 2009).  In the tumor context, 
neutrophils can have intense phagocytic activity and induce T cell responses (Eruslanov 
Figure 5. Neutrophil structure.  
In purple the segmented nucleus and in 
yellow the granules (Blausen.com staff). 
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et al., 2014) or downregulate these functions and develop pro-tumorigenic properties!
(Mishalian et al., 2013). 
During VACV infection, neutrophil infiltration is tissue-protective (Fischer et al., 
2011), neutrophil recruitment to liver microvasculature with NET release defends the 
host cell from viral infection (Jenne et al., 2013), and activated neutrophils mediate 
antitumor effects by blocking vital blood supply to tumors (John et al., 2012).  After 
intradermal and intranasal infection, MVA induces neutrophil recruitment (Abadie et 
al., 2009; Lehmann et al., 2009), which depends on complement component C5 and is 
mediated by CCR1 (chemokine receptor 1) (Price et al., 2015; Price et al., 2014). 
It was recently shown that neutrophils generate polyclonal VACV-specific memory 
CD8 and not CD4 T cells.   Via CCR1, the MVA-GFP+ neutrophils migrated directly 
from dermis to bone marrow without passing through draining lymph nodes (dLN).  
After intradermal MVA infection, neutrophils cannot prime CD8 T cells in the absence 
of myeloid APC in bone marrow (Figure 6), which suggests that neutrophils transport 
the antigens and then are engulfed by typical APC (Duffy et al., 2012). 
 
 
Figure 6.  Scheme of neutrophil antigen transport 
After intradermal injection of MVA, neutrophils transport the virus from the dermis to the bone marrow.  
Distinct phagocytic resident APC are involved in CD8 T cell priming.  DC: dendritic cells, PMN: 
polymorphonuclear neutrophils, Mφ: macrophages (from Duffy et al., Immunity, 2012). 
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1.3.  T cell response 
Antigen-specific T cell responses control and clear pathogen infections! (Ha et al., 
2008); for this reason, inducing T cells responses specific for the pathogen is one of the 
most important goal in vaccine effectiveness.  The quality of this response, defined as T 
cell capacity to produce more than one cytokine after activation, is crucial for challenge 
protection (Seder et al., 2008).  CD8 T cells protect against distinct parasites such as 
Plasmodium falciparum or Trypanosoma cruzi, the causative agents of malaria and 
Chagas disease, respectively (Reyes-Sandoval et al., 2011; Rigato et al., 2011), whereas 
CD4 T cells protect against malaria!(Reece et al., 2004), influenza (Roman et al., 2002) 
and leishmaniasis!(Darrah et al., 2007). 
 
1.3.1 HIV: VACV vaccine and T cell response 
HIV vaccine represents the best long-term solution to eradicate the worldwide HIV 
pandemic of 34 million infected people (Figure 7).  The first HIV-envelope-based 
vaccines induced neutralizing antibodies that failed to protect against the virus due to he 
genetic variability of envelope proteins, which allows viral escape (Burton et al., 2004).  
Since most human HIV non-progressors preferentially maintain highly functional 
HIV-specific CD8 T cells (Betts et al., 2006), efforts focused on developing “T cell” 
vaccine candidates that control HIV replication, leading to attenuation of HIV disease 
and preventing secondary transmission! (McMichael, 2006).  Given the limited 
effectiveness of the ALVAC poxvirus vector in the RV144 phase III HIV/AIDS clinical 
trial (Rerks-Ngarm et al., 2009), there remains a need to improve poxvirus vector 
capacity as immunogen to increase protection levels; several strategies have been 
developed to improve T cell immunogenicity of HIV antigens (Gomez et al., 2012a).  
These approaches have yielded promising results in primates, and elicit protection after 
challenge with simian immunodeficiency virus (SIV) (Barouch et al., 2001; Barouch et 
al., 2013); in this infection model, CD4 and CD8 are associated with protection!(Hansen 
et al., 2009). 
In mice, recombinant MVA virus expressing envelope (Env) monomeric gp120 and 
the codon-optimized polyprotein Gag-Pol-Nef (GPN) from HIV-1 clade B, induced a 
strong, broad, polyfunctional and durable HIV-specific CD4 and CD8 T cell immune 
responses (Garcia-Arriaza et al., 2010; Garcia-Arriaza et al., 2011).  In macaques, a 
similar MVA construct that expressed SIV Env and GPN antigens elicited a strong CD4 
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and CD8 T cell response that protected after SIV challenge (Mooij et al., 2008).  Based 
on these results, this MVA-B vector entered a phase I clinical trial that demonstrated its 
safety and highly immunogenic profile (Cebere et al., 2006; Garcia et al., 2011; Mwau 
et al., 2004).  In healthy human volunteers, MVA induced a robust and polyfunctional 
effector memory CD4 and CD8 T cell response to Gag and Env HIV antigens 
(Goonetilleke et al., 2006; Kibler et al., 2011). 
 
 
Figure 7. Estimated HIV prevalence in young adults (15-49 years) by country (www.unaids.org). 
 
In mice, NYVAC induces a strong T cell response, with immunogenicity levels 
similar to those of MVA!(Gomez et al., 2007b; Gomez et al., 2007c).  Studies in non-
human primates demonstrated that NYVAC expressing Env and/or GPN clade C HIV 
antigens elicited a balanced CD4/CD8 T cell response (Mooij et al., 2015) and robust 
T cell immunity when the virus was used to boost after priming with HIV Gag 
associated to DC-specific antibody (Flynn et al., 2011).  Clinical trials showed the high 
NYVAC immunogenic potential to induce expansion of preexisting T cell responses as 
well as the appearance of newly detected polyfunctional CD4 and CD8 T cell responses 
in healthy volunteers and in chronically HIV-infected patients (Harari et al., 2008; 
Harari et al., 2012).  Recent phase Ib clinical trials confirmed the ability of NYVAC to 
enhance HIV-specific T cell responses when this virus was used to boost after priming 
with recombinant adenovirus HIV-vector!(Bart et al., 2014). 
New HIV-NYVAC and MVA recombinants, with viral genes deleted, were tested in 
mice and demonstrated the ability to enhance the CD4 and CD8 T cell responses 
elicited by the parental MVA-B and NYVAC-C vectors (Garcia-Arriaza et al., 2014; 
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Gomez et al., 2012b).  In this new generation of HIV vaccine candidates, MVA-C 
lacking the C6L gene alone (Garcia-Arriaza et al., 2011) or bearing the K7R (Garcia-
Arriaza et al., 2013) or A41L/B16R genes (Garcia-Arriaza et al., 2010) specifically 
increase the Gag-Pol CD8 T cell response.  In contrast, NYVAC-C that lacks the B8R 
gene alone or bears B19R (Gomez et al., 2012b), or MVA-B lacking the N2L gene 
(Garcia-Arriaza et al., 2014) specifically increased the Env CD8 T cell response. 
 
1.3.2  Leishmania:  VACV vaccine and T cell response 
 In human and in murine models of Leishmania major infection, polyfunctional CD4 
T cells correlate with vaccine-mediated protection!(Macedo et al., 2012).  VACV that 
expresses LACK antigen protects partially against Leishmania infection (Gonzalo et al., 
2001). MVA has been used as a safe, efficient vector for vaccination against 
leishmaniasis in mice (Perez-Jimenez et al., 2006), where it can induce a polyfunctional, 
long-term, LACK-specific CD4 T cell response (Sanchez-Sampedro et al., 2012).  It 
was recently shown that M65, an attenuated, replication-competent vaccinia virus strain 
that expresses LACK antigen, preferentially induces a CD4 T cell response that 
correlates with protection after Leishamina major challenge (Sanchez-Sampedro et al., 
2013). 
Following Leishmania major infection, the T cell response is principally formed by T 
helper (Th) 2 cells, due to the Th2 immunogenicity of the LACK antigen (Mougneau et 
al., 1995).  The Th2 response is associated to greater susceptibility to Leishmania 
infection in mice (Launois et al., 2007).  Th1 cell lines expressing IL-2 and IFN-γ 
induced resistance to parasite infection compared to the Th2 clones expressing IL-4 and 
IL-5, which showed greater susceptibility (Scott et al., 1988).  IL-4, -13 and -10 and 
TGF-β are the principal cytokines in the Th2 response and inhibit the macrophage 
activation that controls infection (Reiner and Locksley, 1995).  IFN-γ and/or TNF-α 
(Th1 cytokines) regulate macrophage activation and, by inducing nitric oxide, control 
parasite expression (Figure 8) (Ding et al., 1988). 
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Although CD8 effector memory T cells are the major subtype present after human 
cutaneous leishmaniasis infection!(Khamesipour et al., 2012) and probably induce Th1 
polarization, CD8 T cells positive for CD107a (a surrogate marker for induction of cell 
killing) correlate with necrosis intensity and lesion size in leishmaniasis (Santos Cda et 
al., 2013).  The magnitude of the CD4 T cell response is the major determining factor 
for the outcome of Leishmania infection (Xin et al., 2011), and CD4 T effector memory 
cells are necessary for protection against reinfection! (Peters et al., 2014).  IL-10 
influences the magnitude and quality of the Th1 response, which correlates with 
protection against Leishmania infection in human (Darrah et al., 2010; Darrah et al., 
2007).  
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Figure 8. A model of pathology 
and protective capacity for 
Leishmania intracellular 
antigens. Intracellular parasite 
antigens are presented to the 
immune system during the natural 
course of infection and stimulate 
antigen-specific Th2-mediated 
humoral responses.  The 
induction of a Th1 immune 
response is an approach to the 
development of Leishmania 
vaccines (adapted from Soto et 
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2009). 
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1.4. Gene expression optimization 
Optimization of poxvirus-based vaccines focuses on improving the generation of 
immune responses to the heterologous antigen.  The regulation of antigen expression 
levels is an alternative vaccine design strategy adopted to induce antigen-specific 
immune responses (Wyatt et al., 2008). 
The late-early vaccinia p7.5 promoter (Cochran et al., 1985) was the first used to 
induce heterologous antigen expression.  Removal of poxvirus transcription termination 
signals from inserted genes!(Earl et al., 1990), the regulation of gene expression under 
the bacteriophage T7 promoter (Fuerst et al., 1987), the vaccinia modified H5 (mH5) 
promoter (Wyatt et al., 1996) and the vaccinia short early-late synthetic promoter (pS) 
(Chakrabarti et al., 1997) have all been used as alternatives to p7.5 to increase the 
quantity of heterologous antigen expressed during infection. 
 
1.4.1 VACV promoters 
Studies of VACV show that the efficiency with which an antigen is processed and 
presented on the surface of infected cells influences its recognition by immune system 
cells (Moutaftsi et al., 2009); 90% of all VACV antigens recognized by CD8 T cells 
rank in the top 50% in terms of temporal mRNA expression (Sette et al., 2009).  The 
timing of viral antigen expression correlates with the generation of antigen-specific 
CD8 T cell immune responses (Bronte et al., 1997).  CD8 T cells specific to early 
expressed antigens have a proliferative advantage over late antigen-specific T cells 
(Kastenmuller et al., 2007).  For this reason, efforts to develop new poxvirus vaccine 
candidates focus on using promoters to improve the timing of antigen expression and 
thus increase immune responses. 
Vaccinia virus genes are classified as early, intermediate and late by the timing of 
expression after virus entry into the cell; their promoters have also been defined in these 
three classes (Yang et al., 2013; Yang et al., 2011).  After the analysis of the VACV 
transcriptome, two research groups defined two categories of early genes based on their 
temporal expression (Assarsson et al., 2008; Yang et al., 2010a).  Using a genome tiling 
array approach, Assarsson et al. differentiated the immediate-early genes from the early 
genes.  Yang et al. used deep RNA sequence analysis to differentiate E1.1 from E1.2 
genes as subclusters of early genes, and also defined a 15-nucleotide consensus 
sequence (AAAA-TGAAAA---A) that corresponds to the core of early gene promoters. 
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The core promoter of E1.1 genes corresponds more closely to the consensus sequence 
than those of E1.2 genes, suggesting that this difference could explain the readiness of 
E1.1 genes to be recognized by the transcription machinery compared to E1.2 genes 
(Yang et al., 2010b). 
Based on these studies, endogenous poxviral early promoters have been compared 
with the p7.5 and pS promoters.  The pC11R and pF11L early promoters induced high 
early antigens expression and T cell immunogenicity to the antigen; these levels were 
similar to those of p7.5 and pS promoters (Orubu et al., 2012).  More recent studies 
demonstrated the possibility of designing poxvirus promoters to improve early antigen 
expression and antigen-specific T cell responses.  Synthetic early promoters such as 
psFJ1-10 (Isshiki et al., 2014) or pHyb (Baur et al., 2010) and native early promoters 
like PrMVA13.5-long (Wennier et al., 2013) have early repeated core sequences.  
Compared to p7.5 and pS, these new promoters, which differ in their early motif 
sequence and in spacer lengths between the gene and the core promoter, are able to 
increase expression of heterologous antigens and the antigen-specific immune 
responses.  They are prototypes for the generation of safe recombinant poxvirus-based 
vaccines to potentiate antigen expression and the immune responses. 
 
 
42
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
  
43
 44
Objectives 
 
 
2. Objectives 
 
Given the current interest in vaccinia virus (VACV) as vaccine vector and its 
optimization as immunogen, various strategies and distinct VACV-based vaccine 
candidates have been developed to improve foreign antigen-specific T cell immune 
responses. 
This work is focused on: 
 
• VACV-dependent activation of the NFκB signaling pathway to increase 
neutrophil migration and T cell responses to HIV antigens 
 
• VACV promoter modifications to enhance antigen expression and T cell 
responses to GFP and Leishmania LACK antigens. 
 
We proposed the following objectives: 
1. Define the mode of action of VACV inhibitors on the NFκB pathway 
2. Describe how VACV modulates the innate immune response 
3. Analyze the role of neutrophils in the generation of T cell responses 
4. Characterize HIV-specific T cell responses 
5. Identify new VACV early promoters 
6. Understand the role of the early promoter sequence in early antigen expression 
7. Demonstrate the role of early promoter spacers in early antigen expression 
8. Study how the timing of antigen expression influences T cell responses 
9. Examine the GFP-specific T cell response profile 
10. Characterize the Leishmania LACK-specific T cell responses. 
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3.1 Summary 
 
3.1.1 NFκB activation by modified vaccinia virus as a novel strategy to enhance 
neutrophil migration and HIV-specific T cell responses 
In the vaccine research, there is major interest in understanding poxvirus vector 
function in the host and its manipulation to trigger optimal immune responses to HIV 
antigens.  Whereas attenuated vaccinia virus (VACV) is a commonly used vector model 
for vaccine development, poxviruses use a sophisticated strategy to escape immune 
surveillance by expressing inhibitory molecules that could compromise immune 
response and thus, vaccine efficiency.  In the context of VACV infection, neutrophils 
generate virus-specific CD8 T cells, but it was nonetheless not known how VACV 
modulates neutrophil recruitment and its significance in immune response triggering. 
To respond to these questions, we generated NYVAC, a highly attenuated VACV 
strain, that expresses HIV-1 clade C antigens but lacks specific viral genes (A52R, K7R, 
B15R).  These genes encode NFκB pathway inhibitors that limit pro-inflammatory 
cytokine/chemokine-dependent neutrophil recruitment.  Using single, double and triple 
deletion mutants, we demonstrated that these genes cooperate to inhibit the NFκB 
signaling pathway, and that combined deletion was necessary for efficient pathway 
triggering. 
Mice treated with this NYVAC-C ΔA52RΔB15RΔK7R vector showed enhanced 
immune responses, based on increased neutrophil recruitment to the viral infection site.  
This recruitment depended on NFκB pathway activation and was essential for induction 
of T cell immune responses to the HIV Gag/Pol antigens delivered by the vector.  To 
generate this response, outgoing neutrophil traffic from the infection site to various 
lymphoid organs was necessary.  After virus infection, NFκB pathway activation led to 
expression of several cytokines and chemokines that recruit specific neutrophil 
populations (Nα and Nβ) to the infection site.  Nβ neutrophils had an enhanced 
activation profile, higher levels of antigen-presenting cell markers, and greater capacity 
to induce antigen-specific T cell activation than Nα cells. These findings suggest a 
design strategy for poxvirus vector use as vaccines. 
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Neutrophils are antigen-transporting cells that generate vaccinia
virus (VACV)-specific T-cell responses, yet how VACV modulates
neutrophil recruitment and its significance in the immune response
are unknown. We generated an attenuated VACV strain that ex-
presses HIV-1 clade C antigens but lacks three specific viral genes
(A52R, K7R, and B15R). We found that these genes act together to
inhibit the NFκB signaling pathway. Triple ablation in modified virus
restored NFκB function in macrophages. After virus in-fection of
mice, NFκB pathway activation led to expression of several cyto-
kines/chemokines that increased the migration of neutrophil popu-
lations (Nα and Nβ) to the infection site. Nβ cells displayed features
of antigen-presenting cells and activated virus-specific CD8 T cells.
Enhanced neutrophil trafficking to the infection site correlated with
an increased T-cell response to HIV vector-delivered antigens. These
results identify a mechanism for poxvirus-induced immune response
and alternatives for vaccine vector design.
vaccinia virus | neutrophils | NFκB | vaccine | HIV
Although attenuated vaccinia virus (VACV) is a commonlyused vector model for vaccine development (1), poxviruses
have a sophisticated strategy to escape immune surveillance by
expressing inhibitory molecules, which could compromise im-
mune response and thus vaccine efficiency. VACV encodes
several proteins involved in host immune evasion that limit virus
recognition by innate immune cells such as neutrophils and could
affect the virus’s ability to induce adaptive immunity (2).
During microbial invasion, neutrophils counteract infection
immediately in a process termed microbial sterilization (3), for
which they engulf extracellular pathogens and infected and
apoptotic cells (4, 5), they produce reactive oxygen intermediates
(6), they release lytic enzymes and antimicrobial peptides from
their granules (3), and they generate neutrophil extracellular
traps (7). Neutrophils can induce an adaptive immune response
after migrating to the lymph nodes (8) and efficiently cross-
prime naïve T cells (9). In the presence of a granulocyte mac-
rophage–colony-stimulating factor (GM-CSF) (10), tumor ne-
crosis factor (TNF)-α, interleukin (IL)-4 (11), or interferon
(IFN)-γ (12), neutrophils can adopt an antigen-presenting cell
(APC) phenotype, thus triggering T-cell activation. In the con-
text of VACV infection, neutrophils generate virus-specific
memory CD8 T cells, transporting antigens from the dermis to
the bone marrow (BM) (13). It is nonetheless not known how
VACV modulates neutrophil recruitment, the factors involved,
or the significance in immune response triggering.
Proinflammatory cytokine/chemokine production by an infected
cell, which signals the recruitment of neutrophils involved in the
immune response, is limited by inhibition of signaling pathways
such as nuclear factor kappa B (NFκB) (2). NFκB pathway acti-
vation depends on the virus’s capacity to interact with Toll-like
receptors (TLRs). Viral pathogen-associated molecular patterns
interact with TLR2 and TLR4 on the plasma membrane (14).
Pathogen-associated molecular pattern binding induces TLR2 and
TLR4 homo- or heterodimerization (15), followed by recruitment
of Toll/IL-1 receptor (TIR) domain-containing adaptor proteins
such as myeloid differentiation factor 88 (MyD88) and TIR
domain-containing adapter protein (TIRAP)/MyD88 adaptor-like
(MAL) or TIR domain-containing adapter-inducing IFNβ (TRIF)
and TRIF-related adaptor molecule (TRAM) (14). In the MyD88-
dependent and the TRIF-dependent pathways, activation of TNF
receptor-associated factor 6 results in IκBα phosphorylation and
degradation, allowing release of the NFκB complex, composed of
p65/p50 or p65/p52 heterodimers, into the cell nucleus. NFκB then
binds the κB site and regulates transcription of proinflammatory
cytokine and chemokine genes (14).
VACV interacts with TLR2 (16) and TLR4 (17) and produces
early direct or indirect viral inhibitors of the NFκB pathway such
as A46 (18), A49 (19), A52 (18), B14 (20), C4 (21), E3 (22), K1
(23), K7 (24), M2 (25), and N1 (26). New York vaccinia virus
(NYVAC), a highly attenuated VACV strain used as vaccine
vector, lacks most of these proteins but encodes NFκB pathway
Significance
Although poxvirus vectors are widely used in preclinical and
clinical trials as candidate vaccines for multiple pathogens, how
these vectors affect the host immune response is not clear. In
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inhibitors A52, K7, and B15 (corresponding to B14 in the
Western Reserve strain) (2).
Given the interest in attenuated VACV vectors as vaccine can-
didates and their optimization as immunogens (1), we generated
several NYVAC deletion mutants that express HIV-1 Envelope
(Env) and group-specific antigen (Gag)–polymerase (Pol)–negative
regulatory factor (Nef) clade C antigens (NYVAC-C) but lack
specific genes to encode NFκB inhibitors. We show that A52, K7,
and B15 viral proteins inhibit the NFκB pathway in macrophages
and that infection with a virus that lacks these three inhibitors
results in NFκB pathway activation. NFκB-dependent induction of
cytokines and chemokines is enhanced in vitro and in vivo by
NYVAC-C ΔA52RΔB15RΔK7R and is essential for specific neu-
trophil recruitment to the infection site. Neutrophils acquire fea-
tures of APCs, activate antigen-specific T cells, and migrate to the
draining lymph nodes and to the spleen, where they induce antigen-
specific CD8 T-cell responses. These findings provide important
insights into the mechanism of the poxvirus-induced immune re-
sponse, which is relevant in vaccine vector design.
Results
Concomitant Deletion of A52R, B15R, and K7R Genes in NYVAC Leads
to Enhanced NFκB Pathway Activation. To define the immune
modulatory role of the VACV viral genes that antagonize the NFκB
pathway, we generated single, double, and triple deletion mutants
for the viral genes encoding A52, K7, and B15 (Materials and
Methods), using as a backbone the NYVAC-C vector expressing
HIV-1 clade C antigens Env (gp120) as a cell-released product and
Gag-Pol-Nef (GPN) as an intracellular polyprotein (27). With this
targeted gene disruption, we generated the following NYVAC de-
letion mutants: NYVAC-CΔB15R, NYVAC-CΔA52R, NYVAC-C
ΔK7R, NYVAC-C ΔB15RΔK7R, NYVAC-C ΔA52RΔB15R,
NYVAC-C ΔA52RΔK7R, and NYVAC-C ΔA52RΔB15RΔK7R
(also termed triple deletion mutant or NYVAC-C Δ3 for short).
Gene deletion was confirmed by PCR, using primers annealed to
flanking sequences of each gene (Fig. S1A). The gp120 and GPN
HIV-1 proteins were expressed correctly by each deletion mu-
tant, as confirmed by Western blot (Fig. S1B).
To determine the contribution of the NYVAC inhibitors to
NFκB activation, we infected murine J774 macrophages with the
different single, double, and triple NYVAC-C deletion mutants
and performed a time-course assay to evaluate IκBα phosphor-
ylation. We observed a clear increase in the level of IκBα
phosphorylation in NYVAC-C Δ3-infected J774 cells compared
with the parental or the other deletion mutants. As predicted,
this phosphorylation was accompanied by enhanced IκBα deg-
radation (Fig. 1A). Similar results between parental virus and
NYVAC-C Δ3 were obtained following infection of human
THP-1 monocytes differentiated into macrophages (Fig. S2A).
To confirm that increased IκBα phosphorylation in triple de-
letion mutant-infected cells enhanced NFκB activity, we used
electrophoretic mobility shift assay (EMSA) to analyze NFκB
binding to its consensus binding sequence motif and an immu-
nofluorescence assay to detect p65 translocation from the cyto-
plasm to the nucleus. EMSA indicated marked NFκB pathway
activation in NYVAC-C Δ3-infected macrophages, with a two-
fold increase from 3 to 5 h postinfection compared with
NYVAC-C–infected macrophages (Fig. 1B), which was con-
firmed by immunofluorescence of p65 migration from the cyto-
plasm to the nucleus (Fig. 1C). These results suggest that these
genes (A52R, K7R, and B15R) must be removed concomitantly
from the viral vector to induce robust pathway activation fol-
lowing VACV infection.
A variety of cytokines and chemokines are known NFκB target
genes. We therefore analyzed their secretion in supernatants of
J774 macrophages infected with the various deletion mutants.
Compared with parental and other deletion mutant viruses,
only NYVAC-C Δ3-infected cells showed significantly increased
production of cytokines such as TNF-α and IL-6 at 24 h post-
infection (Fig. S2B) and of chemokines such as macrophage in-
flammatory proteins (MIPs)-1α, -1β, and -2 at 4 h postinfection
(Fig. 1D). We observed a similar chemokine/cytokine profile in
primary peritoneal macrophages infected with the NYVAC-C
deletion mutants (Fig. S2C). These data indicate enhanced
NFκB-dependent chemokine and cytokine secretion after mac-
rophage infection with the NYVAC-C Δ3.
To demonstrate that only one of the three inhibitory molecules
is sufficient to abolish NFκB activation, we generated the re-
vertant NYVAC-C Δ3 K7R-rev virus, in which the K7R gene was
reinserted in the HA locus (Fig. S1C); expression was confirmed
by RT-PCR (Fig. S1D). IκBα phosphorylation, degradation, and
chemokine secretion levels in NYVAC-C Δ3 K7R-rev–infected
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Fig. 1. Deletion of A52R, B15R, and K7R genes induces robust NFκB activa-
tion. (A) Phosphorylated and total IκBα forms analyzed by Western blot (WB)
in J774 mouse macrophages infected with NYVAC-C or NYVAC-C deletion
mutants (5 PFUs per cell) for 1, 2, and 4 h. α-tubulin was used as the internal
loading control. (B) J774 nuclear extracts incubated with 32P-end–labeled NFκB
probe and assayed by EMSA for DNA binding complexes at 2, 3, 4, and 5 h
postinfection with NYVAC-C or NYVAC-C Δ3. Histone H2A was used as the
internal loading control for WB. Bars show the ratio of NFκB probe bands to
histone H2A bands, quantified using ImageJ. (C) Confocal microscopy of mock-,
NYVAC-C–, or NYVAC-C Δ3-infected J774 cells (3 h postinfection). Cells were
stained with antibodies to E3 VACV protein (red), p65 cell protein (green),
and DAPI probe to detect DNA (blue). (Scale bars, 5 μm.) (D) Concentrations
of chemokines MCP-1, MIP-1α, MIP-1β, and MIP-2 at 4 h postinfection,
quantified by immunoassay in supernatants of J774 cells infected as in-
dicated. (E) Phosphorylated and total IκBα forms analyzed by WB in J774
mouse macrophages infected with NYVAC-C, NYVAC-C Δ3, or NYVAC-C Δ3
K7R-rev (5 PFUs per cell) for 1, 2, and 4 h. α-tubulin was used as the internal
loading control. Bars show the ratio of phospho- or total IκBα bands to
α-tubulin bands, quantified with ImageJ. (F) Concentrations of chemokines
MCP-1, MIP-1α, MIP-1β, and MIP-2 at 4 h postinfection, quantified by im-
munoassay in supernatants of NYVAC-C–, NYVAC-C Δ3-, or NYVAC-C Δ3
K7R-rev–infected J774 macrophages. Values show mean ± SEM of duplicates,
representative of three independent experiments. ***P < 0.001, **P < 0.01.
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J774 macrophages resembled those of the same cells infected
with NYVAC-C (Fig. 1 E and F).
Increased in Vitro and in Vivo Neutrophil Migration After NYVAC-C
Δ3 Infection. Because chemokines such as MCP-1, MIP-1α, -1β,
and -2 or keratinocyte chemoattractant (KC) are essential for re-
cruitment of several cell types, we tested whether a specific cell
subset responds to this chemokine–cytokine mixture. We used an in
vitro migration assay in which total murine BM cells were allowed
to migrate after stimulation with supernatants of the different
NYVAC-infected (4 h) J774 macrophages. Only neutrophils
(Ly6G+CD11b+) exposed to NYVAC-C Δ3-infected macrophage
supernatants showed significantly more migration compared with
the parental virus or the other deletion mutants (Fig. 2A). Mi-
grated neutrophils showed the same percentages of early and late
apoptotic cells when stimulated with supernatants of NYVAC-C–
and NYVAC-C Δ3-infected J774 macrophages (Fig. S3A).
In a similar experiment, we used a supernatant of J774 cells
pretreated with JSH-23, an inhibitor of p65 translocation to the
nucleus (28), and then infected it with the NYVAC virus. The
number of neutrophils that migrated toward supernatants of JSH-
23–treated NYVAC-C Δ3-infected cells was significantly lower than
those that migrated to supernatants of untreated NYVAC-C Δ3-
infected cells and was similar to the other NYVAC-C deletion
mutants (Fig. 2A). These data show that NFκB activation underlies
the differences in neutrophil migration induced by the triple de-
letion mutant virus and its parental strain.
To determine whether infection with the triple mutant virus
also leads to increased neutrophil migration in vivo, BALB/c
mice were infected by i.p. injection of 107 plaque-forming units
(PFUs) of NYVAC-C or NYVAC-C Δ3. Peritoneal exudate cells
(PECs) were collected 1 h postinfection to study NFκB activa-
tion. In PECs of NYVAC-C Δ3-infected mice, IκBα phosphor-
ylation was significantly higher than in PECs of parental virus-
infected mice (Fig. 2B). At 3 and 6 h postinfection, mice that
received the triple deletion mutant virus showed a significant
increase in neutrophils (Ly6G+CD11b+) in the peritoneal cavity
compared with NYVAC-C–infected mice (Fig. 2 C and D).
There were no differences in monocytes (M), macrophages
(Mϕ), B cells (B), or T cells (T) (Fig. 2 C and D), which indicated
that in the first 6 h of infection, the triple deletion mutant virus
promotes neutrophil migration to the infection site before mi-
gration of the other hematopoietic cells. After 12 h, we detected
no difference in neutrophil migration, but triple deletion mutant
virus-infected mice showed a significant increase in monocytes
compared with NYVAC-C–infected mice; resident macrophages
were absent for both viruses (Fig. 2E). The infection kinetics
indicates that neutrophil migration precedes monocyte migration
in NYVAC-C Δ3-infected mice.
To rule out the possibility that increased neutrophil re-
cruitment was caused by differences in virus infective capacity,
we replaced the HIV-1 antigen cassette with the GFP gene to
generate NYVAC-GFP and NYVAC-GFP Δ3 viruses, which
were injected (107 PFUs; i.p.) into BALB/c mice. At 3 h post-
infection, comparison of NYVAC-GFP Δ3- and NYVAC GFP-
injected mice showed similar percentages of GFP+ cells in PEC
types (neutrophils, monocytes, macrophages, and B and T cells;
Fig. 2F). These percentages indicate that both viruses have
similar in vivo infective capacities and that macrophages, which
constitute ∼20% of the total peritoneal cell yield, are the most
susceptible cell type to NYVAC infection (∼80%). The absolute
numbers of GFP+ cells indicated that only GFP+ neutrophils
were significantly higher in NYVAC-GFP Δ3- than in NYVAC-
GFP–infected mice (Fig. S3B), due to a significant increase in
neutrophil migration in NYVAC-GFP Δ3- compared with
NYVAC-GFP–infected mice (Fig. S3C).
The peritoneal exudates of NYVAC-C Δ3-infected mice (6 h
postinfection) showed significantly higher levels of cytokines
such as IL-6 and chemokines such as MCP-1, MIP-1β, and MIP-2
compared with those of NYVAC-C–infected mice (Fig. 2G). We
detected no difference in IL-8 secretion between these two
groups (Fig. S3D). To demonstrate that the neutrophils were
recruited by increased cytokine/chemokine secretion at the in-
fection site, peritoneal exudate pools of 6-h NYVAC-C– and
NYVAC-C Δ3-infected mice, free of PECs and viruses, were
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Fig. 2. Increased neutrophil recruitment after NYVAC-C Δ3 infection.
(A) Absolute number of BM neutrophils that migrated after stimulation with
supernatants of virus-infected J774 cells (4 h). J774 cells were untreated or
pretreated with the p65 inhibitor JSH-23 (30 μM). (B) Phosphorylated IκBα
form analyzed by WB in PECs of BALB/c mice at 1 h after injection with PBS
or 107 PFUs of NYVAC-C or NYVAC-C Δ3. α-tubulin was used as the internal
loading control. Each point represents the ratio of phospho-IκBα to α-tubulin
bands in individual mice, as quantified by ImageJ. Boxes with dashed lines
indicate the ratio for PBS-injected mice. Absolute numbers of neutrophils
(N), monocytes (M), macrophages (Mϕ), B cells (B), and T cells (T) in the
peritoneal cavity of BALB/c mice at 3 h (C), 6 h (D), and 12 h (E) after in-
jection of 107 PFUs of NYVAC-C or NYVAC-C Δ3. Boxes with dashed lines
indicate absolute numbers for PBS-injected mice. (F) Percentages of GFP+
neutrophils (N), monocytes (M), macrophages (Mϕ), B (B), and T cells (T) in
the peritoneal cavity of NYVAC-GFP– or NYVAC-GFP Δ3-injected (107 PFUs)
mice at 3 h postinfection. (G) Cytokine/chemokine levels at 6 h postinfection
in peritoneal exudates of PBS-, NYVAC-C–, or NYVAC-C Δ3- (107 PFUs)
injected mice (n = 5 per group). (H) Absolute number of neutrophils (N) in
the peritoneal cavity of mice 6 h after injection of NYVAC-C– or NYVAC-C
Δ3-peritoneal exudates at 6 h postinfection. Boxes with dashed lines indicate
total numbers in PBS-peritoneal exudate-injected mice. (I) Absolute numbers
of neutrophils (N) in the peritoneal cavity of C57/BL6J WT, CCR1 KO, and
CCR5 KO mice at 6 h after injection with PBS or 107 PFUs of NYVAC-C or
NYVAC-C Δ3. Boxes with dashed lines indicate absolute numbers of cells in
PBS-injected mice. (J) Absolute numbers of neutrophils (N) in the peritoneal
cavity of BALB/c mice at 6 h after injection with 107 PFUs of NYVAC-C,
NYVAC-C Δ3, or NYVAC-C Δ3 K7R-rev. Boxes with dashed lines indicate
absolute numbers of cells in PBS-injected mice. Graphs show mean ± SEM;
each point represents an individual mouse. Data are representative of two
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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injected i.p. into mice, and neutrophils in the peritoneal cavity
were analyzed at 6 h postinfection. Total neutrophils in NYVAC-C
Δ3-peritoneal exudate-injected mice were significantly higher com-
pared with those in NYVAC-C–peritoneal exudate-injected mice
(Fig. 2H). These data indicate that enhanced neutrophil re-
cruitment was dependent on cytokine/chemokines produced
during the infection.
To determine the chemokine(s) involved in increased neu-
trophil migration in NYVAC-C Δ3-infected mice, we performed
the same experiment in C57/BL6J CCR1 and CCR5 knockout
(KO) mice, which are deficient in the CCR1 and CCR5 recep-
tors involved in binding the chemokines MIP and MCP. Total
neutrophil number in the peritoneal cavity of NYVAC-C Δ3-
infected CCR1 KO mice was significantly lower compared with
NYVAC-C Δ3-infected wild-type (WT) mice, although not as
low as in NYVAC-C–infected CCR1 KO mice (Fig. 2I). There
were no differences between CCR5 KO and WT mice (Fig. 2I).
These data suggest that the increased neutrophil migration is
mediated partially by CCR1 and not by CCR5.
To demonstrate that the enhanced neutrophil migration in
NYVAC-C Δ3-infected mice is NFκB-dependent, we infected mice
with NYVAC-C Δ3 K7R-rev and analyzed PEC neutrophils at 6 h
postinfection. The revertant virus induced a significant decrease in
neutrophil number compared with the NYVAC-C Δ3 virus and
resembled the value for the NYVAC-C virus (Fig. 2J).
Enhanced Neutrophil Trafficking After NYVAC-C Δ3 Infection. To
determine how neutrophil trafficking after NYVAC-C Δ3 in-
fection occurs, we quantified neutrophils in BM, spleen, lymph
nodes, peripheral blood, and omentum. We included omentum
in this analysis as it is the primary site of neutrophil exudation and
mediates recruitment from circulation to the peritoneal cavity.
NYVAC-C Δ3-infected mice had significantly fewer neutrophils in
BM but more neutrophils in blood and a larger percentage of
neutrophils in omentum than NYVAC-C–infected mice (Fig. 3A).
These changes were the result of increased IL-6, KC, MCP-1, and
MIP-1β production in sera of triple deletion mutant-infected mice
compared with those infected with the parental strain (Fig. 3B). No
differences were detected in IL-8 levels between the two groups
(Fig. S3E). Compared with neutrophils, at 6 h NYVAC-C Δ3-
infected mice had significantly more monocytes (CD115+) in the
blood than NYVAC-C–infected mice, but we found no difference
between the two groups in the percentage of monocytes in BM or
omentum (Fig. S3F).
In the secondary lymphoid organs such as the spleen and medi-
astinal lymph nodes (MLNs), we found significantly more neu-
trophils in NYVAC-C Δ3- than in NYVAC-C–infected mice (Fig. 3
C and D). In MLNs and in the spleen of NYVAC-C Δ3-infected
mice, the absolute number of neutrophils was significantly reduced
from 6 to 12 h postinfection (Fig. 3 C and D). We also detected
a significant increase in neutrophil death from 6 to 12 h in the
spleens of NYVAC-C Δ3- compared with NYVAC-C–infected
mice (Fig. S3G), as well as a clear trend (P = 0.07) in increased
MLN neutrophil death (Fig. S3H). This increase could explain the
significant reduction in spleen and MLN neutrophils from 6 to 12 h.
To test a common human immunization route, BALB/c mice
also received intramuscular injections of NYVAC-C or NYVAC-C
Δ3 viruses. NYVAC-C Δ3 induced a significant neutrophil
increase in the spleen at 12 h postinfection (Fig. 3E) and in
draining popliteal lymph nodes (PLNs) at 6 and 12 h post-
infection (Fig. 3F) compared with NYVAC-C.
These data indicate that neutrophil migration occurs in
a specific time window and is enhanced after NYVAC-C Δ3
infection. Neutrophils abandon BM, enter the blood stream, and
through the omentum reach the infection site, where they en-
counter infected cells; they subsequently leave toward secondary
lymphoid organs to initiate an adaptive immune response.
Neutrophils Act as APCs After NYVAC-C Δ3 Infection. We next
characterized the neutrophil population recruited to the perito-
neum after infection. Using flow cytometry, we found two pop-
ulations that differed in cell size and complexity, which we
termed Nα and Nβ (Fig. 4A). To evaluate the morphology of Nα
and Nβ populations, we sorted Ly6G+ cells. Both populations
had clear neutrophil-like morphology, but Nβ cells were larger,
more lobulated, and more hypersegmented than Nα cells (Fig.
4B). In PECs, the Nα subset showed a fourfold increase, whereas
the Nβ subset showed a 20-fold increase in NYVAC-C Δ3-
infected compared with parental virus-infected mice (Fig. 4C).
We tested whether acquisition of the Nβ profile depended on
direct virus infection of neutrophils or on the cytokine/chemokine
milieu produced after infection. Mice were initially infected with
NYVAC-C or NYVAC-C Δ3 to induce neutrophil recruitment to
the peritoneal cavity and subsequently injected with NYVAC-GFP
or NYVAC-GFPΔ3 to infect the migrated neutrophils. Most GFP+
neutrophils in mice infected with the parental or triple deletion
mutant virus had a Nβ-like profile (Fig. 4D), indicating that Nβs
were more susceptible to the infection than Nα cells. The majority
of Nβ neutrophils were GFP− in both mouse groups (Fig. 4E),
which indicated that neutrophil viral infection was not directly re-
sponsible for Nβ subset generation. As predicted, the Nβ population
(GFP+ and GFP−) was higher in the NYVAC-C Δ3- than in
NYVAC-C–infected mice (Fig. 4E). To demonstrate that Nβ and
Nα were recruited by increased cytokine/chemokine secretion at
the infection site, peritoneal exudate pools of 6 h NYVAC-C–
and NYVAC-C Δ3-infected mice, free of PECs and viruses, were
injected i.p. into mice; neutrophils in the peritoneal cavity were
analyzed at 6 h postinfection. The absolute numbers of Nα and Nβ
neutrophils in NYVAC-C Δ3-peritoneal exudate-injected mice
were significantly higher than those of NYVAC-C–peritoneal
exudate-injected mice (Fig. S4A).
Examination of Nβ neutrophils in the spleen and MLNs of
NYVAC-C Δ3-infected mice showed significantly more Nβ cells
than in NYVAC-C–infected mice (Fig. 4F).
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Fig. 3. Increased neutrophil trafficking after NYVAC-C Δ3 infection.
(A) Percentages of neutrophils in BM and omentum, and total number of
neutrophils in blood at 6 h postinfection, from NYVAC-C– or NYVAC-C Δ3-
injected mice. Boxes with dashed lines indicate absolute numbers of cells in
PBS-injected mice. (B) Cytokine/chemokine levels at 6 h postinfection in se-
rum of PBS-, NYVAC-C–, or NYVAC-C Δ3-injected mice (n = 5 per group).
Shown are total neutrophil numbers in spleen (C) and MLNs (D) at 6 and 12 h
postinfection, from NYVAC-C– or NYVAC-C Δ3-injected mice, as well as the
total neutrophil numbers in spleen (E) and PLNs (F) at 6 and 12 h post-
intramuscular infection, from NYVAC-C– or NYVAC-C Δ3-injected mice.
Boxes with dashed lines indicate absolute numbers of cells in PBS-injected
mice. Graphs show mean ± SEM; each point represents an individual mouse.
Data are representative of two independent experiments. *P < 0.05, **P <
0.01, ***P < 0.001.
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To characterize Nα and Nβ neutrophil phenotype in NYVAC-C
Δ3-infected mice, we analyzed the expression of several surface
markers including the CD11b activation marker involved in neu-
trophil adhesion and migration, MHC class I and class II molecules
used for presentation of antigenic determinants to T cells, the
CD11c dendritic cell (DC) marker, and CD80/CD86 APC cos-
timulatory markers involved in T-cell activation. All neutrophils
expressed CD11b, MHC class I, and CD80 markers. The percentage
of Nβ neutrophils that expressed MHC class II, CD11c, or CD86
was significantly higher than Nα cells (Fig. 4G). Moreover, levels of
all surface markers were higher in Nβ than in Nα neutrophils, with
significant differences in most cases (Fig. 4H). These results indicate
that Nβs have a more APC-like profile than Nα neutrophils.
To demonstrate the APC potential of Nα and Nβ neutrophils,
both populations were sorted for Ly6G+ (purity, >96%) and cell
size and then incubated 16 h with isolated spleen CD8 T cells
(purity, >97%; ratio, 1:20) from mice that received i.p. injections
of NYVAC or PBS 90 d earlier. Ly6G+ neutrophils (purity,
>96%) sorted from i.p. thioglycolate-injected mice were used as
controls. We measured antigen-specific CD8 T-cell activation by
intracellular cytokine staining (ICS) of IL-2, IFN-γ, and TNF-α.
Nα cells alone did not induce antigen-specific CD8 T activation
(Fig. 4I): The number of cytokine-secreting CD8 T cells was
similar to thioglycolate-induced neutrophils (<0.01% of total CD8
T cells). The Nβ-enriched fraction induced a significant increase in
CD8 T-cell activation compared with Nα alone (Fig. 4I). The CD8
T-cell response in PBS-injected mice was subtracted for each
group; this response was <0.01% of total CD8 T cells, indicating
that the neutrophils did not activate naïve CD8 T cells. These data
indicate that Nα cells alone are unable to activate CD8 T cells and
that the presence of Nβ cells is sufficient to activate antigen-
specific CD8 T cells, suggesting that Nβs have an APC role.
Given the distinct roles of Nα and Nβ in CD8 T-cell activation,
we analyzed the Nβ/Nα ratio in the peritoneal cavity of poxvirus-
infected mice. In NYVAC-C Δ3-infected mice, this ratio was
significantly higher than in NYVAC-C–infected mice, and also
compared with MVA-WT– and MVA-C–infected mice (Fig. 4J).
The total neutrophil percentage in MVA-WT–, MVA-C–, or
NYVAC-C Δ3-infected mice was similar and significantly higher
than in NYVAC-C–infected mice (Fig. S4B).
NYVAC-C Δ3 Enhances the HIV-Specific T-Cell Response Through
Neutrophil Migration. To study the ability of NYVAC-C Δ3 to
induce a specific T-cell response to HIV-1 antigens, we used a
DNA intramuscular prime/poxvirus i.p. boost approach. This
heterologous immunization protocol is more immunogenic than
a homologous combination in activating T-cell responses to
HIV-1 antigens (27).
BALB/c mice were immunized (Materials and Methods), and
adaptive T-cell immune responses were measured by ICS of
spleen cells. To study the HIV-1–specific T-cell response, spleno-
cytes from infected mice were stimulated with HIV-1 Env-1,
Pol-1, or Pol-2 peptides, which are the most immunogenic MHC
class I-restricted cytotoxic T lymphocytes (CTLs) peptides of
HIV clade C in BALB/c mice (29) or with a pool of overlapping
Gag peptides. Alternatively, to study CD8 and CD4 T-cell re-
sponses to Env and GPN antigens, splenocytes were pulsed with
A20 cells previously nucleofected with the mammalian expres-
sion plasmids pcDNA-gp120 (Env) or pcDNA-GPN. To de-
termine the functional profile of CD4 and CD8 T cells, we
measured levels of IFN-γ, TNF-α, and IL-2 as well as of lyso-
somal-associated membrane protein-1 (LAMP-1 or CD107a) as
a surrogate marker for induction of killing. We determined the
magnitude of the T-cell response as the number of T cells that
expressed IFN-γ and/or TNF-α and/or IL-2 and/or CD107a and
the polyfunctionality of the response as T cell’s capacity to ex-
press more than one of these activation markers (13).
NYVAC-C Δ3 induced a significantly higher specific CD8
T-cell response to HIV intracellular antigens than NYVAC-C,
both when Pol and Gag antigens were analyzed separately (Fig.
5A) and when the overall GPN response was studied (Fig. 5B).
There were no significant differences between both viruses in the
magnitude of the specific CD8 T-cell response to the Env ex-
tracellular antigen, using either Env-1 peptide (Fig. S5A) or A20-
ENV+ (Fig. S5B). Neither virus induced a GPN-specific CD4
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Fig. 4. Nβ neutrophil population with APC features is involved in specific
activation of CD8 T cells after NYVAC-C Δ3 infection. (A) FACS plots de-
termined by forward scatter (FSC) and Ly6G, and side scatter (SSC) and FSC of
PEC from NYVAC-C Δ3-injected mice. Nα (black) and Nβ (green) neutrophil
subsets are shown as dot plots. (B) Hematoxylin/eosin staining of peritoneal
neutrophils presorted for Ly6G+. (Scale bar, 10 μm.) (C) Absolute number of
Nα and Nβ neutrophils in the peritoneal cavity at 6 h postinfection in
NYVAC-C– or NYVAC-C Δ3- (107 PFUs) injected mice. Boxes with dashed lines
indicate total number in PBS-injected mice. Graphs show mean ± SEM; each
point represents an individual mouse. (D) Nβ (dark green) and infected
neutrophils (N GFP+; light green) from PECs of NYVAC-GFP Δ3-infected mice.
(E) Absolute numbers of Nβ GFP+/− neutrophils in NYVAC-C (107 PFUs)/
NYVAC-GFP– (107 PFUs) or NYVAC-C Δ3 (107 PFUs)/NYVAC-GFP Δ3- (107 PFUs)
infected mice. Graphs show mean ± SEM; each point represents an individual
mouse. (F) Absolute numbers of Nβ neutrophils in MLNs and spleen at 6 h
postinfection of NYVAC-C– or NYVAC-C Δ3-injected mice. Boxes with dashed
lines indicate absolute number in PBS-injected mice. Graphs show mean ±
SEM; each point represents an individual mouse. (G) Percentages of Nα
(black) and Nβ (green) neutrophils positive for CD11c, MHC II, and CD86
markers. Graphs show mean ± SEM; each square represents an individual
mouse. (H) Layouts and median fluorescence intensity (MFI) of indicated
markers in Nα (black) and Nβ (green) neutrophils at 6 h postinfection in
NYVAC-C Δ3-injected mice. In gray is the isotype control. Columns show
mean ± SEM of five mice. (I) Total numbers of CD8 T cells per spleen se-
creting IFN-γ and/or TNF-α and/or IL-2 after stimulation with thioglycolate-
induced neutrophils, with virus-induced Nα, with virus-induced Nβ-enriched,
or with RPMI. Columns show mean ± SEM of triplicates. (J) Nβ:Nα ratio in
peritoneal cavity at 6 h postinfection in MVA-WT–, MVA-C–, NYVAC-C–, or
NYVAC-C Δ3- (107 PFUs) injected mice. Graphs show mean ± SEM; each point
represents an individual mouse. Data are representative of three in-
dependent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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T-cell response when stimulated with A20-GPN+. We detected
no differences in Env-specific CD4 T-cell response with A20-
Env+ between two-virus–infected mouse groups (Fig. S5C).
The quality of the Gag and Pol responses, defined as cytokine
production and cytotoxic potential, showed that compared with
the parental strain, the triple deletion mutant induced a marked
A
C
E
G
B
D
F
Fig. 5. NYVAC-C Δ3 enhances the magnitude and polyfunctionality of the CD8 T-cell response to HIV-1 Gag–Pol antigens. Vaccine-induced HIV-1–specific
CD8 T-cell response in mice (n = 4 per group) infected with 107 PFUs of NYVAC-WT, NYVAC-C, or NYVAC-C Δ3. The response was measured 11 d after the last
immunization, after splenocyte stimulation with HIV-1 peptides/pools or with A20 GPN+. Total value (magnitude) is the sum of total CD8 T cells per spleen
that secrete IFN-γ and/or TNF-α and/or IL-2 and/or CD107a. (A) Magnitude of Pol-1–, Pol-2–, or Gag pool-specific CD8 T-cell response. Graphs show mean ± CI.
(B) Magnitude of CD8 T-cell response to A20 GPN+. Graphs show mean ± CI. (C) Functional profile of adaptive Pol-1 + Pol-2–specific CD8 T cells. (D) Functional
profile of adaptive Gag pool-specific CD8 T cells. (E) Functional profile of adaptive GPN-specific CD8 T cells. Combinations of responses (x axis) and total
numbers of functionally distinct cell populations (y axis) are shown. Responses are grouped and color-coded based on the number of functions. Pie chart
colors indicate the percentage of cytokine-producing cells based on number of functions (inside) and the different activation markers (outside). (F) Absolute
number of Nα and Nβ neutrophils in the peritoneal cavity at 6 h postinfection in NYVAC-C– or NYVAC-C Δ3- (107 PFUs) injected and IgG2A-pretreated or 1A8-
pretreated mice. Boxes with dashed lines indicate absolute number in PBS-injected mice. Graphs show mean ± SEM; each point represents an individual
mouse. (G) Vaccine-induced HIV-1–specific CD8 T-cell response in mice (n = 4 per group) infected with 107 PFUs NYVAC-WT, NYVAC-C, or NYVAC-C Δ3 and
IgG2A-pretreated or 1A8-pretreated. The response was measured 11 d after the last immunization, after splenocyte stimulation with HIV-1 peptides/pools.
Total value (magnitude) is the sum of total CD8 T cells per spleen that secrete IFN-γ and/or TNF-α and/or IL-2 and/or CD107a. Graphs show mean ± CI. Data are
representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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increase in the CTL polyfunctional profile (Fig. 5 C and D). The
CD8 T-cell subset that produced IFN-γ, TNF-α, and CD107a
was the most representative population induced with Pol and
Gag peptides (Fig. 5 C and D) and with A20-GPN+ (Fig. 5E) in
triple deletion mutant-infected mice. This CD8 T-cell subset
marks the difference in the CTL polyfunctional profile between
two-virus–infected mice (Fig. 5 C–E, pie charts). These results
indicate that the triple deletion mutant enhances the magnitude
and the polyfunctional profile of specific CD8 T cells to HIV-1
GPN intracellular antigens.
We also used a DNA intramuscular prime/poxvirus intramuscular
boost to immunize and measured adaptive CD8 T-cell immune
responses by ICS in spleen cells. NYVAC-C Δ3 induced a signifi-
cantly higher specific CD8 T-cell response to HIV-1 Pol antigen
than NYVAC-C; no significant difference was found between two
groups in the response to Gag antigen (Fig. S5D).
To test whether neutrophils are involved in the enhanced
HIV-specific CTL response, we depleted these cells in vivo using
anti-Ly6G mAb 1A8 administered 24 h before virus boost (30).
Nα and Nβ populations were depleted similarly in 1A8-pre-
treated/virus-infected mice compared with isotype control
IgG2A-pretreated/virus-infected mice (Fig. 5F). The difference
in magnitude of the Pol-1–, Pol-2–, and Gag pool-specific CD8
T-cell responses between viruses was greatly reduced in 1A8-
pretreated mice (Fig. 5G) compared with the significant differ-
ences in IgG2A-pretreated mice between two groups (Fig. 5G).
The increase in HIV antigen-responsive CD8 T cells in mAb
1A8-pretreated/NYVAC-C Δ3-infected mice compared with
mAb IgG2a-pretreated/NYVAC-C Δ3-infected mice might
be due to the greater monocyte activation (based on CD11b
and CD62L overexpression) in 1A8- than in IgG2a-pretreated
mice (Fig. S5E). Monocyte numbers in 1A8-pretreated/NYVAC-C
Δ3-infected mice were significantly lower compared with IgG2A-
pretreated/NYVAC-C Δ3-infected mice, suggesting neutrophil-de-
pendent monocyte migration (Fig. S5F). We found no differences in
DC activation markers (CD80, CD86) or in DC number between
the two groups (Fig. S5 G and H). These data suggest that neu-
trophils are involved in the increase in HIV-1 Gag- and Pol-specific
CD8 T-cell responses after infection with the triple deletion mutant
and that other immune cells induce higher antigen-specific CD8 T-
cell responses in the nonphysiological absence of neutrophils.
Discussion
Here we define the biological contribution of the deletion of three
VACV inhibitors of the NFκB signaling pathway in the NYVAC
genome. The A52, K7, and B15 early proteins, members of the
B-cell lymphoma-2 family (31, 32), are involved in suppression of
host immune responses (2). During infection, A52 and K7 interact
with TNF receptor-associated factor 6 and inhibit its kinase acti-
vation capacity (24, 33), whereas B15 binds the IκB kinase com-
plex to inhibit IκBα phosphorylation and degradation (20). In this
study, we focused on the A52, K7, and B15 proteins; using single,
double, and triple deletion mutants, we demonstrate that the
presence of only one of the three inhibitory molecules is sufficient
to abolish NFκB activation, ruling out synergy between these
proteins as a mode of action. We establish that combined deletion
of A52R, K7R, and B15R is necessary for efficient triggering of the
NFκB pathway and neutrophil recruitment.
Neutrophils treated with GM-CSF and/or other cytokines can
up-regulate MHC class II and the costimulatory molecules
CD80/CD86 (APC markers) and promote T-cell activation (11,
12). Neutrophils can acquire macrophage (34) or dendritic
phenotypes (10), and such hybrid neutrophil populations with
APC-like properties participate in adaptive immune responses
(10). In the context of a tumor, the neutrophil subsets generated
in the cytokine/chemokine environment can affect tumor growth
by influencing CD8 T-cell activation (35). In our study, during
NYVAC-C Δ3 infection, we observed recruitment of Nα and Nβ
neutrophil subsets as a consequence of the cytokine/chemokine
profile produced. Nβ neutrophils are more lobulated, larger, and
morphologically more complex; display an enhanced activation
profile; have higher levels of APC markers (CD11c, CD80, and
CD86); and have greater capacity to induce antigen-specific
T-cell activation than Nα cells.
MVA induces NFκB activation (23) and robust neutrophil
recruitment after intranasal (36) or intradermal infection (37).
We demonstrate that, after i.p. infection, the percentage of
neutrophils in MVA-WT–, MVA-C–, or NYVAC-C Δ3-infected
mice was similar and that the Nβ/Nα ratio is significantly higher
in NYVAC-C Δ3- than in MVA-infected mice. The NYVAC Δ3
vector might thus offer an advantage in generating antigen-spe-
cific CD8 T-cell responses compared with the MVA vector.
Attenuated VACV vectors are considered vaccine candidates;
specifically, NYVAC, MVA, and ALVAC poxvirus strains are
used against emerging infectious diseases and cancer in humans (1).
For HIV/AIDS VACV vectors, several strategies have been de-
veloped to improve immunogenicity to HIV antigens, such as use of
costimulatory molecules, administration of heterologous vectors,
and deletion of immunomodulatory viral genes (38). These ap-
proaches have yielded promising results in primates and elicited
protection after challenge with simian immunodeficiency virus (39),
although effectiveness was limited in the RV144 phase III HIV/
AIDS human clinical trial (40). In this context, NYVAC-CΔ3 could
be considered a valid prototype for future vaccines due to its ability
to activate NFκB, to induce specific neutrophil migration, and to
enhance CD8 T-cell immune responses to Gag and Pol antigens.
Gag and Pol are the best conserved HIV-1 proteins (41) and are
able to shift the CTL response from variable Env epitopes to the
conserved Gag and Pol epitopes in the first years of HIV-1 infection
(42). In untreated chronic HIV-1–infected individuals, a Gag CTL
response correlates with lower HIV viral loads, decreasing HIV vi-
remia (43); furthermore, it correlates with decreasing viremia in early
HIV-1–infected patients with suspension of retroviral therapy (42). A
prophylactic vaccine that induces a Gag CTL response was recently
shown to control simian immunodeficiency virus infection (44).
Because the Gag/Pol-specific CD8 T-cell response in NYVAC-C
Δ3-infected mice is mainly polyfunctional compared with that of
NYVAC-C and because most human HIV nonprogressors prefer-
entially maintain highly functional HIV-specific CD8 T cells (45), the
NYVAC-CΔ3 vaccinia vector might constitute a promising approach
for prophylactic and therapeutic treatment. By triggering enhanced
NFκB activation and specific neutrophil recruitment, the triple de-
letion mutant could offer a considerable advantage over current
NYVAC-based vectors being tested in phase I prophylactic and
therapeutic clinical trials (46).
In contrast to Gag and Pol responses, NYVAC-C Δ3 does not
induce a significant increase in the CD8 T-cell response to Env
compared with NYVAC-C. This difference in antigen response
probably depends on Env extracellular secretion compared with
Gag–Pol intracellular production. Our data suggest greater
neutrophil involvement in the engulfment of VACV-infected
cells that express intracellular Gag and Pol than of a secreted
antigen such as Env, which could be sequestered by macrophages
normally found in the peritoneal cavity.
Neutrophils reportedly have difficulties in priming CD4 T cells
compared with CD8 T cells after vaccinia infection (13); in our
model, we observe no CD4 T-cell response to GPN in NYVAC-C–
or in NYVAC-C Δ3-infected mice.
After migrating to the lymph nodes, neutrophils can compete
with classic APCs (DCs, macrophages) to present antigens (47),
and a direct interaction between antigen-pulsed neutrophils and
CD8 T cells has also been proposed (9). In contrast, VACV-
infected neutrophils cannot induce a CD8 T-cell proliferative
response in BM in the absence of myeloid APCs (13). When
mice were NYVAC-GFP– or NYVAC-GFP Δ3-infected, we did
not detect GFP+-infected neutrophils in secondary lymphoid
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organs, which would suggest indirect neutrophil infection. Based
on this evidence, we speculate that antigen transport results from
neutrophil uptake of apoptotic cells in which the antigen has
already been processed. The neutrophils that transport pro-
cessed antigens are able to prime CD8 T cells directly, which
then respond/proliferate specifically.
In summary, here we identify a mechanism by which the VACV
vector NYVAC lacking A52R, K7R, and B15R genes triggers se-
lective immune responses (Fig. 6). Infection with NYVAC-C Δ3
led to activation of the NFκB signaling pathway in vitro and in
vivo, with increased cytokine/chemokine expression followed by
specific neutrophil activation and recruitment. This enhanced
neutrophil recruitment during infection correlated with an in-
creased CD8 T-cell adaptive immune response specific for het-
erologous antigens. Further analysis of neutrophil populations
identified an activated Nβ cell subtype with APC function that
migrated to MLNs and to the spleen. Based on these inherent
properties, the NYVAC triple deletion mutant demonstrates
a new mechanism for poxvirus-induced immune response that
provides a novel basis for virus vaccine vector design.
Materials and Methods
Mice and Injections. BALB/c and C57/BL6J mice (6–8 wk old) were purchased
from Harlan. C. Combadière (INSERM, Paris) provided C57/BL6J CCR1 KO mice,
and S. Mañes (Centro Nacional de Biotecnología, Madrid) provided C57/BL6J
CCR5 KO mice. NYVAC-WT and NYVAC-C vectors were provided by Sanofi
Pasteur, and their biological properties have been described (27). For the
heterologous DNA prime/NYVAC boost immunization protocol to assay
NYVAC virus immunogenicity, mice received 100 μg DNA-C (50 μg plasmid
construct pcDNA-CN54GP120 + 50 μg plasmid construct pcDNA-CN54GPN) or 100
μg DNA-ϕ (100 μg plasmid construct pcDNA) by the intramuscular route (27).
Plasmids were purified using the Endofree Plasmid Mega Kit (Qiagen). After
2 wk, mice were immunized i.p. or i.m. with 107 PFUs of NYVAC-WT, NYVAC-C,
or NYVAC-C Δ3. Mice immunized with sham DNA (DNA-ϕ) followed by
a NYVAC-WT boost were used as controls. For in vivo neutrophil depletion,
mice were injected i.v. with 200 μg 1A8 mAb (BioXcell) or 200 μg Isotype
Control IgG2A mAb (Abcam) 24 h before the boost immunization. Animal
studies were approved by the Ethical Committee of Animal Experimentation
of the Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones
Cientificas in accordance with national and international guidelines and the
Royal Decree (RD 1201/2005) (permits 12013 and 13013).
Cells. African green monkey kidney cells (BSC-40; American Type Culture
Collection) and primary chicken embryo fibroblast (CEF) cells (Intervet) were
grown in DMEM supplemented with 10% (vol/vol) FCS. Human monocytic THP-1
cells (ATCC), murine macrophage J774.G8 cells (ATCC), and A20 cells (ATCC) were
cultured in RPMI medium 1640 (Sigma-Aldrich) supplemented with 50 μM
2-mercaptoethanol and 10% (vol/vol) FCS. THP-1 cells were differentiated into
macrophages by treatment with 5 ng/mL phorbol 12-myristate 13-acetate
(Sigma-Aldrich) for 24 h before use. Murine macrophage cells were obtained
from peritoneal exudates 4 d after i.p. administration of 1 mL 9% (wt/vol)
casein; total cells were cultured (12 h) in RPMI 1640 with 10% (vol/vol) FCS, and
nonadherent cells were removed. Cells were cultured in a humidified air
5% (vol/vol) CO2 atmosphere at 37 °C.
Viruses. The poxvirus strains used included the genetically attenuated VACV-
based vector NYVAC-WT and the recombinant NYVAC-C (27). Deletion
Fig. 6. NYVAC-C Δ3 capacity to increase neutrophil peritoneal recruitment and spleen migration compared with NYVAC-C.
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mutants were constructed using Discosoma sp. (ds)Red2 and red shifted
(rs)GFP as fluorescent markers. BSC-40 cells were infected with 0.01 PFU per
cell of NYVAC-C (1 h) and transfected with pGem-RG-A52R-wm, pGem-RG-
B15R-wm, or pGem-RG-K7R-wm plasmids using Lipofectamine (Invitrogen)
to generate single, double, and triple deletion mutants. Deletion mutants
were selected from progeny virus by consecutive rounds of plaque purifi-
cation as described (48). NYVAC-GFP and NYVAC-GFP Δ3 were constructed
using rsGFP as a fluorescent marker and β-galactosidase as a reporter gene.
BSC-40 cells were infected with 0.01 PFU per cell of NYVAC-C or NYVAC-C Δ3
(1 h) and transfected with VACV insertional plasmid vector pLZAW1-LEO (49)
to replace the HIV cassette with the GFP gene. Recombinant viruses were
selected from progeny virus by consecutive rounds of plaque purification as
reported (27). NYVAC-C Δ3 Κ7-rev was constructed using the K7R gene and
β-glucuronidase as the reporter gene. BSC-40 cells were infected with 0.01 PFU
per cell of NYVAC-C Δ3 (1 h) and transfected with VACV insertional plasmid
vector pCAR-2/K7R to insert the K7R gene into the HA locus. Recombinant
viruses were selected from progeny virus by consecutive rounds of plaque
purification as reported (50). In vitro virus infections were performed with
2% (vol/vol) FCS. All viruses were grown in primary CEF cells, similarly purified
through two 36% (wt/vol) sucrose cushions, and virus titers were deter-
mined by immunostaining plaque assay in BSC-40 cells as described (51).
Plasmids. The plasmid transfer vectors pGem-RG-A52R-wm, pGem-RG-B15R-
wm, and pGem-RG-K7R-wm, used for deletion of A52R, B15R, and K7R ORF
from the NYVAC-C genome, respectively, were obtained by sequential
cloning of A52R, B15R, and K7R recombination flanking sequences into the
plasmid pGem-Red-GFP-wm as described (52). The plasmid transfer vector
pCAR-2/K7R used for the insertion of the K7R gene was obtained by cloning
the K7R sequence into the plasmid pCAR-2 (patent WO2007132052 A1).
The NYVAC genomewas used as the template to amplify the left flank, the
repeated left flank and the right flank of the three genes, or the sequence
of K7R; the oligonucleotides used are listed in Table S1. The resulting plas-
mids pGem-RG-A52R-wm, pGem-RG-B15R-wm, pGem-RG-K7R-wm, and pCAR-2/
K7R were confirmed by DNA sequence analysis.
PCR. Viral DNA was extracted by the SDS-proteinase K-phenol method. Pri-
mers LF´A52R-Eco and RFA52R-Bam (spanning A52R flanking regions),
LF´B15R-Aat and RFB15R-Bam (spanning B15R flanking regions), and LFK7R-
Aat and fi-FIL-BR (TTATAGGATCCCTCCAGGAGAAAG) (spanning K7R flanking
regions) were used for PCR analysis of A52R, B15R, and K7R loci, respectively.
Primers TK-L and TK-R were used for PCR analysis of the TK (thymidine kinase)
locus as described (53) to confirm the replacement of the HIV cassette with
the GFP gene. Primers HA1 (GTCACGTGTTACCACGCA) and HA2-NYVAC–
reverse (CCGAGTAAGGCATTAGG) were used for PCR analysis of the HA locus
to confirm insertion of the K7R gene.
RT-PCR. Total RNA was extracted using RNeasy Mini Kit (Qiagen) and was
treated with DNase I recombinant, RNase-free. Subsequently, first-strand cDNA
was synthesized with Oligo (dT)12–18 primers (Invitrogen) using SuperScriptIII
Reverse transcriptase (Invitrogen) following the manufacturer’s protocol,
and cDNA was used for PCR amplification. The primers K7RinternalFwd-Bam
and K7RinternalRev-Not used for amplification of K7R cDNA were the same
as for cloning and are described in Table S1.
Western Blot. BSC-40 cells were lysed in Laemmli buffer, and extracts were
fractionated by 8% (vol/vol) SDS/PAGE and analyzed by Western blot using
rabbit polyclonal anti-gp120 (Centro Nacional de Biotecnología), -gag p24
(ARP 432, NIBSC, Centralised Facility for AIDS Reagents), or -E3 antibodies
(Centro Nacional de Biotecnología). J774.G8 and THP-1 cells were lysed in
Cell Lysis Buffer (Cell Signaling) supplemented with PMSF, and extracts were
fractionated by 10% (vol/vol) SDS/PAGE and analyzed by Western blot using
anti-phospho IκBα, -IκBα, and -tubulin (Cell Signaling). Nuclear extracts were
obtained using a Nuclear/Cytosol Fractionation Kit (BioVision Research) and
analyzed by Western blot using anti-H2A mAb (Cell Signaling).
EMSAs. For gel shift assays, nuclear extracts were incubated with 0.5 ng
32P-end–labeled double-stranded oligonucleotide probe 5′-AGTTGAGGGG-
ACTTTCCCAGGC-3′, which has NFκB binding sites. The binding reaction was
performed in binding buffer with 1.5 mg poly (dI-dC), and binding products
were resolved by electrophoresis.
Immunofluorescence. Cells were washed with PBS, fixed with 4% (vol/vol)
paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked
with 20% (vol/vol) FCS. Cells were coincubated with polyclonal anti-p65
(Santa Cruz) and -E3 antibodies (Centro Nacional de Biotecnología).
Bound primary antibodies were detected with AlexaFluor488 or 594-
conjugated antibodies (Invitrogen). Cell nuclei were DAPI-stained
(Sigma). The model of the microscope was LEICA TCS SP5 multispectral
confocal system; type, magnification, and numerical aperture of the
objective lenses were HCX PL APO lambda blue 63.0×/1.4 oil immersion;
the temperature was 25 °C; the imaging medium was Prolong Gold
(Invitrogen); and the acquisition software was Leica LASAF version 2.6.0.
Cytokine/Chemokine Analysis. Sera and peritoneal washes from PBS- or virus-
injected mice, as well as supernatants of mock- or virus-infected J774 and
peritoneal macrophages, were assayed to detect cytokines and chemokines in
multiplex analyses using LuminexXMAP technology. IL-8 levels from sera,
peritoneal washes, and supernatants of J774 macrophages were quantified
by IL-8 ELISA Kit (MyBioSource).
In Vitro Migration Assay. Migration assays were performed in 6.5-mm-
diameter transwell dishes (Corning Costar) with 3-μm pore filters. Murine BM
cells were added to the upper chamber, and supernatants of mock- or virus-
infected J774 cells were added to the bottom chamber. Migration in medium
alone served as the negative control. After 3 h of incubation, cells in themedium
of the bottom chamber were collected and passed for 1 min at a high flow rate
in a LSRII cytometer (BD). The number of cell events was counted, and remaining
cells in the tube were stained with anti-Ly6G (1A8) and -CD11b (M1/70) (BD).
Apoptosis Assay. The annexin V binding assay was performed in combination
with propidium iodide (PI) to monitor the integrity of the neutrophil membrane.
Hematoxylin/Eosin Staining. Ly6G+ cells were fixed with acetone for 10 min
and then stained.
Peptides. The HIV-1 peptides Env-1 (sequence, PADPNPQEM), Pol-1 (LVGPTPVNI),
and Pol-2 (YYDPSKDLI) were described as H-2d–restricted CTL epitopes (29)
and were provided by the CNB-CSIC Proteomics Service. The HIV-1 Gag pool
(60 peptides of Gag-1 + 61 peptides of Gag-2) and Nef pool (49 peptides)
were provided by the EuroVacc Foundation and have been described (27);
they span the entire HIV-1 Gag and Nef regions included in the immunogens
as consecutive 15 mers with 11-amino acid overlaps.
Nucleofection Assay. A20 cells were nucleofected using 4D-Nucleofector
(Lonza) and the Amaxa SF Cell Line Kit (Lonza). Cells were nucleofected with
6 μg pcDNA-CN54gp120 or pcDNA-CN54GPN; pcDNA-ϕ was used as the nega-
tive control. At 24 h postnucleofection, A20 cells were used to restimulate
splenocytes from infected mice (1:10, A20–splenocyte ratio).
Cell Isolation. CD8+ T cells were purified from spleen using the Dynabeads
FlowComp Mouse CD8 Kit (Invitrogen). Ly6G+ cells were sorted using MoFlo
XDP sorter (Beckman Coulter).
Flow Cytometry. For ICS, erythrocyte-depleted splenocytes were rested
overnight and resuspended in RPMI 1640 with 10% (vol/vol) FCS and 1 μg/mL
Golgiplug (BD), monensin (eBioscience), and anti-CD107a (1D4B) (BD). After
restimulation with peptides or A20 cells [6 h, 37 °C, 5% (vol/vol) CO2], splenocytes
were stained for surface markers with anti-CD3 (145-2C11), -CD4 (GK1.5), and
-CD8 (53-6.7) (all from BD); fixed; permeabilized (Cytofix/Cytoperm Kit; BD); and
stained intracellularly with anti–IL-2 (JES6-5H4), –IFN-γ (XMG 1.2), and –TNF-α
(MP6-X722) (all from BD). PECs, obtained after injection of cold PBS into pre-
viously infected mice, were counted and stained with anti-Ly6G (1A8), -CD3 (145-
2C11), -CD11b (M1/70), -CD19 (1D3), -CD80 (16-10A1), -CD86 (GL-1), -MHC class I
(H-2Kd; SF1-1.1), -MHC class II (1-A/1-E; 2G9) (all from BD), -CD45 (30-F11; Bio-
legend), -CD11c (N418; eBioscience), -F4/80 (BM8, eBioscience), and -CD62L (MEL-
14, Beckman Coulter). Peripheral blood, BM, omentum, spleen, and lymph nodes
cells were stained with anti-LyG (1A8), -CD45 (30-F11), -CD11b (M1/70), and
-CD115 (AFS98, eBioscience). The dead cells were stained using the violet LIVE/
DEAD stain kit (Invitrogen) in all cytometry analyses.
Cells were acquired using a GALLIOS (Beckman Coulter) or LSRII (BD) flow
cytometer, and data analyses were performedwith FlowJo software version 8.5.3
(Tree Star). Boolean combinations of single functional gates were created with
FlowJo to determine the frequency of each response based on all possible
combinations of cytokines or of differentiation marker expression.
Statistical Analysis. For statistical analysis of CD8 T-cell response to HIV-1 Gag–
Pol antigens, we used an approach that corrects measurements for medium
response and allows calculation of confidence intervals (CIs) and P values of
Di Pilato et al. PNAS Early Edition | 9 of 10
M
IC
RO
BI
O
LO
G
Y
PN
A
S
PL
US
59
hypothesis tests (50). Only antigen response values significantly larger than
the corresponding RPMI are shown. Background levels (splenocytes in RPMI)
were subtracted from all values used to allow analysis of proportional rep-
resentation of responses. Analysis and presentation of distribution were
performed using SPICE version 5.1, downloaded from exon.niaid.nih.gov.
For statistical analysis of T-cell responses to HIV-1 Env antigen, the Mann–
Whitney t test was used. For statistical analysis of cytokine/chemokine ex-
pression and in vitro neutrophil migration, one-way ANOVA was applied to
compare all viruses used. Student’s t test was used for other analyses to
establish the differences between two groups.
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Fig. S1. Generation and characterization of NYVAC-C mutants. (A) PCR analysis to confirm A52R, B15R, and K7R gene deletion. Viral DNA was extracted from
BSC-40 cells infected with the viruses as indicated (2 PFUs per cell, 24 h). (B) Western blot showing expression of HIV-1 antigens and E3 VACV protein in BSC-40
cells infected as in A. (C) PCR analysis to confirm K7R gene insertion. Viral DNA was extracted from BSC-40 cells infected with the viruses as indicated (1 PFU per
cell, 24 h). (D) RT-PCR analysis to confirm K7R gene expression. RNA was extracted from CEF cells infected with the viruses as indicated (1 PFU per cell, 24 h).
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Table S1. Primers used for the deletion of A52R, B15R, and K7R genes and for the insertion of
K7R gene
Genes Flanks of genes Name of primers Sequence of primers
A52R Left LFA52R-Apa TATATTGGGCCCTACTACGATTAA
A52R Left LFA52R-Sph CTTTATGCATGCGGTGATCACACA
A52R Repeated left LF′A52R-Eco ATTAGAGAATTCTACGATTAACGA
A52R Repeated left LF′A52R-Cla CTTTATATCGATGGTGATCACACA
A52R Right RFA52R-Cla GGAAATATCGATGAAAGTTAAAAG
A52R Right RFA52R-Bam TCTGCCGGATCCAATGTAGTAATG
B15R Left LFB15R-Kpn-F TTTATAGGTACCTTCTTTGAGGACT
B15R Left LFB15R-Kpn-R GTTGGCGGTACCCTTACCAATTGCA
B15R Repeated left LF′B15R-Aat TTCTTTGACGTCTGTTTTCCTGAAG
B15R Repeated left LF′B15R-Xba GTTGGCTCTAGACTTACCAATTGCA
B15R Right RFB15R-Kpn CGTATGGGTACCTGAGTTGTACATC
B15R Right RFB15R-Bam GTGTCGGGATCCGAATTAGCATATT
K7R Left LFK7R-Aat CAAAGGACGTCATCATCATTTTTTCACC
K7R Left LFK7R-Xba GCTCTAGAGACTATCTCACAAAAG
K7R Repeated left LF′K7R-Eco CGGAATTCATCATCATTTTTTCACC
K7R Repeated left LF′K7R-Cla CCATCGATGACTATCTCACAAAAG
K7R Right RFK7R-Cla CCATCGATTCTAGAAAAAAAATTGAATTG
K7R Right RFK7R-Bam CGGGATCCAACAAGGGGTTGG
K7F K7RinternalFwd-Bam CGCGGATCCATGGCGACTAAATTAG
K7R K7RinternalRev-Not AAGGAAAAAAGCGGCCGCTCAATTCAATTTTTTTTC
Restriction enzyme cleavage sites are underlined.
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Results 
 
 
3.2 Summary 
3.2.1  New vaccinia virus promoter as a potential candidate for future vaccines 
Modified vaccinia Ankara (MVA) vector is being tested as a candidate vaccine to 
express heterologous pathogen antigens, and is being further improved to potentiate 
antigen-specific immune responses.  In this respect, efforts to develop new MVA 
vaccine candidates focus on using promoters to improve the timing of antigen 
expression and thus, increasing immune responses. 
Two categories of VACV early genes have been defined, based on their temporal 
expression.  We selected the first temporal early class of genes and performed sequence 
alignment to define the appropriate promoter consensus sequence of these genes and the 
spacer between the core sequence and the gene start codon.  Using the motif discovery 
program Multiple EM for Motif Elicitation (MEME), we observed that 82% of the 
genes studied contain a promoter core that corresponds to a newly defined consensus 
sequence; 73% of the genes presented this sequence between nucleotides (nt) -70 and -
20 upstream of the open reading frame. 
With these data, we designed a new synthetic late-early optimized (LEO) VACV 
promoter that contains the late part of the synthetic VACV pS promoter and the newly 
defined early consensus sequence, followed by a 38-nt spacer.  We compared the 
strength of the new LEO promoter with the viral synthetic early/late pS promoter, since 
pS has been used successfully to express high levels of heterologous antigens in 
poxvirus-based vaccine candidates. 
We generated the attenuated recombinant viruses MVA-LEO-GFP and MVA-PS-
GFP to define the temporal expression of GFP under the control of the two promoters 
and to study GFP-specific immunogenicity.  In contrast to the synthetic VACV 
promoter (pS), LEO induced significantly higher in vitro GFP expression within the 
first hour after infection, which correlated with an enhanced GFP-specific CD8 T cell 
responses in vivo, which demonstrates its potential for use in future vaccines. 
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Here we describe the design and strength of a new synthetic late-early optimized (LEO) vaccinia
virus (VACV) promoter used as a transcriptional regulator of GFP expression during modified
vaccinia Ankara infection. In contrast to the described synthetic VACV promoter (pS), LEO
induced significantly higher levels of GFP expression in vitro within the first hour after infection,
which correlated with an enhancement in the GFP-specific CD8 T-cell response detected in vivo,
demonstrating its potential use in future vaccines.
Vaccines against intracellular human pathogens such as
human immunodeficiency virus (HIV), hepatitis C virus,
malaria and leishmania are designed to induce efficient
antigen-specific T-cell immune responses that, in some
cases, correlate with protection (Go´mez et al., 2012b; Good
& Doolan, 2010; Sa´nchez-Sampedro et al., 2012; Vijayan
et al., 2012; Yusim et al., 2013). One of the most popular
vectors selected to trigger such responses are the pox-
viruses, and, in particular, highly attenuated vaccinia virus
(VACV) strains such as modified vaccinia Ankara (MVA),
NYVAC and ALVAC have been used successfully against
emergent infectious diseases and cancer in humans (Go´mez
et al., 2012a).
It is known that the timing of expression of heterologous
antigens in the VACV system affects the capacity to induce
antigen-specific T-cell immune responses (Baur et al.,
2010) since the efficiency with which an antigen is pro-
cessed and presented on the surface of infected cells
influences its recognition (Moutaftsi et al., 2009). Con-
sidering that immunodominance is defined as the phe-
nomenon whereby only a small fraction of all the possible
epitopes from a particular pathogen elicits an immune
response in an infected individual (Pasquetto et al., 2005),
it is possible to modulate such immunodominance hier-
archy, changing the timing and the quantity of intracellular
antigen production (Wilson & Hunter, 2008). In fact, it has
been described that, in VACV, 90% of the most recognized
antigens by CD8 T-cells were ranked in the top 50% in
terms of mRNA expression (Sette et al., 2009), and there is
a correlation between viral gene expression and immuno-
dominance hierarchy after a second immunization due to a
mechanism of cross-competition between T-cells specific
for early and late viral epitopes (Kastenmuller et al., 2007).
Recently, after a deep analysis of the VACV transcriptome,
two groups have defined two categories of early genes
based on their temporal expression (Assarsson et al., 2008;
Yang et al., 2010). Assarsson et al. (2008), using a genome
tiling array approach, differentiated the immediate-early
genes from the early genes, whereas Yang et al. (2010),
using deep RNA sequence analysis, differentiated the E1.1
genes from E1.2 genes as subclusters of early genes and also
defined a 15 nt consensus sequence (AAAANTGAAAA-
NNNA) that corresponds to the core of early genes
promoter. Both authors underline that there is a difference
in the time of expression between the two early classes of
genes, but Yang et al. (2010) avoided the terminology of
immediate-early and early genes because both subclusters
(E1.1 and E1.2) were transcribed in the presence of the
protein synthesis inhibitor cycloheximide, while the
transcription of early genes depends on the synthesis of
one or a few immediate-early proteins (Honess & Roizman,
1975; Ross & Guarino, 1997; Salser et al., 1970).
The core promoter of E1.1 genes more closely corresponds to
the consensus sequence than those of E1.2 genes, suggesting
that this difference could explain the readiness of E1.1 genes
to be recognized by the transcription machinery before
recognition of E1.2 genes (Yang et al., 2010).
In an effort to select an optimized virus promoter for
antigen expression, in this study we selected the first
temporal early class of genes (immediate-early and E1.1)
described by both groups (Table S1, available in JGV
Online), comprising 45 genes in total, and performed a
sequence alignment using a region of 200 nt upstream of
the translation initiation site in order to define the
One supplementary table is available with the online version of this
paper.
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Fig. 1. Design of the synthetic LEO promoter. (a) Alignment of the core promoter sequence of 37 selected early genes using
the MEME program. For the analysis, we used the 200 nt upstream of the start codons of the genes. The distribution of motif
attributed was zero or unity for the sequence. The maximum width of the motif selected for the analysis was 20 nt. The P value
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appropriate consensus sequence of the promoter of these
genes and to determine the spacer between the core
sequence and the start codon of the genes. Using the motif
discovery program Multiple Em for Motif Elicitation
(MEME), we observed that 82% of the studied genes (37/
45) contained the core of a promoter that closely corres-
ponded to a newly defined consensus sequence, AAAANT-
GAAAAAATA (Fig. 1a), and in 73% of them (27/37) the
first nucleotide of the core was between positions 270 and
235 and the last nucleotide of the core was between
positions 255 and 220 (Fig. 1a, b).
With all these data, we designed a new synthetic late-early
optimized (LEO) VACV promoter that contained the same
late part present in the widely used synthetic VACV pS
promoter (Chakrabarti et al., 1997) prior to the newly
defined early consensus sequence, with a T in position 5,
and followed by a spacer of 38 nt (Fig. 1c). The purpose of
using this LEO promoter in the transcriptional control of a
heterologous antigen is to increase the immediate expres-
sion of such an antigen during VACV infection. With this
aim, we decided to compare the strength of the new LEO
promoter with the viral synthetic early/late pS promoter
(Chakrabarti et al., 1997), since pS has been used successfully
for the expression of high levels of heterologous antigens in
vaccine candidates based on poxviruses (Go´mez et al., 2007a)
and has been described previously as a better promoter than
p7.5 and pC11R, and similar to pB8R, pA44L and pF11L in
terms of gene expression levels during the first 8 h of
infection (Orubu et al., 2012). The pS promoter contains a
different early motif that shares 5 nt with the following late
part and has a spacer of 11 nt (Fig. 1c).
The new LEO promoter sequence was synthesized by
GENEART GmbH (Regensburg) and inserted into the
VACV insertional plasmid vector pLZAW1, which contains
the right thymidine kinase (TK) flanking arm, a multi-
cloning site, a T5NT sequence and the b-galactosidase
reporter gene between two repetitions of the left TK flanking
arm (Go´mez et al., 2007a, b). GFP expression was used as a
readout in order to evaluate the promoter strength. For this
purpose, the GFP gene was inserted into the pLZAW1 vector
under the transcriptional control of the LEO (pLZAW1–
LEO) or pS (pLZAW1–pS) promoter. These transfer vectors
were used to generate the recombinant viruses MVA–LEO–
GFP and MVA–PS–GFP following standard procedures
described previously (Go´mez et al., 2007b). The purity of the
recombinant viruses was assessed by PCR amplification of
the insert in the TK locus. The viruses were grown in
primary chicken embryo fibroblasts, purified through two
36% (w/v) sucrose cushions and titrated by immunostain-
ing assay as described previously (Ramı´rez et al., 2000).
To define the temporal expression of GFP under the
control of the two different promoters, non-permissive
HeLa cells were infected at an m.o.i. of 5 with MVA–LEO–
GFP or MVA–PS–GFP recombinant viruses. In the first
4 h of infection, cells infected with MVA–LEO–GFP
expressed higher levels of GFP compared with cells
infected with MVA–PS–GFP as determined by flow
cytometry (Fig. 2a) and measured as mean fluorescence
intensity (MFI) (Fig. 2b). At 8 h post-infection, no
differences in the MFI between both viruses were
observed, underlining that the strength of the late part
of both promoters equals the fluorescence levels. These
results were confirmed in a permissive chicken DF-1 cell
line (data not shown).
To check if higher levels of antigen expression at early times
post-infection correlated with an enhancement of the
antigen-specific T-cell immune responses, we performed an
immunization protocol using MVA–LEO–GFP and MVA–
PS–GFP. BALB/c mice (n58 per group) were injected by the
intraperitoneal route with two doses of 16107 p.f.u. of each
virus with an interval of 1 week between the two inocula-
tions. As a negative control, we used the parental virus
MVA–WT. At 11 and 53 days after the last immunization,
mice were sacrificed and spleens were processed for
intracellular cytokine staining assay to study CD8 T-cell
primary and memory immune responses, respectively. The
splenocytes were stimulated for 6 h with 10 mg ml21 of the
GFP peptide HYLSTQSAL (GFP200–208) (Centro Nacional de
Biotecnologı´a Proteomics Facility, Spain), which is able to
induce a specific CD8 T-cell response, as reported previously
(Gambotto et al., 2000). The functional profile of the
vaccine-induced T-cell response was determined by meas-
uring the intracellular expression of the cytokines IFN-c, IL-2
and TNF-a, as well as the exposure of lysosomal-associated
membrane protein-1 (LAMP-1 or CD107a) on the surface of
activated antigen-specific CD8 T-cells as a surrogate marker
for induction of killing.
The magnitude of the CD8 T-cell response was defined as
the number of CD8 T-cells expressing IL-2 and/or IFN-c
and/or CD107a and/or TNF-a, and the polyfunctionality as
the capacity of CD8 T-cells to express more than one of these
four activation markers. In primary and memory immune
responses, the magnitude and polyfunctionality of the
vaccine-induced GFP-specific CD8 T-cell immune response
were significantly higher in mice infected with MVA–LEO–
GFP than in those infected with MVA–PS–GFP (Fig. 3). In
primary immune responses, the absolute frequencies of
quadruple, triple, double and single GFP-specific CD8 T-cell
populations were significantly higher in mice infected with
MVA–LEO–GFP compared with MVA–PS–GFP-infected
mice (Fig. 3c), whereas in memory immune responses only
of a site was computed from the match score of the site with the position-specific score matrix for the motif. Only sequences
with P,0.001 are represented. (b) Alignment of all 37 sequences of 200 nt. The height of the motif ‘block’ is proportional to –
log (P value) and the position in the panel corresponds to the motif location. The red box emphasizes the region between ”70
and ”20 nt upstream of the start codons of the genes. (c) Schematic representation and sequence of LEO and pS promoters.
The double solid line represents the nucleotides shared by early and late fractions.
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the quadruple CD8 T-cell subset was increased significantly
(Fig. 3d). These results demonstrated that the enhanced
immediate expression of the heterologous GFP antigen
increased the quality of the antigen-specific T-cell response.
The LEO promoter represents the first example of a VACV
synthetic promoter designed after bioinformatics analysis
that shows an enhanced antigen expression within the first
hour after infection and, importantly, is able to generate a
significant increase in the antigen-specific CD8 T-cell
immune response compared with that of the commonly
used pS. This novel promoter represents an excellent
prototype for future use to potentiate the expression of
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Fig. 2. GFP expression levels driven by LEO or pS promoters. (a) Expression of GFP in HeLa cells infected with MVA–LEO–
GFP (LEO) or MVA–PS–GFP (pS) viruses at an m.o.i. of 5 at 1, 2, 4 and 8 h post-inoculation. (b) Mean fluorescence intensity
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antigens from different pathogens and to generate safe
VACV recombinant-based vaccines able to induce potent
immune responses that prevent development of the disease.
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Results 
 
 
3.3 Summary 
3.3.1  Modification of promoter spacer length in vaccinia virus as a strategy to 
control the antigen expression 
Several new early VACV promoters have been tested with different heterologous 
antigens and demonstrated to be more effective compared to the widely used pS 
synthetic promoter.  These promoters differ in the spacer lengths between the gene and 
the early promoter sequence.  It was nonetheless unknown how the length of the spacer 
between the early promoter motif and the gene under promoter control affect early 
antigen expression.  To respond to this question, we generated several MVA vectors 
that express GFP under the transcriptional control of the synthetic late-early optimized 
(LEO) VACV promoter, using different spacer lengths.  LEO promoter with a spacer 
length of 160 nucleotides (nt) increased significantly the GFP early expression 
compared to that of 99 and of 38 nt spacers. 
In human and in murine models of Leishmania major infection, polyfunctional Th1 
CD4 T cells correlated with vaccine-mediated protection.  It was nevertheless unclear 
whether inducing heterologous early antigen expression can potentiate antigen-specific 
CD4 T cell responses.  To answer this question, we generated two MVA vectors that 
express the LACK antigen (Leishmania homologue of receptors for activated C-kinase) 
under the transcriptional control of the LEO and LEO160 promoters.  We demonstrated 
that LEO160 significantly enhanced LACK antigen expression compared to the LEO 
promoter.  We showed that enhancement of Leishmania LACK early expression 
increased LACK-specific CD4 and CD8 T memory cell responses.  Based on these 
inherent properties, we demonstrate that MVA-LEO160 is a prototype for the design of 
new poxvirus-based vaccine vectors. 
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Vaccinia viruses (VACV) with distinct early promoters have been developed to enhance antigen expression and improve 
antigen-specific CD8 T cell responses. It has not been demonstrated how the length of the spacer between a gene and its 
early promoter motif influences antigen expression, and whether the timing of gene expression can modify the antigen-
specific CD4 T cell response.  We generated several recombinant VACV based on the attenuated modified vaccinia 
Ankara (MVA) strain, which express GFP or the Leishmania LACK antigen under the control of an optimized promoter, 
using different spacer lengths. Longer spacer length increased GFP and LACK early expression, which correlated with 
an enhanced LACK-specific memory CD4 and CD8 T cell response. These results show the importance of promoter 
spacer length for early antigen expression by VACV and provide alternative strategies for the design of poxvirus-based 
vaccines. 
 
 
INTRODUCTION 
 
Poxvirus-based vaccines are used to generate 
strong antigen-specific T cell responses that 
control and clear pathogen infections (Ha et al., 
2008).  Poxvirus vectors are thus being tested as 
candidate vaccines to express heterologous 
pathogen antigens, and are being further 
improved to potentiate antigen-specific immune 
responses (immunogenicity) (Garcia-Arriaza and 
Esteban, 2014). 
 
During a poxvirus infection, T cell immunogenicity 
correlates with antigen expression (Wyatt et al., 
2008).  The quantity of antigen production can 
affect the T cell immunodominance hierarchy 
(Wilson and Hunter, 2008), that is, the distinct 
levels of immunogenicity of all antigens expressed 
by a virus (Yewdell and Bennink, 1999). Recent 
studies of vaccinia virus (VACV) show that the 
efficiency with which an antigen is processed and 
presented on the surface of infected cells 
influences its recognition by immune system cells 
(Moutaftsi et al., 2009); 90% of all antigens 
recognized by CD8 T cells rank in the top 50% in 
terms of mRNA temporal expression (Sette et al., 
2009).  For this reason, efforts to develop new 
poxvirus vaccine candidates focus on using 
promoters to improve the timing of antigen 
expression and thus increase immune responses. 
 
Vaccinia gene expression is controlled by early, 
intermediate and late promoters (Yang et al., 
2013; Yang et al., 2011b).  In mice, the timing of 
viral antigen expression correlates with better 
antigen-specific CD8 T cell responses (Bronte et 
al., 1997); early antigen-specific T cells have a 
proliferative advantage over late antigen-specific T 
cells (Kastenmuller et al., 2007).  Early VACV 
promoters such as pHyB (Baur et al., 2010) 
psFJ1-10 (Isshiki et al., 2014; Sato et al., 2013) 
and PrMVA13.5-long (Wennier et al., 2013), which 
bear different tandem early promoter elements, 
have been tested with different heterologous 
antigens; they were shown to be more effective 
compared to the widely-used p7.5 and pS 
promoters (Chakrabarti et al., 1997; Cochran et 
al., 1985). A new LEO (late-early optimized) 
promoter, with an optimization of the early 
promoter motif was also compared to pS and used 
to increase heterologous early antigen expression 
and antigen-specific CD8 T cell responses (Di 
Pilato et al., 2013).  These promoters differ in their 
early motif sequence and in spacer lengths 
between the gene and the early promoter. It is 
nonetheless not known how the length of the 
spacer between the early promoter motif and the 
gene under promoter control affects the early 
antigen expression. 
 
CD4 T cells recognize VACV intermediate 
antigens better than early or late gene products 
(Yang et al., 2011b).  CD4 T cells have a crucial 
role in mediating protection against a variety of 
pathogens such as human immunodeficiency 
virus (HIV), influenza, Plasmodium falciparum and 
Leishmania (Darrah et al., 2007; Reece et al., 
2004; Roman et al., 2002; Younes et al., 2003). In 
man and in mouse models of Leishmania major 
infection, multifunctional T helper type 1 (Th1) 
CD4 T cells correlate with vaccine-mediated 
protection (Darrah et al., 2010; Macedo et al., 
2012).  It is nevertheless unclear whether it is 
possible to potentiate antigen-specific CD4 T cell 
responses by inducing heterologous early antigen 
expression during vaccinia virus infection. 
Modified vaccinia virus (MVA), a highly attenuated 
VACV, expressing LACK antigen (Leishmania 
homologue of receptors for activated C kinase), 
has been used as a safe, efficient vector able to 
induce a multifunctional, long-term, LACK-specific 
CD4 T cell response (Sanchez-Sampedro et al., 
2012). 
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We generated several MVA vectors that express 
GFP or LACK antigens under the transcriptional 
control of the LEO promoter, with different spacer 
lengths.  LEO promoter with a spacer length of 
160 nucleotides (nt) increased GFP or LACK early 
expression compared to that of 38 nt. We show 
that enhancement of LACK early expression 
correlated with the length of the spacer, leading to 
increased LACK-specific CD4 and CD8 T memory 
cell responses. 
 
RESULTS 
Promoter spacer length and GFP antigen 
expression 
We constructed LEO promoters with different 
spacer lengths.  The LEO promoter has 29 
nucleotides (nt) of the late element, 15 nt of the 
early motif and a 38 nt MCS spacer (Di Pilato et 
al., 2013).  We designed two new promoters, 
LEO99 and LEO160 with the same late-early LEO 
composition and two MCS spacers of 99 or 160 nt 
Figure 1(A).  The GFP open reading frame (ORF) 
was cloned downstream of LEO99 and LEO160 
promoters into the VACV insertional pLZAW1 
plasmid vector (Gomez et al., 2007a; Gomez et 
al., 2007b) and introduced into the MVA thymidine 
kinase (TK) locus (Gomez et al., 2007a; Gomez et 
al., 2007b). The MVA-LEO99-GFP and MVA-
LEO160-GFP viruses were selected from MVA-
WT by consecutive purification rounds (Gomez et 
al., 2007b).  Absence of MVA-WT contamination 
and correct GFP insertion in the TK locus were 
confirmed by PCR amplification Figure 1(B). 
 
Early GFP expression by MVA-LEO99-GFP and 
MVA-LEO160-GFP viruses was compared with 
that of the MVA-LEO-GFP virus, which induces 
significantly more early GFP expression than 
MVA-pS-GFP (Di Pilato et al., 2013).  We infected 
human HeLa cells with the distinct MVA-GFP 
viruses at a multiplicity of infection (MOI) of 10 
plaque-forming units (PFU) per cell and evaluated 
GFP expression in a time-course assay. In the 
first 6 h of infection, MVA-LEO160-GFP induced 
higher GFP levels compared to MVA-LEO99-GFP 
and MVA-LEO-GFP virus, as determined by flow 
cytometry Figure 2(A).  To analyze early gene 
expression specifically, and to avoid 
contamination by late gene expression, the HeLa 
cells were treated for 6 h with cytosine 
arabinoside (AraC), an inhibitor of DNA 
replication.  In these conditions of early phase 
MVA infection cycle arrest, MVA-LEO160-GFP 
induced more GFP expression than the other 
viruses Figure 2(A).  Median fluorescence 
intensity (MFI) analysis of HeLa GFP levels 
showed that in the first 6 h of infection, alone or 
with AraC, MVA-LEO160-GFP significantly 
increased HeLa GFP production compared to 
MVA-LEO99-GFP or MVA-LEO-GFP Figure 2(B).  
The difference in GFP expression between MVA-
LEO160-GFP and MVA-LEO-GFP was 
approximately two-fold from 2 to 6h post-infection.  
During the same period, MVA-LEO99-GFP 
induced significantly more GFP expression than 
MVA-LEO-GFP, indicating a correlation between 
spacer length and gene expression Figure 2(B).  
 
 
Results were similar for MVA-GFP viruses 
following infection of murine J774 macrophages 
and human THP-1 monocytes differentiated into 
macrophages Figure 2(C), (D).  MVA-LEO160-
GFP and MVA-LEO99-GFP significantly increased 
GFP levels compared to those induced by MVA-
LEO-GFP; the difference between MVA-LEO160-
GFP and MVA-LEO99-GFP was statistically 
significant from 4 h post-infection Figure 2(C), (D). 
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Figure 1. Scheme and insertion of LEO, LEO99 and LEO160 
promoters with GFP gene into MVA virus genome.  (A) Sequence 
of LEO, LEO99 and LEO160 promoters and scheme with the GFP 
gene.  Late promoter element, grey box; early promoter motif, black 
box; spacer, white box with dashed line.  (B) Promoter and GFP gene 
insertion into the MVA virus TK locus confirmed by PCR analysis.  An 
873 bp product was obtained in parental MVA, whereas in MVA-LEO-
GFP, MVA-LEO99-GFP and MVA-LEO160-GFP recombinant viruses 
we observed 1312, 1373 and 1434 bp products, respectively. 
 
Figure 2. In vitro GFP expression driven by LEO, LEO99 and 
LEO160 promoters. (A) GFP expression in HeLa cells infected with 
MVA-WT, MVA-LEO-GFP, MVA-LEO99-GFP and MVA-LEO160-GFP 
viruses (MOI of 10 PFU/cell) at 1, 2, 4, 6 h post-infection, and with 
AraC (40 µg ml-1) at 6 h post-infection.  Graphs show x-fold increase 
in GFP median fluorescence intensity (MFI) of MVA-GFP compared 
to MVA-WT viruses in HeLa (B), J774 (C) and THP-1 cells (D).  Note 
y axis scale difference for each condition.  One representative 
example is shown of two independent experiments assayed in 
triplicate. Values shown as mean ± SEM. * p<0.05, ** p<0.01, *** 
p<0.001. 
 
 
 
 
To determine whether infection with MVA-
LEO160-GFP increased GFP expression in vivo, 
we infected BALB/c mice by i.p. injection of 107 
PFU MVA-LEO-GFP or MVA-LEO160-GFP.  
Since macrophages are one of the most 
susceptible cell types to MVA infection (Brandler 
et al., 2010) and constitute ~30% of the total 
peritoneal cell yield (Ray and Dittel, 2010), only 
GFP+ F4/80high macrophages were analyzed 
Figure 3(A); both viruses showed similar infective 
capacity (>80%) Figure 3(B).  GFP+ macrophages 
from MVA-LEO160-GFP-infected mice had 
significantly higher GFP levels than those from 
MVA-LEO-GFP-infected mice at 4 h post-infection 
Figure 3(C). 
 
 
 
Promoter spacer length and LACK antigen 
expression 
Considering the strength of LEO160 promoter in 
inducing better early antigen expression among 
the promoters studied in vitro, we decided to 
compare its capacity to generate antigen-specific 
CD8 and CD4 T cell responses with the LEO 
promoter; we cloned the Leishmania LACK ORF 
downstream of LEO or LEO160 promoters Figure 
4(A).  To demonstrate that differences in early 
antigen expression were spacer length-dependent 
and not spacer sequence-dependent, we modified 
the spacer MCS sequence and maintained the 
same nt number in MVA-LEO160-LACK.  The new 
VACV insertional pLZAW1 plasmid vectors were 
used to generate the MVA-LEO-LACK and MVA-
LEO160-LACK viruses, which were selected from 
MVA-WT by consecutive purification rounds 
(Gomez et al., 2007b).  Absence of MVA-WT 
contamination and correct LACK insertion in the 
TK locus were confirmed by PCR amplification 
Figure 4(B). 
 
 
The difference in LACK levels between these two 
viruses was tested by Western blot Figure 5(A) in 
HeLa cells infected at a MOI of 10 PFU/cell.  From 
2 to 6 h post-infection, alone or with AraC, MVA-
LEO160-LACK significantly increased LACK 
expression (approximately two-fold) compared to 
MVA-LEO-LACK Figure 5(B), which confirmed the 
results obtained for the GFP antigen.  LACK levels 
were normalized to E3 (VACV constitutive early 
protein) levels to show that the difference in 
heterologous antigen expression was the result of 
distinct promoter strength and not of different virus 
infective capacity.  We found no differences in E3 
expression between the viruses Figure 5(A).  
These in vitro and in vivo results indicate that 
promoter spacer length positively influences gene 
early expression under its control. 
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Figure 3. In vivo macrophage GFP expression driven by LEO and 
LEO160 promoters.  (A) FACS plot (F4/80 macrophage marker vs. 
GFP) of peritoneal cells from MVA-LEO160-GFP-injected mice (107 
PFU).  (B) Percentage of GFP+ macrophages from the peritoneal 
cavity of MVA-LEO-GFP- or MVA-LEO160-GFP-injected (107 PFU) 
mice at 4 h post-infection.  (C) Expression (left panel) and median 
fluorescence intensity (MFI; right panel) of peritoneal GFP+ 
macrophages at 4 h post-infection in MVA-LEO-GFP- or MVA-
LEO160-GFP-injected mice. Graph shows x-fold increase in these 
macrophages compared to MVA-WT-injected mice.  Values are mean 
± SEM; each point represents an individual mouse. Data 
representative of two independent experiments. ** p<0.01. 
 
Figure 4. Scheme and insertion of LEO and LEO160 promoters 
with the LACK gene into MVA virus genome.  (A) Sequences of 
LEO and LEO160 promoters and scheme with LACK gene.  Late 
promoter element, grey box; early promoter motif, black box; spacer, 
white box with dashed line.  (B) Promoter and LACK gene insertion 
into the MVA virus TK locus analyzed by PCR.  An 873 bp product 
was obtained in parental MVA, whereas in MVA-LEO-LACK and 
MVA-LEO160-LACK recombinant viruses we observed 1486 and 
1608 bp products, respectively. 
 
Figure 5. In vitro LACK 
expression driven by LEO 
and LEO160 promoters.  
(A) LACK expression in 
HeLa cells infected with 
MVA-WT, MVA-LEO-LACK 
or MVA-LEO160-LACK 
viruses (MOI of 10 PFU/cell) 
at 2, 4, 6 h and with AraC at 
6 h post-infection.  a-tubulin 
was used as a protein 
loading control.  (B) Bars 
show the ratio of LACK to 
E3 bands, quantified using 
ImageJ software. Arbitrary 
unit (AU) values show the 
mean  SEM of two 
independent experiments. * 
p<0.05.  
 
 
 
LACK antigen-specific memory T cell 
responses  
To determine whether increased LACK early 
expression enhances LACK-specific T cell 
responses, we infected BALB/c mice i.p. with two 
doses of MVA-LEO-LACK or MVA-LEO160-LACK 
virus, spaced by one week to avoid a high anti-
vaccinia IgG antibody response (Hagensee et al., 
1995) that could impair the MVA infective 
capacities. This homologous immunization 
protocol, in which mice were virus-inoculated 
more than once, was used because it is reported 
that differential antigen presentation changes the 
T cell immunodominance hierarchy between 
primary and secondary immunization (Crowe et 
al., 2003) and that this hierarchy correlates with 
viral gene expression after secondary 
immunization (Kastenmuller et al., 2007).  
 
 
 
Since memory T cell responses are essential for 
inducing long-term protection against pathogen 
infection (Darrah et al., 2007; Reyes-Sandoval et 
al., 2011; Schmidt et al., 2008), at 66 days after 
the final virus dose, we measured the splenocyte 
T cell memory profile by intracellular cytokine 
staining (ICS). Splenocytes from infected mice 
were stimulated with purified LACK protein to 
study LACK-specific CD4 T cell responses, or with 
A20 cells previously nucleofected with the 
mammalian expression plasmid pcDNA-LACK to 
study LACK-specific CD8 T cell responses.  To 
determine the functional profile of T cells, we 
measured levels of lysosomal-associated 
membrane protein-1 (LAMP-1/CD107a) as a 
surrogate marker for induction of killing, as well as 
gamma interferon (IFN-γ), tumor necrosis factor 
alpha (TNF-α) and interleukin-2 (IL-2) levels.  We 
defined the magnitude of the response as LACK-
specific T cells that expressed CD107a or the sum 
of the frequencies of LACK-specific T cells 
secreting IFN-γ and/or TNF-α and/or IL-2.  
Polyfunctionality, defined as T cell capacity to 
express more than one of these four activation 
markers, determined the quality of the T memory 
cell response. 
 
MVA-LEO160-LACK induced significantly more 
LACK-specific IFN-γ and/or TNF-α and/or IL-2-
secreting CD4 T cells than MVA-LEO-LACK, 
when splenocytes were stimulated with LACK 
protein Figure 6(A). MVA-LEO160-LACK also 
generated significantly more LACK-specific 
CD107a-expressing CD4 T cells than MVA-LEO-
LACK in virus-infected mice Figure 6(B). The 
quality of the LACK-specific CD4 T cell response 
showed that compared to MVA-LEO-LACK, MVA-
LEO160-LACK induced a significant increase in 
quadruple activation marker-positive CD4 T cells 
Figure 6(C). The high polyfunctional profile 
generated was also represented by IFN-γ, TNF-α 
and IL-2 triple-positive CD4 T cells Figure 6(C); 
TNF-α single-positive CD4 T cells were the third 
most representative group.  
 
The LACK-specific CD8 T cell profile showed that 
MVA-LEO160-LACK induced a significantly higher 
IFN-γ and/or TNF-α and/or IL-2+ CD8 T cell 
response to LACK antigen Figure 6(D) compared 
to MVA-LEO-LACK; this significance difference 
was also detected in LACK-specific CD107a+ CD8 
T cells between two groups Figure 6(E). The 
polyfunctional CD8 T cell profile showed a clear 
predominance of the IFN-γ+TNF-α+CD107a+ 
subset, followed by the quadruple marker-positive 
population Figure 6F).  All of these data indicate 
that increased LACK-specific CD4 and CD8 T cell 
response induced by MVA-LEO160-LACK 
correlates with the enhanced LACK antigen 
expression.  
 
DISCUSSION 
 
Two categories of VACV early genes have been 
defined based on their temporal expression 
(Assarsson et al., 2008; Yang et al., 2010); their 
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Figure 6. Vaccine-induced LACK-specific CD4 T and CD8 T 
memory cell responses in MVA-WT-, MVA-LEO-LACK- or MVA-
LEO160-LACK-infected mice. The response was measured 66 days 
after the last immunization in mice (n = 4 per group). (A) Percentage 
of LACK-specific CD4 T cells secreting cytokines after two virus 
doses (107 PFU/mouse) spaced by one week.  Values are the sum of 
the percentages of IL-2- and/or IFN-g- and/or TNF-a-secreting CD4 T 
cells. (B) Percentage of LACK-specific CD4 T cells expressing 
CD107a. (C) Functional profile of LACK-specific CD4 T memory cells. 
Combinations are shown of the responses (x axis) and percentages 
of functionally distinct populations (y axis).  (D) Percentage of LACK-
specific CD8 T cells secreting cytokines. Values are the sum of the 
percentages of IL-2- and/or IFN-g- and/or TNF-a-secreting CD8 T 
cells. (E) Percentage of LACK-specific CD8 T cells expressing 
CD107a. (F) Functional profile of LACK-specific CD8 T memory cells. 
Combinations are shown of the responses (x axis) and percentages 
of functionally distinct populations (y axis). Values shown as mean ± 
CI. * p<0.05, ** p<0.01, *** p<0.001. 
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promoter motif (consensus sequence) and their 
promoter spacers were also recently reported 
(Yang et al., 2011a).  To define the role of the 
promoter spacer in the optimization of early 
antigen expression, we designed two new 
promoters, LEO99 and LEO160, with distinct 
spacer lengths and compared them with the 
previously reported LEO promoter (Di Pilato et al., 
2013). 
 
Compared to LEO, the LEO99 and LEO160 
promoters (with 99 and 160 nt spacers) increased 
early antigen expression.  The 50-nt window, from 
-70 nt to -20 nt before the ORF, is the most 
frequent site for the promoter motif of early genes 
and was used to generate the LEO promoter with 
a 38-nt spacer (Di Pilato et al., 2013).  This result 
suggests that VACV, whose early genes rarely 
have spacers longer than 70 nucleotides, does not 
alone induce the highest possible gene 
expression.  The DNA footprint of vaccinia RNA 
polymerase ternary complexes is less than 50 nt 
(Hagler and Shuman, 1992).  The vaccinia virus 
early transcription factor (ETF) (Broyles et al., 
1988) and RNA polymerase-associated protein 
(RAP94) (Ahn et al., 1994) mediate the promoter-
RNA polymerase link.  We hypothesized that 
spacers >50 nt would offer greater space to the 
transcription machinery, possibly accelerating 
gene expression, and defined here that spacers 
with more than 99 nt offer advantages of early 
gene expression. These new long spacers are 
maintained in the virus during multiple passages 
in cells, indicating stability within the virus 
genome. 
 
Attenuated VACV vectors (MVA, ALVAC and 
NYVAC poxvirus strains) are used as candidate 
vaccines for emerging infectious diseases and 
cancer (Gomez et al., 2011).  Several strategies 
have been developed to improve immunogenicity 
to heterologous antigens expressed by these 
vectors, including use of costimulatory molecules, 
administration of heterologous vectors, deletion of 
immunomodulatory viral genes and insertion of 
host range viral genes (Garcia-Arriaza and 
Esteban, 2014; Gomez et al., 2012, 2013). Early 
gene expression mediated by promoter 
optimization is another strategy to increase 
immunogenicity of the foreign antigen (Baur et al., 
2010). Although it is reported that VACV 
intermediate antigens are the preferentially 
recognized by CD4 T cells (Yang et al., 2011b), 
we demonstrate that the early LACK expression 
driven by the early promoter of MVA-LEO160-
LACK can positively influence LACK-specific CD4 
T cell responses. While antigen-specific T cell 
responses can provide protective immunity 
against parasites (Belnoue et al., 2004), in a 
Leishmania infection model, only CD4 T cell 
immunogenicity correlated with this protection 
(Darrah et al., 2007).  
 
Following Leishmania major infection, BALB/c 
mice show principally a Th2 response, due to the 
Th2 immunogenicity of the LACK antigen 
(Mougneau et al., 1995). As it is associated to 
greater susceptibility to Leishmania infection in 
BALB/c mice (Launois et al., 2007), a Th2 
response must be avoided when using a LACK 
vaccine strategy in this strain.  Conversely, the 
Th1 response protects against leishmaniasis 
infection (Darrah et al., 2010; Darrah et al., 2007). 
Th1 immune response was triggered by the MVA-
LEO-LACK and MVA-LEO160-LACK, with clear 
differences in magnitude and polyfunctionality. We 
found that MVA-LEO160-LACK increased the 
number of IL-2+IFNγ+TNFα+ CD4 Th1 cells.  
Compared to MVA-LEO-LACK, MVA-LEO160-
LACK induced more antigen-specific CD4 T 
effector memory cells, which are necessary for 
protection against Leishmania reinfection (Peters 
et al., 2014).  MVA-LEO160-LACK also enhanced 
CD107a+ memory CD4 T cells to LACK.  CD107a+ 
CD4 T cells are resistant to HIV-1 infection, which 
implies that these cells could control the infection 
(Terahara et al., 2014). Compared to MVA-LEO-
LACK, we also demonstrated that MVA-LEO160-
LACK increased the magnitude of polyfunctional 
CD8 T cells that express IL-2 and IFNγ; these cell 
subsets have a role in maintaining Th1 
polarization of CD4 T cells (Gurunathan et al., 
2000), limiting the natural Th2 response (Uzonna 
et al., 2004).  
 
Although the role of memory CD8 T cells against 
Leishmania remains to be defined, CD8 T memory 
cells have a clear protective function against 
parasites (Reyes-Sandoval et al., 2011; Rigato et 
al., 2011). The capacity of MVA-LEO160-LACK 
viral vector to increase CD8 and CD4 T memory 
cell responses against a heterologous antigen 
could be useful in other infection models where a 
robust presence of both T cell subtypes has been 
associated with protection and control of disease 
(Hansen et al., 2011; Hansen et al., 2009). 
 
In summary, we have identified how VACV 
promoters with different spacer lengths can be 
used to enhance the levels of foreign antigens in 
infected cells. We defined in vitro and in vivo the 
strength of MVA-LEO160, as a valid strategy to 
induce early heterologous antigen expression.  In 
mouse studies, the magnitude and the quality of 
the CD4 and CD8 T memory responses defined 
the improved immune properties of this vector.  
Based on its capacity to increase early antigen 
expression and antigen-specific CD4 and CD8 T 
cell responses, MVA-LEO160 is a prototype for 
the design of new poxvirus-based vaccine vectors. 
 
METHODS   
 
Mice and injections 
BALB/c mice (6-8 weeks old) were purchased 
from Harlan (Interfauna Ibérica, Sant Feliu de 
Codines, Spain).  For the homologous 
immunization protocol to assay T cell 
immunogenicity, mice received two intraperitoneal 
(i.p.) injections (one every 7 days) of 107 PFU of 
MVA-WT, MVA-LEO-LACK or MVA-LEO160-
LACK. Animal studies were approved by the 
Ethical Committee of Animal Experimentation 
(CEEA-CNB) of the Centro Nacional de 
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Biotecnologia (CNB-CSIC, Madrid, Spain) in 
accordance with national and international 
guidelines and Royal Decree (RD 1201/2005) 
(permit nº 11037, 13012). 
 
Cells 
Human epithelial cervix adenocarcinoma cells 
(HeLa), immortalized chicken embryo fibroblast 
cells (DF-1; both from the American Type Culture 
Collection, Manassas, VA) and primary chicken 
embryo fibroblasts (CEF; Intervet, Salamanca, 
Spain) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% 
(v/v) FCS. Human monocytic THP-1 cells, murine 
macrophage J774.G8 cells and B lymphocytes 
derived from a reticulum cell sarcoma (A20; all 
from ATCC) were cultured in RPMI 1640 medium 
(Sigma-Aldrich) supplemented with 50 µM 
2-mercaptoethanol and 10% (v/v) FCS.  THP-1 
cells were differentiated into macrophages by 
treatment with 5 ng ml-1 phorbol 12-myristate 13-
acetate (Sigma-Aldrich) for 24 h before use.  Cells 
were cultured in humidified air, 5% (v/v) CO2 at 
37°C. 
 
Viruses 
The recombinant MVA-GFP and MVA-LACK 
viruses were constructed using GFP as 
fluorescent marker and β-galactosidase as 
reporter gene, respectively.  DF-1 cells were 
infected with 0.01 PFU/cell MVA-WT (1 h) and 
transfected with VACV insertional plasmid vectors 
pLZAW1-LEO (Di Pilato et al., 2013), pLZAW1-
LEO99 or pLZAW1-LEO160 using Lipofectamine 
(Invitrogen).  Recombinant viruses were selected 
from progeny virus by consecutive rounds of 
plaque purification, as reported (Gomez et al., 
2007a; Gomez et al., 2007b). In vitro virus 
infections were performed in medium with 2% 
(v/v) FCS.  All viruses were grown in primary CEF 
cells, similarly purified through two 36% (w/v) 
sucrose cushions, and titers were determined by 
immunostaining plaque assay in DF-1 cells, as 
described (Ramirez et al., 2000). 
 
Plasmids 
The plasmid transfer vectors pLZAW1-LEO99 and 
pLZAW1-LEO160 were obtained by inserting part 
of the pGEM-7Zf(-) (Promega) multi-cloning site 
(MCS) into the pLZAW1-LEO plasmid.  The 
plasmid transfer vectors pLZAW1-LEO-GFP, 
pLZAW1-LEO99-GFP, pLZAW1-LEO160-GFP, 
pLZAW1-LEO-LACK and pLZAW1-LEO160-LACK 
were obtained by cloning the GFP or Leishmania 
infantum LACK sequences into the pLZAW1-LEO, 
pLZAW1-LEO99 or pLZAW1-LEO160 plasmids. 
 
Protein 
Leishmania infantum LACK protein was 
expressed as a fusion protein with an N-terminal 
histidine tag using the E. coli strain BL21 pLysS 
transformed with the pRSET-B-LACK plasmid 
(Gonzalez-Aseguinolaza et al., 1999), which 
allows affinity chromatography purification on a 
Ni2+ column.  LACK expression was induced by 
addition of isopropyl thio-β-D-galactoside (37ºC). 
 
PCR 
Viral DNA was extracted by the SDS-proteinase 
K-method (Perdiguero et al., 2013).  Primers TK-L 
and TK-R were used for PCR analysis of the TK 
locus, as described (Gomez et al., 2007a), to 
confirm GFP and LACK gene insertion.  The 
primers GFP-Fwd CCGCTCGAGATGGCTAGCAA 
AGGAGAAGAAC and GFP-Rev AACTGCAGTTC 
TCAAGCTATGCATCCAAC, the primers LACK-
Fwd CTAGCTAGCTCGAGATGAACTACGAGGG 
TCACC and LACK-Rev AACTGCAGTTACTCGG 
CGTCGGAGATGG, and the primers MCS-Fwd 
CCGCTCGAGGAATTCGGTACCCC and MCS-
Rev CCGCTCGAGGTTGGGAGCT CTCC were 
used for GFP, LACK and MCS amplification, 
respectively. 
 
Western blot 
HeLa cells were lysed in Laemmli buffer, extracts 
fractionated by 8% (v/v) SDS-PAGE and analyzed 
by Western blot using rabbit polyclonal anti-LACK, 
-E3 (both from the Centro Nacional de 
Biotecnología) or -tubulin antibodies (Cell 
Signaling). 
 
Nucleofection assay 
A20 cells were nucleofected using 4D-
Nucleofector (Lonza) and the Amaxa SF Cell Line 
kit (Lonza).  Cells were nucleofected with 6 µg of 
pCIneo-LACK plasmid; pCIneo-φ was used as 
negative control.  At 24 h post-nucleofection, A20 
cells were used to restimulate splenocytes from 
infected mice (1:10 A20:splenocyte ratio). 
 
Flow cytometry 
For intracellular cytokine staining (ICS), 
erythrocyte-depleted splenocytes were rested 
overnight, resuspended in RPMI 1640 with 10% 
(v/v) FCS and 1 µg ml-1 Golgiplug (Becton 
Dickinson; BD), monensin (eBioscience) and anti-
CD107a (1D4B; BD). After restimulation with 
25 µg ml-1 LACK protein or A20 cells (6 h, 37°C), 
splenocytes were stained for surface markers 
using anti-CD3 (145-2C11), -CD4 (GK1.5), -CD8 
(53-6.7), -CD62L (MEL-14) (all from BD) and -
CD127 (A7R34) (eBioscience), then fixed, 
permeabilized (Cytofix/Cytoperm kit; BD), and 
stained intracellularly with anti-IL-2 (JES6-
5H4), -IFN-γ (XMG 1.2) and -TNF-α (MP6-X722) 
(all from BD).  Peritoneal exudate cells (PEC), 
obtained after injection of cold PBS into previously 
infected mice, were counted and stained with anti-
F4/80 (BM8, eBioscience).  Dead cells were 
stained using the violet LIVE/DEAD stain kit 
(Invitrogen) in all flow-cytometry analyses. Cells 
were acquired using a GALLIOS (Beckman 
Coulter) or LSRII (BD) flow cytometer; data 
analyses were performed with FlowJo software v. 
8.5.3 (Tree Star).  Boolean combinations of single 
functional gates were created with FlowJo to 
determine the frequency of each response based 
on all possible combinations of cytokines or of 
differentiation marker expression. 
 
Statistical analysis 
For statistical analysis of the T cell response to 
LACK antigen, we used an approach that corrects 
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measurements for medium response and allows 
calculation of confidence intervals (CI) and p 
values of hypothesis tests (Najera et al., 2010).  
Only antigen response values significantly larger 
than the corresponding RPMI condition are 
shown.  Background values were subtracted from 
all values used to allow analysis of proportional 
representation of responses.  Distribution was 
analyzed and presented using SPICE version 5.1, 
downloaded from http://exon.niaid.nih.gov.  For 
statistical analysis of antigen expression, 
Student’s t-test was applied to compare the 
viruses used. 
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Results 
 
 
3.4 Summary 
3.4.1 Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR 
signalling, is an effective approach to enhance the immunogenicity in mice of the 
HIV/AIDS vaccine candidate NYVAC-C 
Distinct MVA (modified vaccinia virus Ankara) recombinants have been generated 
to target Toll-like receptor (TLR) pathways that, by inducing innate immune responses 
after pathway activation, are indirectly involved in the generation of antigen-specific 
T cell responses.  By binding the Toll-like-interleukin-1 receptor adaptors and 
disrupting the interaction between TLR and these adaptors, vaccinia virus A46 protein 
inhibits activation of the interferon (IFN) type I signal.  The role of A46 in the 
generation of immune responses to heterologous antigens has not been described. 
To respond to this question, we generated NYVAC, a highly attenuated VACV strain 
that expresses HIV-1 clade C antigens but lacks the specific A46R viral gene.  The 
NYVAC-C ΔA46R virus induced a higher pro-inflammatory response compared to 
NYVAC-C virus, as indicated by cytokine/chemokine levels in infected macrophages.  
In mice, the new deletion mutant increased the HIV-1 CD8 T cell memory and adaptive 
responses as well as the HIV-1 CD4 T cell adaptive response. 
These results confirm the role of A46 in inducing pro-inflammatory signals, 
demonstrate the link between the TLR pathway and heterologous antigen-specific    
adaptive/memory responses, and lay a foundation for similar approaches in the design 
of vaccinia virus candidate vaccines. 
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Abstract
Viruses have developed strategies to counteract signalling through Toll-like receptors (TLRs) that are involved in the
detection of viruses and induction of proinflammatory cytokines and IFNs. Vaccinia virus (VACV) encodes A46
protein which disrupts TLR signalling by interfering with TLR: adaptor interactions. Since the innate immune response
to viruses is critical to induce protective immunity, we studied whether deletion of A46R gene in a NYVAC vector
expressing HIV-1 Env, Gag, Pol and Nef antigens (NYVAC-C) improves immune responses against HIV-1 antigens.
This question was examined in human macrophages and in mice infected with a single A46R deletion mutant of the
vaccine candidate NYVAC-C (NYVAC-C-ΔA46R). The viral gene A46R is not required for virus replication in primary
chicken embryo fibroblast (CEF) cells and its deletion in NYVAC-C markedly increases TNF, IL-6 and IL-8 secretion
by human macrophages. Analysis of the immune responses elicited in BALB/c mice after DNA prime/NYVAC boost
immunization shows that deletion of A46R improves the magnitude of the HIV-1-specific CD4 and CD8 T cell immune
responses during adaptive and memory phases, maintains the functional profile observed with the parental NYVAC-
C and enhances anti-gp120 humoral response during the memory phase. These findings establish the immunological
role of VACV A46R on innate immune responses of macrophages in vitro and antigen-specific T and B cell immune
responses in vivo and suggest that deletion of viral inhibitors of TLR signalling is a useful approach for the
improvement of poxvirus-based vaccine candidates.
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Introduction
The search for a safe and effective HIV vaccine able to elicit
long-lasting protective immunity has encouraged the
development of recombinant live vaccine candidates with good
safety and immunogenicity profiles. The Thai phase III clinical
trial (RV144) using the recombinant poxvirus vector ALVAC
and the protein gp120 in a prime-boost strategy and showing a
31.2% protection against HIV infection [1], has raised
considerable interest in the use of improved attenuated
poxvirus recombinants as HIV vaccine candidates. Among
poxviruses, the highly attenuated vaccinia virus (VACV) strain
NYVAC is under intense preclinical and clinical evaluation as a
vaccine against emergent infectious diseases and cancer [2].
The NYVAC strain was derived from a plaque clone isolate
of the Copenhagen vaccinia virus strain (VACV-COP) by the
deletion of 18 open reading frames (ORFs) involved in
virulence, pathogenesis and host range functions [3]. In spite of
its limited replication in human and most mammalian cell types,
NYVAC provides a high level of gene expression and induces
antigen-specific immune responses when administered to
animals and humans [2,4,5,6]. However, the vector still
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contains other immunomodulatory viral genes that may
suppress host immunity, particularly genes encoding proteins
that antagonize the innate immune response mediated by Toll-
like receptor (TLR) signalling. The deletion of these
immunomodulatory genes could be a strategy to further
improve NYVAC-based vaccines with the aim to obtain
enhanced magnitude, breadth, polyfunctionality and durability
of the immune responses.
The sensing of viral pathogens and the subsequent innate
immune responses triggered are critical to produce protective
immunity. Cells of the innate immune system detect viruses
through the recognition of specific pathogen-associated
molecular patterns (PAMPs) by pattern recognition receptors
(PRRs) [7,8,9,10], among which TLRs are the best
characterized [11]. TLR3, TLR7/8 and TLR9 reside
predominantly within the endosomes where they recognize
viral nucleic acids being involved in the generation of potent
antiviral responses [12] while viral glycoprotein products have
been shown to interact with TLR2 and TLR4 expressed on the
cell surface [13,14]. The implication of TLR2 in the induction of
type I IFN in inflammatory monocytes following in vivo infection
with VACV has been reported and depletion of these cells
leads to elevated levels of VACV in ovaries of mice [15]. TLR2
signalling has also been shown to be important for clonal
expansion and memory CD8 T cells formation following VACV
infection [16] and in VACV-induced production of
proinflammatory cytokines by murine denditic cells (DCs) [17].
The best known role of TLR4 is the detection of
lipopolysaccharide (LPS) but this receptor is also involved in
the immune response to viruses. For example, TLR4 has been
reported to be protective in pulmonary VACV infection since
mice deficient for TLR4 signalling showed enhanced viral
replication, hypothermia and mortality compared to control
animals [18]. Because TLRs are expressed both on specific
nonimmune cells, such as epithelial cells at potential sites of
entry, and on a variety of immune cells including macrophages,
DCs, B cells and certain types of T cells, they play a key role in
the defence against pathogens through the induction of
proinflammatory cytokines and type I IFNs but also in shaping
pathogen-specific humoral and cellular adaptive immune
responses.
All TLRs are type I transmembrane glycoprotein receptors
comprised of an extracellular N-terminal leucine-rich repeat
(LRR) domain involved in ligand binding, a single
transmembrane domain and an intracellular C-terminal domain,
known as the Toll/IL-1 receptor (TIR) domain, which mediates
the interaction and recruitment of various adaptor proteins to
activate the downstream signalling pathway [19]. PAMP
binding induces receptor homo- or heterodimerization [20,21]
and this activated conformation of the receptor triggers the
recruitment of TIR domain-containing adaptor proteins that
connect downstream signalling molecules leading to the
activation of transcription factors such as IFN regulatory factors
(IRFs) and NF-κB and the induction of type I IFNs and
proinflammatory cytokines, respectively. Ligand recognition by
TLRs induces the recruitment of five different adaptor proteins:
Myeloid differentiation factor 88 (MyD88), MyD88-adaptor-like
(Mal), TIR domain-containing adaptor protein-inducing IFN-β
(TRIF), TRIF-related adaptor molecule (TRAM) and sterile α-
and armadillo-motif-containing protein (SARM) [22]. Two major
pathways can be activated by TLRs: the MyD88-dependent
pathway, used by all TLRs except TLR3 [23] and the TRIF-
dependent pathway, used by TLR3 and TLR4. TLR4 is the only
receptor being able to signal via both pathways due to the
differential use of two adaptors, TRAM and Mal. TLR4 uses
TRAM to recruit TRIF and induce a type I IFN response via the
TRIF-dependent pathway while the use of the coadaptor Mal to
recruit MyD88 via the MyD88-dependent pathway induce a
proinflammatory response [24]. Crystal structures of the TIR
domains of TLR2 [25], TLR10 [26], interleukin-1 receptor
accessory protein-like (IL-1RAPL) [27] and Mal [28,29] and
NMR structure of the TIR domain of MyD88 [30] have been
determined. These studies identified a conserved protruding
BB loop between the βB strand and the αB helix, which is
essential for functional TLR signalling [31,32,33,34,35].
Viruses have developed strategies to target TLR-mediated
signalling to manipulate and evade the host innate immune
response [36]. VACV encodes some intracellular negative
regulators of TLR signalling including A46 [37], A52 [38], N1
[39], B14 [40], K7 [41] and C6 [42]. A46 was the first virally
encoded protein identified to contain a TIR domain [37,43].
Through this domain, A46 binds directly to the TIR domain-
containing adaptors MyD88, Mal, TRIF and TRAM, disrupting
the formation of Receptor: Adaptor TIR interactions [37] and
therefore inhibiting downstream signalling to MAPKs, NF-κB
and IRF-3 and interfering with both proinflammatory and type I
IFN responses [37]. However, A46 does not interact with
SARM, which is a negative regulator of TLR signalling [37]. It
has also been shown that A46 protein contributes to virulence
since VACV A46R deletion mutant was attenuated in a murine
intranasal model [37]. An 11 amino acid peptide derived from
A46 (called VIPER) has been reported to specifically inhibit
TLR4 responses by directly targeting Mal and TRAM [44] and
that A46 binds to Mal via a Bcl-2-like α-helical dimer
subdomain [45]. The molecular basis for A46 antagonism of
TLR4 has been recently reported [46]. A46 has been shown to
impair TLR4 signalling by targeting the conserved BB loop of
TIR proteins and thereby disrupting Receptor: Adaptor TIR
interactions [46].
Since VACV has been reported to be sensed by TLR2
[15,16,17], TLR4 [18], TLR2-TLR6-MyD88, MDA-5/IPS-1 and
NALP3 inflammasome [47] and A46R targets the TIR domain
of the adaptors MyD88, Mal, TRIF and TRAM [37], in the
present study we have asked to what extent A46R impacts on
the immune responses against VACV. This question was
addressed with NYCAC-C, an attenuated poxvirus vector
expressing HIV-1 Env and Gag-Pol-Nef (GPN) antigens from
clade C [48], where A46R was deleted (NYVAC-C-ΔA46R).
Specific innate, adaptive and memory immune responses to
HIV-1 antigens were evaluated in human macrophages and in
a BALB/c mouse model comparing the recombinant virus in the
presence or absence of A46R. Our findings provided evidence
for an immunomodulatory role of VACV A46 protein.
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Results
Generation and in vitro characterization of NYVAC-C-
ΔA46R deletion mutant
NYVAC-C-ΔA46R deletion mutant was generated as detailed
under Materials and Methods using as parental virus the
recombinant NYVAC-C that expresses the HIV-1 Env, Gag, Pol
and Nef antigens from clade C [48] and following a strategy
that allows the deletion of the gene of interest with no
fluorescent marker included in the final deletion mutant. The
correct deletion of A46R gene was confirmed by PCR using
primers annealing in A46R flanking sequences. As shown in
Figure 1A, A46R ORF was successfully deleted and no wild-
type contamination was present in NYVAC-C-ΔA46R
preparation. Analysis by Western-blot confirmed that the A46R
deletion mutant expresses the HIV-1 proteins gp120 and GPN
at the same level as the parental virus NYVAC-C (Figure 1B).
Moreover, analysis by immunostaining showed that all virus
plaques have immunoreactivity to anti-WR, anti-gp120 and
anti-gag p24 antibodies (data not shown), demonstrating the
stability of the antigens expressed by the A46R deletion
mutant. To determine if deletion of A46R gene affects virus
replication, we compared the growth kinetic of NYVAC-C-
ΔA46R deletion mutant with its parental virus NYVAC-C in CEF
cells. Figure 1C shows that the growth kinetics were similar
between parental and deletion mutant, indicating that A46R
gene is not required for virus replication in cultured cells and its
deletion does not affect virus growth kinetics.
NYVAC-C-ΔA46R up-regulates TNF, IL-6 and IL-8
production by human macrophages
To define whether A46R impairs the response of innate
immune cells to NYVAC-C, we measured by ELISA the
concentrations of proinflammatory cytokines and chemokines
released by human THP-1 macrophages infected for 6 hours
with 1 or 5 PFU/cell of NYVAC-WT, NYVAC-C or NYVAC-C-
ΔA46R. Compared to NYVAC-WT and to NYVAC-C, the A46R
deletion markedly up-regulated the production of TNF, IL-6 and
IL-8 by THP-1 cells (Figure 2). Thus, the single deletion of
A46R in the NYVAC-C genome triggers a stronger innate
immune sensing than NYVAC-C, providing evidence for
immune suppression by A46R.
Deletion of the viral gene A46R in NYVAC-C induces high,
broad and polyfunctional HIV-1-specific T cell adaptive immune
responses in BALB/c mice in heterologous prime/boost
combination
To assay in vivo the effect of A46R gene deletion on the
cellular immunogenicity against HIV-1 antigens, we analyzed
the HIV-1-specific T cell adaptive immune responses elicited in
mice by using a DNA prime/Poxvirus boost approach since it
has been extensively reported that this heterologous
immunization protocol is more immunogenic than either
component alone to activate T cell responses to HIV-1 antigens
[48,49,50].
BALB/c mice, 4 in each group, were immunized as described
in Materials and Methods and adaptive T cell immune
responses were measured 10 days after the last immunization
by polychromatic intracellular cytokine staining (ICS) assay.
Splenocytes from immunized animals were stimulated ex vivo
for 6 hours with a panel of 464 peptides (15 mers overlapping
by 11 amino acids) grouped in three pools: Env (112 peptides),
Gag (121 peptides) and GPN (231 peptides) and stained with
specific antibodies to identify T cell lineage (CD3, CD4 and
CD8), degranulation (CD107a) and responding cells (IL-2, IFN-
γ and TNF-α). The percentages of T cells producing IFN-γ
and/or IL-2 and/or TNF-α established the overall CD4+ T cell
responses whereas the percentages of T cells producing
CD107a and/or IFN-γ and/or IL-2 and/or TNF-α determined the
overall CD8+ T cell responses.
As shown in Figure 3A, in both immunization groups DNA-C/
NYVAC-C and DNA-C/NYVAC-C-ΔA46R the magnitudes of the
HIV-1-specific CD4 or CD8 T cell responses, determined as the
sum of the individual responses obtained for Env, Gag and
GPN peptide pools, were significantly higher than those
obtained in the control group DNA-ϕ/NYVAC-WT (p<0.001).
Furthermore, the magnitudes of the HIV-1-specific CD4 or CD8
T cell responses in the group immunized with NYVAC-C-
ΔA46R were significantly higher than those obtained in the
group DNA-C/NYVAC-C (p<0.001). In animals immunized with
the parental NYVAC-C, the CD4+ T cell response was only
directed against the Env pool while in the group boosted with
the NYVAC-C-ΔA46R deletion mutant this response was
mainly mediated by Env pool but the response against Gag
and GPN peptide pools also contributes to the total HIV-1-
specific CD4 T cell response. On the other hand, the CD8+ T
cell responses were higher in magnitude and A46R gene
deletion induced a significant enhancement in the magnitude of
the CD8+ T cell responses against the Env pool (p<0.001)
whereas the anti-GPN response was maintained.
Representative functional profiles of Env-specific CD4 or CD8
T cell responses are shown in Figure 3B.
The quality of a T cell response can be characterized in part
by the pattern of cytokine production and by the cytotoxic
potential. On the basis of the analysis of IFN-γ, IL-2 and TNF-α
secretion, as well as the study of CD107a expression on the
surface of activated T cells as an indirect marker of cytotoxicity,
8 HIV-specific CD4 T cell populations and 16 HIV-specific CD8
T cell populations were identified. Vaccine-induced CD4 T cell
responses were highly polyfunctional in both DNA-C/NYVAC-C
and DNA-C/NYVAC-C-ΔA46R groups, with more than 60% of
CD4 T cells exhibiting two or three functions. CD4 T cells
producing IFN-γ+IL-2+TNF-α, IL-2+TNF-α or only TNF-α or
IL-2 were the most representative populations induced by the
parental NYVAC-C and the A46R deletion mutant, although the
percentages of cells producing cytokines were low (Figure 3C).
The HIV-1-specific CD8 T cell responses, higher in magnitude,
were also polyfunctional in both immunization groups, with
more than 50% of CD8+ T cells exhibiting two, three or four
functions. CD8+ T cells producing CD107a+ IFN-γ+TNF-α,
CD107a+ TNF-α or only CD107a were the most representative
populations induced by the parental NYVAC-C and NYVAC-C-
ΔA46R deletion mutant (Figure 3C).
Overall, these results indicate that deletion of A46R gene
from NYVAC-C genome improved the magnitude of the HIV-1-
specific adaptive CD4 and CD8 T cell immune responses and
maintained the polyfunctional profile observed with the parental
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Figure 1.  In vitro characterization of NYVAC-C-ΔA46R deletion mutant.  (A) Confirmation of A46R gene deletion by PCR
analysis. Viral DNA was extracted from BSC-40 cells infected with NYVAC-WT or NYVAC-C-ΔA46R at 5 PFU/cell. Primers
LFA46R-Aat and RFA46R-Bam spanning A46R flanking sequences were used for PCR analysis of A46R locus. In parental NYVAC,
a 1342 bp-product is obtained while in deletion mutant a unique 777 bp-product is observed. (B) Expression of HIV antigens by
Western-blot. BSC-40 cells were mock-infected or infected at 5 PFU/cell with NYVAC-WT, NYVAC-C or NYVAC-C-ΔA46R. At 24
hours post-infection, cells were lysed in Laemmli buffer, cells extracts were fractionated by 8% SDS-PAGE and analyzed by
Western-blot using a polyclonal anti-gp120 antibody or a polyclonal anti-gag p24 serum to evaluate the expression of gp120 and
GPN proteins, respectively. (C) Analysis of virus growth of NYVAC-C-ΔA46R in CEF cells. Monolayers of CEF cells were infected
with NYVAC-C or NYVAC-C-ΔA46R at 0.01 PFU/cell. At different times post-infection (0, 24, 48 and 72 hours), cells were collected
and infectious viruses were quantified by immunostaining plaque assay in BSC-40 cells.
doi: 10.1371/journal.pone.0074831.g001
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NYVAC-C. Since the contribution of DNA priming is the same
for NYVAC-C and NYVAC-C-ΔA46R immunization groups, the
differences observed should be attributed to the A46R deletion.
Deletion of the viral gene A46R impacts on the HIV-1-
specific CD8 T cell memory phase of the immune
response
Phenotypic analysis of memory vaccine-induced T cell
immune responses was performed by polychromatic ICS assay
53 days after the last immunization. Splenocytes from
immunized mice were stimulated ex vivo for 6 hours with the
HIV-1 peptide pools Env, Gag and GPN and stained with
specific antibodies to identify T cell lineage (CD3, CD4 and
CD8), degranulation (CD107a), responding cells (IL-2, IFN-γ
and TNF-α) as well as memory stages (CD127 and CD62L).
The magnitudes of the memory HIV-1-specific CD4 or CD8 T
cell responses, determined as the sum of the individual
responses obtained for Env, Gag and GPN peptide pools, were
significantly higher in the groups boosted with the parental
NYVAC-C or with the NYVAC-C-ΔA46R deletion mutant than in
the control group immunized with NYVAC-WT (p<0.001)
(Figure 4A).
The magnitude of the HIV-1-specific CD4 T cell response in
the group immunized with DNA-C/NYVAC-C-ΔA46R was
similar to that obtained in the group DNA-C/NYVAC-C and in
both cases it was mainly directed against Env. On the other
hand, the CD8+ T cell responses were higher in magnitude and
A46R gene deletion clearly induced a significant enhancement
in the magnitude of the CD8+ T cell responses against Env and
GPN (p<0.001). Representative functional profiles of Env-
induced CD8 T cell responses are shown in Figure S1.
HIV-specific CD8 T cell responses were polyfunctional in
both immunization groups with 75% of CD8 T cells exhibiting
two, three or four functions. CD8 T cells producing CD107a+
IFN-γ+TNF-α, CD107a+ IFN-γ+IL-2+TNF-α, CD107a+ TNF-α
or only CD107a were the most representative populations
induced (Figure 4B).
Since previous studies have shown that CD127 and CD62L
define functionally distinct populations of memory antigen-
specific T cells [51], we characterized the differentiation stages
of the responding CD8 T cells into central memory (TCM;
CD127+CD62L+), effector memory (TEM; CD127+CD62L-) or
effector (TE; CD127-CD62L-) populations. As shown in Figure
4C, about 60% of the HIV-specific CD8 T cells were of TEM
phenotype in the DNA-C/NYVAC-C and DNA-C/NYVAC-C-
ΔA46R groups.
Overall, these results indicate that deletion of A46R gene
from NYVAC-C genome improved the magnitude of the HIV-1-
specific memory CD8 T cell immune response and maintained
the polyfunctional profile and memory differentiation pattern
observed with the parental NYVAC-C.
Figure 2.  Deletion of A46R gene from NYVAC-C enhances innate immune responses.  Human macrophages were mock-
infected (0) or infected with NYVAC-WT, NYVAC-C or NYVAC-C-Δ46R (1 or 5 PFU/cell). 24 hours later, cell-free supernatants were
collected to quantify the concentrations of TNF and IL-6 by bioassay and of IL-8 by ELISA. Data are means ± SD of duplicates and
are representative of three independent experiments. * p<0.05, ** p<0.005.
doi: 10.1371/journal.pone.0074831.g002
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Figure 3.  Adaptive HIV-specific T cell immune responses elicited by A46R deletion mutant in the spleen of BALB/c mice in
heterologous prime/boost immunization protocol.  (A) Magnitude of the vaccine-specific CD4 or CD8 T cell response. The HIV-
specific CD4 or CD8 T cells were measured 10 days after the last immunization by ICS assay following stimulation of splenocytes
derived from immunized animals (n=4) with the different HIV peptide pools. The total value in each group represents the sum of the
percentages of CD4+ or CD8+ T cells secreting IFN-γ and/or IL-2 and/or TNF-α (CD4) or CD107a and/or IFN-γ and/or IL-2 and/or
TNF-α (CD8) against all HIV peptide pools. All data are background-subtracted. *** p<0.001. p value indicates significantly higher
responses compared to parental group or between DNA-C/NYVAC-C-ΔA46R and DNA-C/NYVAC-C immunization groups. (B) Flow
cytometry profiles of vaccine-induced CD4 or CD8 T cell responses against Env pool. (C) Functional profile of the adaptive HIV-
specific CD4 or CD8 T cell response in the different immunization groups. The possible combinations of the responses are shown
on the x axis, whereas the percentages of the functionally distinct cell populations within the total CD4 or CD8 T cell population are
shown on the y axis. Combinations that did not contribute significantly to the functional profile are not shown. Responses are
grouped and colour-coded on the basis of the number of functions. The non-specific responses obtained in the control group DNA-
ϕ/NYVAC-WT were subtracted in all populations. ** p<0.005, *** p<0.001. p values indicate significantly higher responses compared
to DNA-C/NYVAC-C immunization group.
doi: 10.1371/journal.pone.0074831.g003
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Figure 4.  Memory HIV-specific T cell immune responses elicited by A46R deletion mutant in the spleen of BALB/c mice
after prime/boost immunization.  (A) Magnitude of the vaccine-specific CD4 or CD8 T cell responses. The HIV-specific CD4 or
CD8 T cells were measured 53 days after the last immunization by ICS assay following stimulation of splenocytes derived from
immunized animals (n=4) with the different HIV peptide pools. The total value in each group represents the sum of the percentages
of CD4+ or CD8+ T cells secreting IFN-γ and/or IL-2 and/or TNF-α (CD4) or CD107a and/or IFN-γ and/or IL-2 and/or TNF-α (CD8)
against all HIV peptide pools. All data are background-subtracted. *** p<0.001. p value indicates significantly higher responses
compared to parental group or between DNA-C/NYVAC-C and DNA-C/NYVAC-C-ΔA46R immunization groups. (B) Functional
profile of the memory HIV-specific CD8 T cell response in the different immunization groups. The possible combinations of the
responses are shown on the x axis, whereas the percentages of the functionally distinct cell populations within the total CD8 T cell
population are shown on the y axis. Combinations that did not contribute significantly to the functional profile are not shown.
Responses are grouped and colour-coded on the basis of the number of functions. *** p<0.001. p values indicate significantly higher
responses compared to DNA-C/NYVAC-C immunization group. (C) Phenotypic profile of memory HIV-specific CD8 T cells.
Representative FACS plots showing the percentage of Env-specific CD8 T cells with central memory (TCM; CD127+CD62L+),
effector memory (TEM; CD127+CD62L-) or effector (TE; CD127-CD62L-) phenotype.
doi: 10.1371/journal.pone.0074831.g004
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Deletion of the viral gene A46R in NYVAC-C enhances
the anti-gp120 humoral response during the memory
phase
Since cells infected with NYVAC-C release monomeric
gp120 [48], we also evaluated the impact of the deletion of viral
gene A46R on the humoral response at day 68. We quantified
by ELISA the Env-specific IgG titers against the purified gp120
protein from the HIV-1 isolate CN54 (clade C). As shown in
Figure 5, the IgG titer obtained in the pool of sera of animals
immunized with NYVAC-C-ΔA46R is significantly higher
(p<0.005) than the titer obtained in the sera of animals
immunized with NYVAC-C indicating that deletion of the viral
gene A46R enhances the humoral response induced in mice
during the memory phase.
Deletion of the viral gene A46R impacts on the anti-
vector CD8 T cell adaptive and memory phases of the
immune response
Vaccine-induced anti-vector T cell immune response was
measured 10 and 53 days after the last immunization by
polychromatic ICS assay. Splenocytes from immunized
animals were stimulated ex vivo for 6 hours with VACV E3
peptide, which is specific for CD8 T cells [52]. During the
adaptive phase of the immune response, the magnitude of the
E3-specific CD8 T cell response was significantly lower in the
DNA-C/NYVAC-C and DNA-C/NYVAC-C-ΔA46R immunized
groups than in the control group immunized with DNA-ϕ/
NYVAC-WT (p<0.001) (Figure 6A). No statistical differences
were observed between the DNA-C/NYVAC-C and DNA-C/
NYVAC-C-ΔA46R groups. E3-specific CD8 T cell responses
were polyfunctional in all the immunization groups with almost
50% of CD8+ T cells exhibiting two, three or four functions. CD8
T cells producing only CD107a were the most representative
population induced (Figure 6B). During the memory phase, the
magnitude of the E3-specific CD8 T cell response in both
immunization groups DNA-C/NYVAC-C and DNA-C/NYVAC-C-
ΔA46R was significantly lower than that obtained in the control
group DNA-ϕ/NYVAC-WT (p<0.001) and the magnitude of the
E3-specific CD8 T cell response observed in the group DNA-C/
NYVAC-C-ΔA46R was significantly lower than that obtained in
the group DNA-C/NYVAC-C (p<0.001) (Figure 7A). E3-specific
CD8 T cell responses were polyfunctional in all the
immunization groups with almost 90% of CD8+ T cells
Figure 5.  Memory humoral immune response elicited by the A46R deletion mutant against HIV-1 gp120 protein.  Levels of
Env-specific IgG binding antibodies were measured in serum from naïve and immunized mice at day 68. The values represent the
mean antibodies titer for each group. ** p<0.005.
doi: 10.1371/journal.pone.0074831.g005
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exhibiting two, three or four functions. CD8 T cells producing
CD107a+ IFN-γ+TNF-α or CD107a+ IFN-γ+IL-2+TNF-α were
the most representative populations induced (Figure 7B).
Overall, these results indicate that deletion of A46R gene from
NYVAC-C genome reduced the magnitude of the VACV E3-
specific adaptive and memory CD8 T cell immune response but
maintained the polyfunctional profile observed with the parental
NYVAC-C. Since adaptive and memory immune responses to
HIV antigens were enhanced by the A46R deletion mutant
(Figures 3 and 4), the reduced T cell immune response
induced by the E3 peptide indicates an immunodominance of
HIV antigens.
Discussion
Development of non-replicating VACV vectors with enhanced
immunogenicity against foreign expressed antigens is a major
goal in the poxvirus field, aiming at the application of these
vectors as HIV/AIDS vaccines. This is in view of the restricted
immunogenicity triggered in clinical trials by the parental
vectors expressing HIV antigens, like MVA, NYVAC, canarypox
and fowlpox [53]. In fact, the reduced efficacy against HIV
infection, 31.2%, of the non-replicating canary poxvirus vector
combined with gp120 protein in the RV144 clinical trial [1],
highlighted the need of novel poxvirus vectors with improved
immunogenicity. With regard to non-replicating poxvirus
vectors, different strategies have been pursued to enhance
their potency, like the combination of heterologous vectors, use
of co-stimulatory molecules and disruption of viral genes
encoding immunosuppressive molecules [53]. The latter
strategy provides the additional advantage that the
immunomodulatory role of a viral gene can be easily quantified
in an organism.
A number of MVA deletion mutants in viral immune
modulators have been generated to date and tested in mice
[54,55,56,57,58] and macaques [59,60]. These studies have
shown that MVA recombinant viruses with a single deletion of
viral genes encoding inhibitors of type 1 IFN signalling pathway
(C6L [55]), apoptosis (F1L [56]), IL-18 binding protein (C12L
[57]) or the uracyl-DNA glycosylase gene (UDG [60]),
enhanced the overall immune responses to HIV-1 antigens.
The HIV-1-specific CD4 and CD8 T cell immune responses
were further increased by MVA vectors with deletions of two
(A41L/B16R [54]; or C6L/K7R; Garcia-Arriaza, submitted) or
four [IL-18 binding protein (MVA008L; C12L), Toll/IL-1 receptor
homolog (MVA159R; A46R), CC-chemokine binding protein
(MVA153L; B7R) and secreted IL-1β receptor (MVA184R;
B16R)] immunomodulatory genes [59], while an additional fifth
deletion of the uracyl-DNA glycosylase gene (MVA101R)
decreased the responses [59]. Similarly, NYVAC vectors with
single or double deletions in VACV genes B19R and B8R
encoding type I and type II IFN binding proteins, respectively,
increased the immune responses to HIV antigens in the mouse
model [61].
In an effort to uncover the role of VACV genes as immune
modulators and search for potential applications of these
vectors in the development of optimized vaccines, in this
investigation we showed that deletion of the viral TLR inhibitor
A46R gene in the NYVAC-C genome has no effect on the
replication capacity of the virus in CEF cells but triggers
expression of immunoregulatory genes in infected
macrophages. NYVAC-C also enhances, though to a lesser
extent, the production of these proinflammatory cytokines and
chemokines compared to NYVAC-WT indicating that the
expression of HIV-1 antigens has an effect on innate immune
cells. The impact on antigen-presenting cells of the expression
of HIV antigens from an attenuated poxvirus vector has been
previously reported by using microarray technology in human
dendritic cells infected with an MVA-based recombinant virus
expressing gp120 and GPN from clade B [62].
Significantly, in mice immunized following a DNA prime/
NYVAC boost protocol, the deletion mutant NYVAC-C-ΔA46R
enhanced HIV-specific T cell immune responses. Both CD4
and CD8 T cells specific for HIV antigens were activated. In the
adaptive phase, the magnitudes of the HIV-1-specific CD4 or
CD8 T cell responses in the group immunized with NYVAC-C-
ΔA46R were significantly higher than those obtained in the
group DNA-C/NYVAC-C (p<0.001), maintaining the
polyfunctional profile observed with the parental NYVAC-C. In
the memory phase, deletion of A46R gene from NYVAC-C
genome improved again the magnitude of the HIV-1-specific
memory CD8 T cell immune response, while both the
polyfunctional profile and memory differentiation pattern
observed were similar as those obtained with the parental
NYVAC-C. The main phenotype of the memory response was
TEM, which is of immunological relevance as this phenotype
has been correlated with protection in the macaque-SIV model
[63,64].
This enhanced HIV-specific T cell immune response is in
contrast with the lack or reduced effect of A46R deletion on
VACV E3-specific T cell responses during adaptive or memory
phases of the immune response, respectively (Figures 6 and
7). The absence or decrease of immune stimulatory effect
observed when E3 was used to stimulate mouse splenocytes in
comparison with the increased responses against HIV antigens
is likely to be related to the immune dominance of the HIV
antigens versus the viral E3 peptide and such
immunodominance may be due to the effect of the priming with
a DNA encoding the HIV-1 antigens and also to the fact that
NYVAC-C expresses E3 under its natural early promoter while
the HIV antigens are expressed at early and late times from a
strong synthetic early/late promoter. Since both explanations
can be applied to NYVAC-C or NYVAC-C-ΔA46R-induced
immune responses, the lower E3-specific CD8 T cell adaptive
and memory immune responses elicited by NYVAC-C-ΔA46R
deletion mutant compared with that induced by NYVAC-C are
inversely correlated with the higher HIV-1-specific CD8 T cell
responses triggered by the A46R deletion mutant. A similar
trend for E3 response in relation to foreign expressed antigens
has been observed for other recombinant VACV vectors [65].
Therefore, a reduction of immune responses to NYVAC-C-
ΔA46R vector antigens has the additional vaccine advantage
that HIV antigens are favoured over viral antigens, thus
enhancing the specific immune responses to HIV.
Since humoral response against HIV antigens has been
described to be important for protection against HIV acquisition
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Figure 6.  Adaptive VACV vector-specific T cell immune responses elicited by A46R deletion mutant in the spleen of
BALB/c mice after prime/boost immunization.  (A) Magnitude of the VACV-specific CD8 T cell response. The VACV-specific
CD8 T cells were measured 10 days after the last immunization by ICS assay following stimulation of splenocytes derived from
immunized animals (n=4) with VACV E3 peptide. The total value in each group represents the sum of the percentages of CD8+ T
cells secreting CD107a and/or IFN-γ and/or IL-2 and/or TNF-α against E3 peptide. All data are background-subtracted. *** p<0.001.
p value indicates significantly higher response compared to DNA-C/NYVAC-C and DNA-C/NYVAC-C-ΔA46R immunization groups.
(B) Functional profile of the VACV-specific CD8 T cell response in the different immunization groups. The possible combinations of
the responses are shown on the x axis, whereas the percentages of the functionally distinct cell populations within the total CD8 T
cell population are shown on the y axis. Combinations that did not contribute significantly to the functional profile are not shown.
Responses are grouped and colour-coded on the basis of the number of functions. * p<0.05, ** p<0.005, *** p<0.001.
doi: 10.1371/journal.pone.0074831.g006
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Figure 7.  Memory VACV vector-specific T cell immune responses elicited by A46R deletion mutant in the spleen of BALB/c
mice after prime/boost immunization.  (A) Magnitude of the VACV-specific CD8 T cell response. The VACV-specific CD8 T cells
were measured 53 days after the last immunization by ICS assay following stimulation of splenocytes derived from immunized
animals (n=4) with VACV E3 peptide. The total value in each group represents the sum of the percentages of CD8+ T cells secreting
CD107a and/or IFN-γ and/or IL-2 and/or TNF-α against E3 peptide. All data are background-subtracted. *** p<0.001. p values
indicate significantly higher response compared to DNA-C/NYVAC-C and DNA-C/NYVAC-C-ΔA46R immunization groups or
between DNA-C/NYVAC-C and DNA-C/NYVAC-C-ΔA46R groups. (B) Functional profile of the VACV-specific CD8 T cell response
in the different immunization groups. The possible combinations of the responses are shown on the x axis, whereas the
percentages of the functionally distinct cell populations within the total CD8 T cell population are shown on the y axis. Combinations
that did not contribute significantly to the functional profile are not shown. Responses are grouped and colour-coded on the basis of
the number of functions. ** p<0.005, *** p<0.001.
doi: 10.1371/journal.pone.0074831.g007
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[1], we also evaluated the presence of anti-gp120 antibodies in
the serum of immunized animals. This analysis showed an
enhanced anti-gp120 humoral response in the mice immunized
with NYVAC-C-ΔA46R deletion mutant suggesting that the
deletion of A46R gene is also able to modulate positively the
humoral response against gp120.
How deletion of A46R impacts on the immune response of
NYVAC-C? As previously described, A46 impairs TLR
signalling by targeting the TIR domain of the adaptors MyD88,
Mal, TRIF and TRAM disrupting Receptor: Adaptor TIR
interactions [37]. Hence, deleting A46R in NYVAC restores
TLR signalling upon viral infection, enhancing the expression of
proinflammatory molecules, which in turn will enhance T cell
activation. According to the intraperitoneal route used in the
present study, the effect of A46R gene deletion on
immunogenicity against HIV-1 antigens should be explained by
the effect of TLR signalling restoration in the cell types present
in the peritoneal cavity (mainly B cells, macrophages and
granulocytes and, to a lesser extent, T cells [66]). In this
context, the increased secretion of proinflammatory cytokines
and chemokines by NYVAC-C-ΔA46R-infected macrophages
could induce an enhanced recruitment of immature DCs and
lymphocytes, generating an appropriate environment for the
uptake and presentation of HIV-1 antigens to T cells. Immature
NYVAC-C-ΔA46R-infected DCs can also migrate to the lymph
nodes, maturing in route, and activate HIV-1-specific T cells
enhancing the overall immunogenicity against HIV antigens.
According to this, it has been previously reported that the total
number of cells in the lungs of mice immunized intranasally
with a VACV A46R deletion mutant was increased on day 2
post-infection compared with parental virus whereas on days 5
and 8 was reduced [37]. Since the main innate sensors of
VACV vectors are TLR2 [15,16,17], TLR2-TLR6-MyD88,
MDA-5/IPS-1 and NALP3 inflammasome [47] and A46R targets
the TIR domain of the adaptors MyD88, Mal, TRIF and TRAM
[37], our findings of enhanced production of TNF, IL-6 and IL-8
in conjunction with an increase in the magnitude of CD4 and
CD8 T cell immune responses to HIV antigens and an
enhanced gp120-specific humoral response, reveal that A46R
plays an important role as immune modulator. This
observation, in combination with the biochemical data on the
mode of action of A46, establishes the immunological role of
VACV A46R on T and B cell responses.
Materials and Methods
Ethics statement
The animal studies were approved by the Ethical Committee
of Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005) (Permit numbers: 152/07 and 080030).
Cells and viruses
African green monkey kidney cells (BSC-40; American Type
Culture Collection, Manassas, VA) and primary chicken embryo
fibroblast cells (CEF; Intervet, s.a, Salamanca, Spain) were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 100 IU/ml of penicillin, 100 µg/ml of
streptomycin and 10% newborn calf serum (NCS) for BSC-40
cells or 10% fetal calf serum (FCS) for CEF cells. The human
monocytic THP-1 cells (American Type Culture Collection,
Manassas, VA) were cultured in RPMI 1640 medium containing
2 mM L-glutamine, 50 µM 2-mercaptoethanol, 100 IU/ml of
penicillin, 100 µg/ml of streptomycin and 10% FCS. Cells were
maintained in a humidified air 5% CO2 atmosphere at 37°C.
The poxvirus strains used in this work included the genetically
attenuated vaccinia virus-based vector NYVAC-WT and the
recombinant NYVAC-C expressing gp120 as a cell-released
product and Gag-Pol-Nef as an intracellular polyprotein from
the clade C CN54 HIV-1 isolate [48], used as the parental
vector for the generation of the A46R deletion mutant. Virus
infections were performed with 2% NCS or FCS. All viruses
were grown in primary CEF cells, similarly purified through two
36% (w/v) sucrose cushions and the virus titers were
determined by immunostaining plaque assay in BSC-40 cells
as previously described [67]. The titer determinations of the
different viruses were performed at least three times.
Construction of plasmid transfer vector pGem-RG-
A46R wm
The plasmid transfer vector pGem-RG-A46R wm, used for
the construction of the recombinant virus NYVAC-C-ΔA46R,
with A46R ORF deleted, was obtained by the sequential
cloning of A46R recombination flanking sequences into the
plasmid pGem-Red-GFP wm, containing dsRed2 and rsGFP
genes as fluorescent markers, and previously described [68].
NYVAC genome was used as the template to amplify the left
flank of A46R gene (432 bp) with oligonucleotides LFA46R-Aat
(5´-CACGATGACGTCAGAGGAGTTAT-3´) (AatII site
underlined) and LFA46R-Xba (5´-
CGTATGTCTAGATTATTTTGCTGAG-3´) (XbaI site
underlined). This left flank was digested with AatII and XbaI
and cloned into plasmid pGem-Red-GFP wm previously
digested with the same restriction enzymes to generate pGem-
RG-LFsA46R wm (4939 bp). The repeated left flank of A46R
gene (432 bp) was amplified by PCR from NYVAC genome
with oligonucleotides LFA46R’-Eco (5´-
CACGATGAATTCAGAGGAGTTAT-3´) (EcoRI site underlined)
and LFA46R’-Cla (5´-CGTATGATCGATT TATTTTGCTGAG-3
´) (Cla I site underlined), digested with EcoRI and Cla I and
inserted into the EcoRI / Cla I-digested pGem-RG-LFsA46R
wm to generate pGem-RG-LFdA46R wm (5330 bp). The right
flank of A46R gene (360 bp) was amplified by PCR from
NYVAC genome with oligonucleotides RFA46R-Cla (5´-
CTGAGAATCGATAGGATGAATTTG-3´) (Cla I site underlined)
and RFA46R-Bam (5´-ATTTAAGGATCCAGAACGGCAAC-3´)
(BamHI site underlined), digested with Cla I and BamHI and
inserted into the Cla I / BamHI-digested pGem-RG-LFdA46R
wm. The resulting plasmid pGem-RG-A46R wm (5660 bp;
Figure S2) was confirmed by DNA sequence analysis and
directs the deletion of A46R gene from NYVAC-C genome.
Construction of NYVAC-C-ΔA46R deletion mutant
The deletion mutant NYVAC-C-ΔA46R was constructed
using dsRed2 and rsGFP as fluorescent markers. 3 x 106
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BSC-40 cells were infected with 0.01 PFU/cell of NYVAC-C
and transfected 1 hour later with 6 µg DNA of plasmid pGem-
RG-A46R wm using Lipofectamine (Invitrogen) according to the
manufacturer’s recommendations. Forty-eight hours post-
infection, the cells were harvested, lysed by freeze-thaw
cycling, sonicated and used for recombinant virus screening.
Deletion mutant was selected from progeny virus by
consecutive rounds of plaque purification in BSC-40 cells
during which plaques were screened for Red2/GFP
fluorescence. In the first three passages, viruses from selected
plaques expressed both fluorescent proteins, while in the next
two passages viral progeny from selected plaques expressed
only one fluorescent marker (Red2). In the last two passages
(seven passages in total), viruses from selected plaques do not
express any marker due to the loss of the fluorescent marker
by homologous recombination within the repeated flanking
DNA sequences. The resulting NYVAC-C-ΔA46R virus was
expanded in BSC-40 cells and the crude preparation obtained
was used for the propagation of the virus in large cultures of
primary chicken fibroblasts (CEF) followed by virus purification
through two 36% (w/v) sucrose cushions and titrated by
immunoplaque assay in BSC-40 cells.
PCR analysis of NYVAC-C-ΔA46R deletion mutant
To test the identity and purity of the recombinant virus
NYVAC-C-ΔA46R, viral DNA was extracted from BSC-40 cells
infected at 5 PFU/cell with NYVAC-WT or NYVAC-C-ΔA46R.
Cell membranes were disrupted using sodium dodecyl sulphate
(SDS) followed by proteinase K treatment (0.2 mg/ml
proteinase K in 50 mM Tris-HCl pH 8, 100 mM EDTA pH 8, 100
mM NaCl and 1% SDS for 1 hour at 55°C) and phenol
extraction of viral DNA. Primers LFA46R-Aat and RFA46R-
Bam spanning A46R flanking regions were used for PCR
analysis of A46R locus. The amplification reactions were
carried out with Platinum Taq DNA polymerase (Invitrogen)
according to the manufacturer’s recommendations. The correct
sequence of deleted A46R locus was confirmed by DNA
sequence analysis.
Expression of HIV-1 proteins gp120 and GPN
To test the correct expression of HIV-1 antigens by the A46R
deletion mutant, monolayers of BSC-40 cells were mock-
infected or infected at 5 PFU/cell with NYVAC-WT, NYVAC-C
or NYVAC-C-ΔA46R. At 24 hours post-infection, cells were
lysed in Laemmli buffer, cells extracts fractionated by 8% SDS-
PAGE and analyzed by Western-blot using the polyclonal anti-
gp120 antibody (Centro Nacional de Biotecnología; diluted
1:3000) or the polyclonal anti-gag p24 serum (ARP 432,
NIBSC, Centralised Facility for AIDS reagent, UK; diluted
1:1000) to evaluate the expression of gp120 and GPN proteins,
respectively. The anti-rabbit-HRPO (SIGMA; diluted 1:5000)
was used as secondary antibody. The immunocomplexes were
detected by enhanced chemiluminescence (ECL, GE
Healthcare).
Analysis of virus growth
To determine virus growth profiles, monolayers of CEF cells
grown in 12-well plates were infected in duplicate at 0.01 PFU/
cell with NYCAC-C or NYVAC-C-ΔA46R deletion mutant.
Following virus adsorption for 60 min at 37°C, the inoculum
was removed. The infected cells were washed once with
DMEM without serum and incubated with fresh DMEM
containing 2% FCS at 37°C in a 5% CO2 atmosphere. At
different times post-infection (0, 24, 48 and 72 hours), cells
were harvested by scraping (lysates at 5 x 105 cells/ml), freeze-
thawed three times and briefly sonicated. Virus titers in cell
lysates were determined by immunostaining plaque assay in
BSC-40 cells using rabbit polyclonal anti-vaccinia virus strain
WR (Centro Nacional de Biotecnología; diluted 1:1000),
followed by anti-rabbit-HRPO (SIGMA; diluted 1:1000).
Measurement of cytokine production by macrophages
THP-1 cells were differentiated into macrophages by
treatment with 0.5 mM phorbol 12-myristate 13-acetate (PMA,
Sigma-Aldrich) for 24 h. The medium was changed and cells
were either mock-infected or infected with 1 or 5 PFU/cell of
NYVAC-WT, NYVAC-C or NYVAC-C-Δ46R. Cell-free
supernatants were collected after 6 hours to quantify the
concentrations of TNF, IL-6 and IL-8. The concentrations of
human IL-8 (BD Biosciences) in cell-culture supernatants were
measured by ELISA as previously described [47]. TNF and IL-6
concentrations were measured by bioassay as described
elsewhere [69].
DNA vectors
The two DNA constructs expressing the HIV-1 CN54gp120
(pcDNA- CN54gp120) and HIV-1 CN54Gag-Pol-Nef (GPN)
polyprotein (pcDNA- CN54GPN) have been previously reported
[48]. Plasmids were purified using Maxi-prep purification kits
(Qiagen) and diluted for injection in endotoxin-free PBS.
Peptides
The HIV-1 peptide pools Gag-1, Gag-2, Env-1, Env-2,
GPN-1, GPN-2, GPN-3 and NEF were provided by the
EuroVacc Foundation and were previously described [48].
They spanned the HIV-1 Env, Gag, Pol and Nef antigens from
clade C included in the immunogens as consecutive 15-mers
overlapping by 11 amino acids. For immunological analyses we
grouped the pools as follows: Env pool (Env-1+Env-2), Gag
pool (Gag-1+Gag-2) and GPN pool
(GPN-1+GPN-2+GPN-3+NEF). The VACV E3140-148 peptide
(VGPSNSPTF; CNB), previously described as
immunodominant epitope in BALB/c mice [52], was used to
detect the anti-vector cellular immune response.
Mouse immunization schedule
BALB/c mice (6-8 weeks old) were purchased from Harlan.
For the heterologous DNA prime/NYVAC boost immunization
protocol performed to assay the immunogenicity of NYVAC-C-
ΔA46R deletion mutant, groups of animals (n=8) received 100
µg of DNA-C (50 µg of pcDNA- CN54gp120 + 50 µg of pcDNA-
CN54GPN) or 100 µg of DNA-ϕ (100 µg of pcDNA) by
intramuscular route (i.m.). Two weeks later, animals were
immunized with 1 x 107 PFU of NYVAC-WT, NYVAC-C or
NYVAC-C-ΔA46R by intraperitoneal route (i.p.). Mice
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immunized with sham DNA (DNA-ϕ) followed by NYVAC-WT
boost were used as control group. At 10 and 53 days after the
last immunization, 4 mice in each group were sacrificed and
spleens processed for Intracellular Cytokine Staining (ICS)
assay to measure the adaptive and memory cellular immune
responses against HIV-1 antigens, respectively. Two
independent experiments have been performed for the different
groups.
Intracellular Cytokine Staining assay (ICS)
The magnitude, polyfunctionality and phenotype of the HIV-
specific T cell responses were analyzed by ICS. After an
overnight rest, 4 x 106 splenocytes (depleted of red blood cells)
were seeded on 96-well plates and stimulated during 6 hours in
complete RPMI 1640 media supplemented with 10% FCS
containing 1 µl/ml GolgiPlug (BD Biosciences), anti-CD107a-
Alexa 488 (BD Biosciences) and 5 µg/ml of the different HIV
peptide pools. At the end of the stimulation period, cells were
washed, stained for the surface markers, fixed and
permeabilized (Cytofix/Cytoperm Kit; BD Biosciences) and
stained intracellularly using the appropriate fluorochromes.
Dead cells were excluded using the violet LIVE/DEAD stain kit
(Invitrogen). For functional analyses the following
fluorochrome-conjugated antibodies were used: CD3-PE-
CF594, CD4-APC-Cy7, CD8-V500, IFN-γ-PE-Cy7, IL-2-APC
and TNF-α-PE (all from BD Biosciences). In addition, for
phenotypic analyses the following antibodies were used:
CD62L-Alexa 700 (BD Biosciences) and CD127-PerCP-Cy5.5
(eBioscience). Cells were acquired using a GALLIOS flow
cytometer (Beckman Coulter). Analyses of the data were
performed using the FlowJo software version 8.5.3 (Tree Star,
Ashland, OR). The number of lymphocyte-gated events ranged
between 1 x 105 and 1 x 106. After gating, Boolean
combinations of single functional gates were then created
using FlowJo software to determine the frequency of each
response based on all possible combinations of cytokine
expression or all possible combinations of differentiation
marker expression. For each population, background
responses detected in the non-stimulated control samples were
subtracted from those detected in stimulated samples for every
specific functional combination and the percentages of cells
producing cytokines obtained in the DNA-ϕ/NYVAC-WT control
populations were also subtracted in all the groups in order to
remove the non-specific responses detected as background.
Only positive responses are represented.
Antibody measurement by ELISA
Binding antibodies to Env protein in serum were determined
by enzyme-linked immunosorbent assay (ELISA) as previously
described [48]. Serum samples from naïve and immunized
mice were serially 2-fold diluted in duplicate and reacted
against 2 µg/ml of the recombinant CN54gp120 purified protein
(ARP683, HIV-1 CN54gp120 clade C; EU Programme EVA
from the Centre for AIDS Reagents). The antibody titer of Env-
specific IgG was defined as the last dilution of serum that
resulted in 3 times the mean optical density at 450 nm of the
naïve control.
Data analysis and statistics
For the statistical analysis of ICS data, we used a novel
approach that corrects measurements for the medium
response (RPMI) and allows the calculation of confidence
intervals and p values of hypothesis tests [54,70]. Only antigen
responses values significantly higher than the corresponding
RPMI are represented and the background for the different
cytokines in the unstimulated controls never exceeded 0.05%.
Analysis and presentation of distributions was performed using
SPICE version 5.1, downloaded from http://exon.niaid.nih.gov
[71]. Comparison of distributions was performed using a
Student’s T test and a partial permutation test as described
[71]. All values used for analyzing proportionate representation
of responses are background-subtracted. For the statistical
analysis of ELISA data, a 1-way ANOVA with Tukey’s honestly
significant difference criterion as post-hoc analysis was
performed.
Supporting Information
Figure S1.  Profile of memory HIV-specific T cell immune
responses elicited by A46R deletion mutant in the spleen
of BALB/c mice after prime/boost immunization. Flow
cytometry profiles of vaccine-induced CD8 T cell responses
against Env pool in splenocytes from immunized animals.
(TIF)
Figure S2.  Scheme of construction of the plasmid transfer
vector pGem-RG-A46R wm. The plasmid transfer vector
pGem-RG-A46R wm was obtained by the sequential cloning of
A46R recombination flanking sequences into the plasmid
pGem-Red-GFP wm, containing dsRed2 and rsGFP genes as
fluorescent markers. NYVAC genome was used as the
template to amplify the left flank of A46R gene by PCR. This
left flank was digested with AatII and XbaI and cloned into
plasmid pGem-Red-GFP wm previously digested with the
same restriction enzymes to generate pGem-RG-LFsA46R wm
(4939 bp). The repeated left flank of A46R gene was amplified
by PCR from NYVAC genome, digested with EcoRI and Cla I
and inserted into the EcoRI / Cla I-digested pGem-RG-
LFsA46R wm to generate pGem-RG-LFdA46R wm (5330 bp).
The right flank of A46R gene was amplified by PCR from
NYVAC genome, digested with Cla I and BamHI and inserted
into the Cla I / BamHI-digested pGem-RG-LFdA46R wm. The
resulting plasmid pGem-RG-A46R wm (5660 bp) directs the
deletion of A46R gene from NYVAC-C genome.
(TIF)
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4.  Discussion 
 
Here we define distinct poxvirus strategies to improve T cell responses to 
heterologous antigens and we characterize the immune responses elicited by the new 
attenuated recombinant NYVAC and MVA virus vectors.  We identify the immune 
properties of these vectors, demonstrate a new mechanism for poxvirus-induced 
immunity, and provide a basis for the design of novel virus vaccine vectors. 
 
4.1 Neutrophil migration 
In the first study, we focused on neutrophil recruitment after NFκB activation induced 
by NYVAC-C ΔA52RΔB15RΔK7R (NYVAC-C-Δ3) infection.  Recent studies showed 
that the neutrophil migration after intradermal and intranasal MVA infection is CCR1-
dependent! (Duffy et al., 2012; Price et al., 2014).  We nonetheless found that after 
NYVAC-C-Δ3 infection, neutrophil recruitment to the peritoneal cavity is only partially 
mediated by CCR1 and not by CCR5, the classical receptors of the chemokine 
macrophage inflammatory protein (MIP)-1! (Kaufmann et al., 2001).  We detected 
higher levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) in peritoneal 
exudates and sera from NYVAC-C-Δ3-infected mice compared to those from 
NYVAC-C infected mice.  MCP-1/CCL2 is the primary chemokine involved in 
monocyte recruitment in murine peritonitis!(Takahashi et al., 2009), but also participates 
in neutrophil recruitment (Johnston et al., 1999).  In our model, neutrophil recruitment 
might also be partially mediated by CCR2 (MCP-1/CCL2 receptor), and the combined 
deletion of CCR1 and CCR2 in NYVAC-C-Δ3-infected mice could lead to peritoneal 
neutrophil levels similar to those of NYVAC-C-infected mice.  
 
4.2 Neutrophils with antigen-presenting cell (APC) features 
When compared to NYVAC-C-infected mice, the peritoneal cavity of NYVAC-C-
Δ3-infected mice showed a significant increase in two neutrophil populations (Nα and 
Nβ).  Although the Nβ subset is more susceptible to VACV infection than Nα, we found 
that the presence of Nβ neutrophils in peritoneal exudates was dependent on the post-
infection cytokine/chemokine environment and was not the result of direct neutrophil 
infection.  In vitro and in vivo, the cytokine/chemokine environment (e.g., presence of 
GM-CSF; granulocyte-macrophage colony-stimulating factor) polarizes neutrophils to 
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acquire an APC phenotype (upregulation of MHC class II and the costimulatory 
molecules CD80/CD86) (Fanger et al., 1997; Oehler et al., 1998), to trigger CD8 T cell 
activation (Matsushima et al., 2013).  In tumor tissue, the cytokine/chemokine milieu 
(the presence of TGF-β; transforming growth factor β) polarizes tumor-associated 
neutrophils (TAN) from the anti-tumor N1 to the pro-tumor N2 phenotype, which is 
characterized by impaired ability to activate CD8 T cells (Fridlender et al., 2009).  In 
tumors treated with SM16 (a TGF-β receptor kinase inhibitor), CD8 T cells showed 
strong anti-tumor cytolytic effects (Suzuki et al., 2007), and infiltrated neutrophils were 
more lobulated and hypersegmented than in untreated tumor-bearing controls 
(Fridlender et al., 2009).  In our study, Nβ neutrophils were more lobulated and 
hypersegmented than the Nα subtype, which confirms neutrophil ability to acquire a 
distinct phenotype in specific cytokine/chemokine conditions.  Although we detected no 
difference in TGF-β or GM-CSF secretion between these two groups (not shown), APC 
markers (CD80 and CD86) were upregulated in Nβ cells, which showed a greater 
capacity to induce antigen-specific CD8 T cell activation than Nα cells. 
 
4.3 Neutrophil-dependent T cell responses 
We demonstrated that the presence of Nβ is insufficient to activate naïve CD8 T cells 
ex vivo; in similar conditions, naïve CD8 T cells did not proliferate (not shown).   Our 
data demonstrated that Nβ neutrophils present antigen to effector CD8 T cells to induce 
their activation and do not prime naïve CD8 T cells to induce proliferation.  We 
speculate that other APC-activating signals such as CD40, which is involved in 
dendritic cell stimulation of CD8 T cells (Hernandez et al., 2007), could help neutrophil 
induction of naïve CD8 T cell proliferation.  Recent in vivo studies demonstrated that 
neutrophils do not prime vaccinia virus-specific CD8 T cell responses in the absence of 
myeloid DC (dendritic cells) (Duffy et al., 2012). 
Although we showed that neutrophils are involved in the increase in antigen-specific 
CD8 T cell responses after NYVAC-C-Δ3 infection, this was not the case for the CD4 
T cell response.  We speculate that neutrophils prime CD4 T cells with difficulty, and 
probably negatively control CD4 T cell activation, which would explain the reduction in 
antigen-specific CD4 T cell responses induced in NYVAC-C Δ3-infected mice.  
Another study indicated that after protein-adjuvant immunization, neutrophils establish 
very brief contacts with DC in the draining lymph nodes, with a subsequent poor 
antigen-specific CD4 response; in neutrophil-depleted mice, these authors showed that 
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the number and periodicity of DC-T cell interactions increased with enhancement of the 
antigen-specific CD4 response (Yang et al., 2010a), which supports our hypothesis. 
An in vivo study of the mechanisms of neutrophil-dependent control of CD4 and 
CD8 T cell responses to vaccinia virus-delivered antigens would be of great interest.  In 
mice, we did not detect GFP-infected neutrophils in secondary lymphoid organs.  We 
speculate that antigen transport results, not from direct neutrophil infection, but rather 
from neutrophil uptake of apoptotic infected cells in which antigen has been processed 
(Figure 9).  These neutrophils could transport processed antigens and cross-prime naïve 
CD8 T cells; peritoneal neutrophils efficiently cross-prime naïve CD8 T cells in vivo 
(Beauvillain et al., 2007) and the cross-priming of viral antigens is a robust process able 
to generate vigorous CD8 T cell responses (Chen et al., 2004). 
 
 
Figure 9.  Model of neutrophil-dependent CD8 T cell activation 
Apoptotic infected macrophages (Mφ) are engulfed by neutrophils (Nβ) that cross-prime CD8 T cells with 
the help of dendritic cells (DC). 
 
4.4 T cell responses to HIV 
The attenuated vaccinia virus MVA, which lacks an anti-apoptotic gene (F1L), 
generates higher specific Gag-Pol HIV responses than the parental virus by inducing 
extensive apoptosis (Perdiguero et al., 2012).  Neutrophil cross-priming of apoptotic 
peritoneal cells could explain why CD8 T cell responses to non-secreted Gag-Pol 
antigens were significantly higher in NYVAC-C Δ3- than in NYVAC-C-infected mice.  
In contrast to the induction of Gag and Pol responses, NYVAC-C Δ3 does not increase 
the CD8 T cell response to Env.  This difference in antigen response probably depends 
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on extracellular secretion of Env compared to intracellular production of Gag-Pol.  Our 
data suggest greater neutrophil involvement in the cross-priming of antigen from 
vaccinia virus-infected cells such as Gag and Pol than of Env secreted antigen. 
 The ability to generate high polyfunctional Gag- and Pol-specific CD8 T cell 
responses is an important immune property of the NYVAC-C Δ3 vector for future 
vaccine applications.  Human HIV non-progressors preferentially maintain highly 
functional HIV-specific CD8 T cells (Betts et al., 2006).  Gag and Pol, the best 
conserved HIV-1 proteins (Goulder and Watkins, 2008), can shift the CD8 T cell 
response from the variable Env epitope in the first years of HIV-1 infection (Yang et al., 
2011a). In untreated chronic HIV-1-infected individuals, a Gag CD8 T cell response 
correlates with lower HIV viral loads (Kiepiela et al., 2007); furthermore, it correlates 
with decreased viremia in early HIV-1-infected patients with suspension of retroviral 
therapy (Yang et al., 2011a).  A prophylactic vaccine that induces a Gag T cell response 
was recently shown to control simian immunodeficiency virus (SIV) infection (Iwamoto 
et al., 2014).  Due to the limited vaccine effectiveness (31.2%) of ALVAC poxvirus in 
the RV144 phase III HIV/AIDS human clinical trial (Rerks-Ngarm et al., 2009) and to 
the promising results for MVA poxvirus in SIV-challenged primates (Barouch et al., 
2013), new poxvirus vectors will be tested and NYVAC-C ΔA52RΔB15RΔK7R could 
be a valid vaccine candidate for prophylactic and therapeutic treatment of HIV. 
 
4.5 NYVAC and NFκB inhibitors 
 We defined the biological effect of the deletion of three VACV inhibitors (A52, K7 
and B15) in the NYVAC genome on the NFκB signaling pathway.  These early 
proteins, members of the B cell lymphoma-2 family (Bcl-2) (Graham et al., 2008; 
Kalverda et al., 2009), are involved in suppression of Toll-like receptor (TLR)-induced 
host immune responses (Smith et al., 2013).  Using single, double and triple deletion 
mutants, we demonstrated that A52, K7 and B15 do not act in synergy in their inhibition 
of the NFκB pathway; combined deletion of A52R, K7R and B15R genes is thus 
necessary for efficient triggering.  With the generation of NYVAC-C Δ3 K7R-rev, we 
also determined that the presence of only one of the three inhibitory molecules is 
sufficient to abolish NFκB activation.  It will be interesting analyze the role of these 
three proteins in the activation of TLR-dependent transcriptional factors such as IFN-
regulatory factors (IRF) 3 and 7 and activator protein 1 (AP-1). 
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We defined that A46, another Bcl-2 protein involved in suppression of TLR-induced 
immune responses (Smith et al., 2013), induces cytokine/chemokine secretion that 
correlates with an increased HIV-specific T cell immune response.  It has not been 
established whether the pro-inflammatory signals induced by NYVAC-C ΔA46R are 
NFκB-dependent or are mediated by distinct transcriptional factors.  In the 
TLR2/TLR4-dependent pathway, the contributions of A46 and of C49, a newly defined 
NFκB inhibitor (Mansur et al., 2013), could be better determined by removing their 
genes in conditions of strong NFκB activation, such as those elicited by NYVAC-C Δ3 
(Figure 10). 
  
 
 
4.6 Poxvirus promoter modification: sequence 
In the second study, we focused on poxvirus promoter sequence modification to 
increase expression of the early heterologous antigen.  We showed that compared to the 
early-late pS promoter, the late-early optimized (LEO) promoter increased GFP 
expression in the first hours post-infection; this increase in early antigen expression 
correlated with a significant enhancement of GFP-specific CD8 T cell responses in 
MVA-LEO-GFP-infected mice compared to those injected with MVA-pS. 
Several recent studies report that new early promoters increase the expression of 
antigen under their transcriptional control as well as antigen-specific CD8 T cell 
responses (Baur et al., 2010; Isshiki et al., 2014; Wennier et al., 2013) when compared 
to p7.5, the first promoter described (Cochran et al., 1985), and to the widely used pS 
(Chakrabarti et al., 1997).  All of these new promoters have early motif repetitions and 
have been compared with pS and p7.5, which have one early motif. Although the 
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advantage is evident for early antigen expression induced by promoters with more than 
one repetition, it was not known whether this antigen expression could be improved 
using a different promoter with one repetition.  The LEO promoter has a single early 
motif, like the pS promoter, which increases antigen expression in HeLa cells when 
compared to p7.5 (Baur et al., 2010). 
We demonstrate that the LEO promoter improves early antigen expression compared 
to pS; the LEO promoter sequence is based on our bioinformatics analysis of E1.1 
promoter sequences, which are recognized more rapidly than those of E1.2.  Although 
the E1.1 core promoter corresponds more closely to the consensus sequence than that of 
E1.2 (Yang et al., 2010b), whether the LEO promoter early sequence is better than that 
of pS remains to be defined due to differences in spacer length and late motif position.  
The generation of a new pS inverted (pS INV), in which the late pS sequence precedes 
the pS early motif and LEO spacer sequence (Figure 11A), and its comparison with 
LEO and pS promoters will help us respond to this question (Figure 11 B). 
 
Figure 11.  (A) Scheme of pS INV and LEO promoters.  Late promoter element, grey box; early 
promoter motif, black box; spacer, dashed line beneath the sequence.  (B) GFP expression in HeLa cells 
infected with MVA-WT, MVA-pS-GFP, MVA-ps INV-GFP or MVA-LEO-GFP viruses. Graphs 
show the x-fold increase in GFP median fluorescence intensity (MFI) of MVA-GFP compared to MVA-
WT virus.  Values shown as mean ± SEM.  ** p<0.01, *** p<0.001. 
 
We showed that the LEO promoter significantly increased GFP expression compared 
to pS INV, which differ in three early motif nucleotides (AAA to TTT); there were no 
differences between pS and pS INV.  These results demonstrate that the new early motif 
sequence of the LEO promoter is more effective than the early motif in pS. 
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4.7 Poxvirus promoter modification: spacer 
In the next study, we focused on the role of the poxvirus promoter spacer in the 
optimization of early antigen expression.  We designed two new promoters with distinct 
spacer lengths, LEO99 and LEO160, and compared them with the previously reported 
LEO promoter (Di Pilato et al., 2013).  Compared to LEO, the LEO99 and LEO160 
promoters (with 99 and 160 nucleotide [nt] spacers) increased early antigen expression, 
demonstrating a positive correlation between spacer length and antigen expression. 
The 50-nt window, from -70 to -20 nt upstream of the open reading frame, is the 
most frequent site for the promoter motif in early genes (Di Pilato et al., 2013).  Our 
result suggests that VACV, whose early genes rarely have spacers longer than 70 nt, 
does not alone induce the highest possible gene expression.  Viruses save on genome to 
gain replicative and genome stability advantages (Ojosnegros et al., 2011), which could 
explain how vaccinia viral genes maintain short spacers between the gene and their 
early promoter cores. 
  The DNA footprint of vaccinia RNA polymerase ternary complexes is less than 
50 nt (Hagler and Shuman, 1992).  The vaccinia virus early transcription factor (ETF) 
(Broyles et al., 1988) and RNA polymerase-associated protein (RAP94) (Ahn et al., 
1994) mediate the promoter-RNA polymerase link.  We hypothesized that spacers 
>50 nt would offer greater space to the transcription machinery, possibly accelerating 
gene expression.  Further research is needed to determine which is the most appropriate 
spacer length to increase gene expression.  Spacers with more than 99 nt offer 
advantages of early gene expression, although it remains unknown whether spacers with 
more or less than 160 nt are similarly advantageous. 
Early gene expression mediated by promoter optimization is another strategy to 
increase CD8 T cell immunogenicity to a foreign antigen (Baur et al., 2010).  Although 
VACV intermediate antigens are recognized preferentially by CD4 T cells (Yang et al., 
2011b), we demonstrate that early antigen expression driven by the MVA-LEO160 
early promoter can also positively influence antigen-specific CD4 T cell responses. 
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4.8 LACK-specific T cell responses 
We demonstrated that MVA-LEO160 increases the CD4 and CD8 T cell response to 
the LACK Leishmania antigen compared to MVA-LEO; mice infected with MVA-
LEO160-LACK presented higher numbers of antigen-specific polyfunctional CD4 and 
CD8 T cells compared to those infected with MVA-LEO. 
The Th1:Th2 CD4 subtype ratio is crucial for leishmaniasis protection, as the Th2 
response is associated to greater susceptibility to Leishmania (Launois et al., 2007) and 
the Th1 response protects against leishmaniasis infection (Darrah et al., 2010; Darrah et 
al., 2007).  By increasing the number of IL-2+IFNγ+TNFα+ CD4 Th1 cells, MVA-
LEO160-LACK could be a valid vaccine candidate for leishmaniasis.  MVA-LEO160-
LACK also enhanced CD107a+ memory CD4 T cells to LACK.  These cells are 
resistant to HIV-1 infection, which implies that they could control the infection 
(Terahara et al., 2014); there is no evidence in the Leishmania model of a role for 
CD107a+ CD4 T cells that correlates with protection from leishmaniasis. 
Although several studies attempted to identify the phenotype and the role of CD8 
T cells in natural Leishminia infection!(Nateghi Rostami et al., 2010; Khamesipour et 
al., 2012) and after therapy (Papadogiannakis et al., 2010), it is not yet clear whether 
CD8 T cells have a positive or negative role in control of the disease.  We defined 
LACK-specific CD8 T cells expressing IL-2, IFNγ, TNFα and CD107a, or IFNγ, TNFα 
and CD107a as the subsets most elicited by MVA-LEO-LACK and MVA-LEO160-
LACK; both cell subsets were significantly higher in MVA-LEO160-LACK-injected 
mice.  Polyfunctional CD8 T cells that express IL-2 and IFNγ induce Th1 polarization 
of CD4 T cells, limiting the natural Th2 response (Uzonna et al., 2004), and could thus 
have a function in Leishmania protection.  CD8 T cells expressing IFNγ and TNFα 
could have a central role in control of the disease; by inducing macrophage activation 
and nitric oxide synthesis (Bogdan et al., 1990), both cytokines have a protective role 
against Leishmania.  The CD8 T cell subsets elicited by MVA-LEO160-LACK also 
produced CD107a.  CD107a+ CD8 T cells correlate with necrosis intensity and lesion 
size in leishmaniasis (Santos Cda et al., 2013); if the excessive cytolytic activity of 
CD107a+ CD8 T cells induces development of metastatic lesions (Launois et al., 2007), 
vaccine induction of these cells should be avoided.  
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5. Conclusions 
 
1. The vaccinia virus (VACV) A52, B15 and K7 proteins are directly involved in 
inhibition of the NFκB signaling pathway, and the concomitant deletion of their 
genes is crucial for inducing robust activation of this pathway after NYVAC 
infection. 
 
2. In vivo and in vitro, NYVAC-C-ΔA52RΔB15RΔK7R-dependent NFκB activation 
increases neutrophil migration compared to the parental NYVAC-C due to 
cyotokine/chemokine milieu generated at the infection site. 
 
3. Nα and Nβ neutrophil subtypes induced by NYVAC-C-ΔA52RΔB15RΔK7R 
infection in mice show distinct antigen-presenting cell features; Nβ cells are 
implicated in CD8 T cell activation. 
 
4. In mice, NYVAC-C-ΔA52RΔB15RΔK7R improves the magnitude and 
polyfunctionality of HIV Gag/Pol-specific CD8 T cell responses compared to the 
parental NYVAC-C, due to neutrophil migration. 
 
5. The VACV late-early-optimized (LEO) promoter, generated based on 
bioinformatics analysis, increases early GFP antigen expression compared to the 
pS promoter, due to an improved temporal early promoter sequence. 
 
6. The enhanced GFP expression induced by recombinant MVA-LEO virus 
correlates with an increase in magnitude and polyfunctionality of GFP-specific 
CD8 T cell responses in mice. 
 
7. The modifications in the spacer length of the LEO promoter demonstrate that a 
longer promoter spacer increases early antigen expression under LEO 
transcriptional control. 
 
8. In mice, MVA-LEO160-LACK enhances Leishmania LACK-specific CD4 and 
CD8 T cell responses compared to MVA-LEO-LACK, which confirms the 
positive correlation between antigen expression and T cell responses to antigen. 
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6. Conclusiones 
1. Las proteínas A52, B15 y K7 del virus vaccinia (VACV) están directamente 
involucradas en la inhibición de la vía de señalización de NFκB y la deleción 
concomitante de sus genes es crucial para inducir una activación robusta de esta vía tras 
la infección por NYVAC. 
 
2. In vivo e in vitro, la activación de NFκB inducida por NYVAC-C-
ΔA52RΔB15RΔK7R aumenta la migración de los neutrófilos en comparación con el 
virus NYVAC-C debido a las citocinas/quimiocinas producidas en el lugar de infección. 
 
3. Los subtipos Nα y Nβ de neutrófilos, inducidos tras la infección en ratón con 
NYVAC-C-ΔA52RΔB15RΔK7R, muestran distintas características de células 
presentadoras de antígeno; los Nβ están implicados en la activación de células T CD8. 
 
4. NYVAC-C-ΔA52RΔB15RΔK7R mejora en ratón la magnitud y la polifuncionalidad 
de la respuesta específica de células T CD8 frente a los antígenos de VIH Gag y Pol en 
comparación con el virus parental NYVAC-C debido a la migración de neutrófilos. 
 
5. El promotor tardío-temprano optimizado (LEO) de VACV, generado tras el análisis 
bioinformático, aumenta la expresión temprana del antígeno GFP en comparación con el 
promotor pS gracias a una optimización de la secuencia temprana del promotor. 
 
6. La expresión mejorada de la GFP inducida por el virus recombinante MVA-LEO se 
correlaciona en ratón con el aumento de la magnitud y polifuncionalidad de las 
respuestas de células T CD8 específicas frente a la GFP. 
 
7. Las modificaciones en la longitud del espaciador del promotor LEO demuestran que 
un espaciador más grande aumenta la expresión del antígeno. 
 
8. El virus MVA-LEO160-LACK mejora en ratón las respuestas de células T CD4 y 
CD8 frente al antígeno LACK de Leishamina en comparación con MVA-LEO-LACK, 
lo que confirma la correlación positiva entre la expresión del antígeno y la respuesta de 
células T hacia este mismo antígeno. 
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